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Abstract 
 
Introduction: Malignant Melanoma is the most lethal of the skin cancers and the UK 
incidence is rising faster than that of any other cancer. Breslow thickness remains 
the best predictor of metastasis and Sentinel Lymph Node Biopsy is the only method 
of detecting nodal spread in clinically node negative patients. Surgery is the only 
effective therapy. Angiogenesis – the growth of new vessels from pre-existing 
vasculature - is an absolute requirement for tumour survival and progression beyond 
a few hundred microns in diameter. Anti- angiogenic isoforms of VEGF have been 
demonstrated previously to be protective with regard to metastasis. The aims of this 
thesis were to determine whether VEGF expression within the tumour may allow 
prediction of the nodal status. Furthermore another aim was to determine whether 
via the “Seed and Soil” theory, by examination of angiogenic and lymphangiogenic 
profiles of the tumour and node can we determine that the tumour may control the 
microenvironment around the Sentinel Node? Finally, as a cohort of false negative 
patients emerged with a higher mortality rate than their true negative and true 
positive patient cohort counterparts, could any further patterns be established by 
performing the same experiments on these patients? 
 
Methods: Archived human tumour and corresponding Sentinel Node samples were 
used and immunohistochemistry was used to investigate the role of pro and anti 
angiogenic isoforms of VEGF, VEGF-C, LYVE-1 and CD31 within these patients.  
 
3 
Results: VEGF-C expression was significantly increased in the intranodal 
component of positive Sentinel Lymph Nodes (p<0.01 Bonferroni). This increased 
expression appeared to be independent of tumoural influences and no strong 
evidence for the “Seed and Soil” theory was proved.  A significantly higher number 
of lymphatic vessel counts were identified within node negative patients (p<0.05 
ANOVA). No further significant findings were defined on examination of the false 
negative cohort of patients. 
 
Conclusions: This study has shown that positive Sentinel Lymph Nodes exhibit high 
levels of intranodal VEGF-C. This expression does not appear to be related to 
tumoural influences. It would therefore appear that VEGF-C expression within 
Sentinel Nodes warrants further investigation and may aid diagnosis of spread or 
represent a target to slow or even prevent the onset of metastasis.  
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1 CHAPTER ONE 
INTRODUCTION 
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1.1 MELANOMA HISTORY 
References to ‘black cancer’ and ‘fatal black tumours with metastasis’ date to 
the writings of the legendary Greek physician Hippocrates in the fifth century B.C.  
Melanoma was first described in 1787 by John Hunter, who based his account on the 
case of a 35-year-old man with a recurrent mass behind the angle of the jaw[1]. 
Hunter did not describe the tumour as a melanoma, but rather as a “cancerous 
fungous excrescence.”  The resected surgical specimen is preserved in the Hunterian 
Museum of the Royal College of Surgeons of England; in 1968 it was examined 
microscopically and found to be melanomatous infiltration of a lymph node. 
It was not until the time of Napoleon’s Prussian Campaign in 1806 that Renè 
Laennec, inventor of the stethoscope, provided the first description of melanoma as 
a disease entity in his presentation to the Facultéde Médecine in Paris [1]. His 1812 
manuscript reporting a case of disseminated melanoma also marks the first published 
use of the word ‘melanoma’[2]. Several years later, a truly remarkable conceptual 
leap was made in the context of melanoma by a general practitioner William Norris 
(Norris 1820) who arrived at the conclusion that melanoma is a disease controlled to 
some extent by heredity. In his 1820 manuscript, Norris wrote: ‘it is remarkable that 
this gentleman’s father...died of a similar disease. This tumour...originated in a mole 
and it is also worth mentioning that, not only my patient and his children had many 
moles..., but also his own father and brothers....These facts, together with a case that 
has come under my notice, rather similar, would incline me to believe that this 
disease is hereditary.’ This prescient statement is made all the more striking by the 
15 
fact that it was made nearly half of a century before the genetic paradigm was 
articulated by Gregor Johann Mendel in The Transactions of the Brunn Natural 
History Society in 1866 and 1869 [3]. 
 
1.2 EPIDEMIOLOGY OF MALIGNANT MELANOMA 
Malignant melanomas are the least common but most serious type of skin 
cancer, however they are now the most rapidly increasing cancer in the UK. Latest 
available figures at time of writing show that the total number of cases of malignant 
melanoma in the UK for all ages increased from 10,800 in 2007 to 11,700 in 2008 – 
a rise of 8.5 per cent, with alarming tripling in melanoma rates among British 15-34 
year olds since the late seventies. In the late seventies, there were around 290 cases 
of melanoma among 15-34 year-olds (Press Release, Cancer Research UK, 2011).  
According to these recent figures, although the rates are highest in the over 
75s, there is a substantial and increasing number of cases at younger adult age. 
Almost a third (31%) of all cases occur in people aged less than 50 years. This is an 
unusually young age distribution for an adult cancer and emphasises the importance 
of its prevention and early treatment to avert the potential loss of many years of life.  
Unlike most malignancies, malignant melanoma is more common in women 
than men. The rate of young women (15-34 year olds) in Britain being diagnosed 
with malignant melanoma now is 8.0 women per 100,000 (607 cases). This 
compares to 3.9 men per 100,000 (306) for the same age group. These rates and 
cases are based on a three year average from 2006-2008. Over a quarter of the cases 
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(256 out of 913) diagnosed in young adults were women between the ages of 30-34. 
Melanoma was the seventh most common cancer in 15-34 year olds in Britain thirty 
years ago, now it is the second most common for this age group (Average figures 
77-79 and 06-08). For all ages, melanoma is now the sixth most common cancer 
(Press Release, Cancer Research UK, 2011). 
This increase is not limited to the UK however with worldwide incidence of 
cutaneous melanoma increasing faster than any other cancer with an approximate 
doubling of rates every 10-20 years in countries with white populations [4].  
 
1.3 CLINICAL DIAGNOSIS 
 The seven-point checklist emphasising a history of change in size, shape and 
colour of a pre-existing pigmented lesion is recommended for use for both the 
patient and for General Practitioner [5] education to aid the clinical diagnosis and 
the referral process [6]. This checklist is based upon the definition of three major 
features and four minor features. 
 
Major features are:  
• Change in size;  
• Irregular shape;  
• Irregular colour.  
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Minor features are:  
• Largest diameter 7 mm or more;  
• Inflammation;  
• Oozing;  
• Change in sensation. 
Lesions with any of the major features or three minor ones are suspicious of 
melanoma [7]. Suspicious lesions should ideally be seen by specialists, that is, 
clinicians routinely treating large numbers of patients with pigmented lesions. 
Where suspicious lesions are biopsied they should be removed completely and sent 
for histopathological examination.  
Any patient with a pigmented lesion that the specialist feels is clinically 
suspicious of melanoma should have a full skin examination. The site and size of the 
pigmented lesion should be documented and a record should be made of other 
pigmented lesions. Clinical photographs may be helpful. The patient should be 
carefully examined for lymphadenopathy (palpable lymph nodes) and hepatomegaly 
(palpable, enlarged liver) to assess for any signs of distant spread of disease [8]. 
The relatively poor mortality rates for certain cancers in the UK in 
comparison to other European countries has been attributed, in part, to cancer 
patients in this country having more advanced disease by the time they receive 
treatment [9]. In 1999, the United Kingdom Government White Paper entitled ‘The 
new NHS – Modern, Dependable’ was drawn up in an effort to counter increasing 
NHS waiting lists and minimise delays between presentation, diagnosis and 
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treatment. The document pledged that every patient with a suspected cancer, should 
be able to see a specialist within two weeks of referral by their GP. It was introduced 
for carcinomas of the breast in April 1999 and extended to a range of other cancers, 
including melanoma in October 2000.  
Risk factors and referral guidelines for suspected cancers were drawn up by 
Working Parties appointed by the Department of Health for each individual cancer 
type and widely distributed to GPs and hospital trusts.  It is indeterminate however, 
the real impact of these guidelines on mortality. At time of writing, 10-year survival 
figures have yet to be published. The literature regarding changes in mortality 
remains limited and is currently in progress. One paper concluded that in the 
absence of 10 year survival data, provisionally, analysis of patients retrospectively 
over a 4 year period who had rapid access to a clinic to have their lesion reviewed by 
a specialist appeared to have thinner Breslow thickness melanomas at time of 
excision as well as improved survival times [9].  
 
1.4 HIGH RISK INDIVIDUALS 
1.4.1 ENVIRONMENTAL FACTORS: SUN EXPOSURE 
It is estimated that at least two-thirds of melanomas and 90% of non-
melanoma skin cancers are caused by sun exposure [10, 11]. Sun or ‘actinic’ damage 
is recognised as a major factor in the development of skin cancer. Sun-exposed skin 
represents the main sites of basal and squamous cell carcinoma [12]. Furthermore, in 
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the 1980’s, it emerged that many epidemiologic studies attested a direct relationship 
between actinic exposure and melanoma [13-19]. 
The ability to tan is one of the most important defences of the skin against 
developing a skin malignancy.  Tanning ability is directly related to the amount of 
melanin in a person’s skin, which in turn determines photosensitivity.   The 
damaging effects of ultraviolet (UV) radiation from the sun are attenuated through 
both reflection/refraction by the stratum corneum of the epidermis and through 
direct UV radiation absorption by the melanin pigment.  Tanning is the body’s 
protective response to UV rays as radiation damage is ameliorated by increasing 
melanin production and hence UV absorption by pigment. The number of melanin-
producing cells in the skin is genetically determined and cannot be externally 
manipulated.   
Fitzpatrick classified skin into six types according to melanin content, 
inherent pigmentation, and sensitivity to UV light (Figure 1). The lower the 
Fitzpatrick type, the less melanin pigment within the skin, therefore the most 
susceptible to damage from UV light[20]. 
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Figure 1 The Fitzpatrick Scale of Classification of Skin Type 
The electromagnetic spectrum consists of (in order of increasing wave 
frequency and decreasing wavelength) radio, infrared, visible light, ultraviolet, x-
ray, gamma ray, and cosmic ray waves (see Figure 2).  The ultraviolet band 
comprises the middle of the spectrum and is further divided into UVA (400–315 
nm), UVB (315–290nm), and UVC (290–200 nm) [20]. 
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Figure 2 The electromagnetic spectrum, illustrating the differing types of 
radiation and their corresponding wavelengths 
 
There are oncologically significant wavelengths in the ultraviolet spectrum as shown 
in Figure 2 and these have been strongly associated with the development of skin 
cancer[20].  The ozone-rich stratosphere effectively absorbs UV wavelengths below 
290 nm, so that only UVB and UVA reach the earth’s crust. Over 95% of solar UV 
radiation reaching the earth’s surface is in the UVA waveband; the rest is UVB. The 
solar radiation that penetrates the atmosphere is almost devoid of UVC[20]. UVB 
rays are the most carcinogenic and have the most profound effect on skin cells.  
UVB induces skin cancer through direct photochemical damage to cutaneous DNA, 
injury to DNA repair mechanisms, and partial suppression of cellular mediated 
immunity [21, 22]. Although UVA rays were initially thought to be harmless, they 
are now known to potentiate the effects of UVB and to act as a potential co-
10/11/2014 17:59Exploring the Power of UV Light: Types, Effects, and Utilization for Sanitization Purposes
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UV light is invisible to the eye, but greatly affects our world.
What Are the Pros & Cons of UV Light?
There are three types of UV light:
- UV-A (320-400 nm wavelength): This type of radiation can cause sunburn on the skin and
cataracts in the eye. However, it also plays a helpful and essential role in helping the body form
Vitamin D, which ensures that the body can absorb calcium to build strong bones. Vitamin D helps
muscles move, nerves transmit information, and the immune system fight off invading pathogens.
- UV-B (290-320 nm wavelength): This type of radiation can burn the skin or lead to skin cancer.
That “drained” feeling of being out in the sun for too long is often caused by too much UV-B
exposure. However, this ultraviolet light produces melanin in the body, which gives some people that
bronze “tanned” look, and also helps the body form essential Vitamin D.
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carcinogen [23]. Indeed, exposure to high doses of UVA for a significant time can 
induce cancer in laboratory mice [24]. 
Infrared energy also seems to accelerate the carcinogenic process: Animals 
kept in heated environments develop tumours more rapidly than those in temperate 
climates [12].  Whilst wind and high humidity also increase the amount of UV 
damage and rate of tumour formation [20].   
Although the sun is the natural source of UV radiation, the long-term effects 
of artificial UVA radiation from tanning lamps cannot be ignored [25]. UVC is a 
potent carcinogen but is fortunately filtered out by the ozone layer in our 
atmosphere. As the ozone layer thins from the use of fluorocarbons, more UVC will 
penetrate the atmosphere and UVC will become a new factor in the development of 
skin cancer.  The depleted ozone layer will also allow more UVB to reach the earth, 
potentially increasing skin cancer rates by the year 2050 [26].  
Risk of melanoma is most strongly linked to intermittent exposure to high-
intensity sunlight, often resulting in sunburn rather than to chronic exposure, typical 
of that received by people with outdoor occupations[27]. A history of sunburn 
doubles the risk of melanoma [28]. Furthermore, Holman et al, Armstrong et al and 
Lew et al found that painful or blistering sunburn during childhood and adolescence 
was associated with subsequent increased risk of developing cutaneous 
melanoma[10, 17, 19].  
Furthermore, there are racial and ethnic trends within the incidence and 
survival rates of patients who are diagnosed with cutaneous malignant melanoma. A 
recent paper which compared melanoma rates and survival amongst differing ethnic 
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groups in America found that although the numbers of non white patients were still 
relatively small despite broad population coverage (67% of United States), the high 
percentages of advanced and thicker melanomas among nonwhites highlight the 
need to improve melanoma awareness for all races and ethnicities. This was likely to 
be due to the most common histological type of melanoma being acral lentiginous 
melanoma among blacks (higher mortality rates associated with this type) and 
superficial spreading melanoma among all other racial and ethnic groups [29]. 
 
Melanomas are most common on the skin of the head and neck and least 
common in body areas covered by clothing.  Women have a relatively higher 
incidence of lower extremity melanomas than men, whereas melanomas of the trunk 
are proportionately more frequent in men than in women[13, 14]. The reasons for 
this distribution have been suggested as patterns of sun exposure. 
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1.4.2 HOST RISK FACTORS: PRE-EXISTING LESIONS OR MEDICAL HISTORY 
 
People with a large number of naevi or just one or more unusually shaped or 
large moles, have an increased risk of melanoma [27]. This risk further increases 
with the number of moles. People with very high numbers (100+) of common moles 
on their bodies have nearly seven times the risk compared to people with very few 
(0-15 moles) [27]. People with dysplastic naevi and a family history of melanoma 
(dysplastic mole syndrome) have a 500-fold increased risk of developing 
melanoma[30].  
Another group at greatly increased risk of melanoma (quoted in some studies 
to be at least 100 times that of the general population) are patients with giant 
congenital melanocytic (pigmented) hairy naevi [31, 32]. Data regarding these naevi 
varies however and needs to be interpreted carefully. Multiple definitions have been 
used to classify congenital pigmented naevi into small, medium, or giant. These 
include diameter size, total body surface area (TBSA), and ability to excise in one 
surgical setting. Based on diameter, these naevi are characterized as small (< 1.5 
cm), medium (1.5-19.5 cm), and large or giant (>20 cm in adolescents and adults or 
predicted to reach 20 cm by adulthood)[20]. An expert should monitor these patients 
throughout their lifetime because of the risk of malignant change, which is 
significant but poorly quantified. Excision biopsy of suspicious areas in large 
congenital naevi may be necessary but requires expert histopathological review. By 
25 
contrast, surgical excision of small congenital naevi is not considered necessary in 
the absence of suspicious features[20].  
First-degree relatives of patients with melanomas are at increased risk of 
developing melanoma themselves [33-35]. At some time during the life of a 
melanoma patient, 5% to 11% will have a family member with a melanoma [36, 37]. 
The lifetime risk of developing a second primary melanoma is approximately 4% to 
6% and is actually higher in patients with dysplastic naevi or a strong family history 
of melanoma[36, 38]. Patients with a previous melanoma may also be at slightly 
increased risk for other non-melanoma, invasive non-cutaneous malignancies [39]. 
One such example is the reported association of familial malignant melanoma with 
pancreatic cancer due to p16 mutations[40]. 
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1.5 TYPES OF MALIGNANT MELANOMA 
 There are differing growth patterns described within cutaneous melanoma: 
superficial spreading melanoma (SSM), nodular melanoma [41], lentigo maligna 
(LM), and acral lentiginous melanoma [42] as well as the least common 
desmoplastic and amelanotic types. These are all distinct pathological entities with 
different prognoses and clinical courses, however in the current guidelines for 
management of malignant melanoma, the pathological subtype does not specifically 
affect the management plan.[30, 43].   
 
27 
1.5.1 SUPERFICIAL SPREADING MELANOMA (SSM) 
 SSM accounts for approximately 70% of primary melanoma [30]. It usually 
arises from a pre-existing naevus and exhibits a slow growth over years (in a 
horizontal growth phase) followed by rapid changes (of vertical growth) in the 
weeks preceding diagnosis. It is more common on the backs of men and the legs of 
women. The appearance is often one of irregular dark pigmentation within the 
brown of a junctional naevus. Initially the lesion is flat but progression is associated 
with scaling and crusting. (See figure 3). The formation of a central nodule confirms 
vertical growth and there may be areas of lighter skin due to the amelanosis of 
regression and a surrounding pink halo [44].  
 
1.5.2 NODULAR MELANOMA [41] 
 15-30% of melanomas are nodular [45]. They are typically blue- black nodules 
or papules often resembling a blood blister. (See figure 3). 
Nodular melanomas lack the horizontal growth phase and hence have a sharply 
demarcated boundary. 5% are amelanotic [20]. 
1.5.3 LENTIGO MALIGNA (LM) 
 4-10% of melanomas are lentigo maligna- LM (in situ and preinvasive). They 
have the distinct appearance of a skin stain in multiple shades of brown. (See figure 
3).  They are found on sun-exposed areas such as the face and are seen in the elderly 
most commonly [20]. Vertical growth (Lentigo Maligna Melanoma- LMM) 
 28 
develops in up to 50% of LM lesions. These tumours follow a more indolent course 
over 5-15 years with a low metastatic rate.  
 
1.5.4 ACRAL LENTIGINOUS MELANOMA [42] 
 These are seen most commonly on the soles of the feet and palms of the hands 
and nail beds. (See figure 3).  They account for only 2-8% of melanoma in whites 
but 35-60% in blacks, Asians and Hispanics [20]. There is no difference in the 
incidence of plantar melanomas between whites and blacks, but blacks have less 
melanoma elsewhere [46]. Tumours are usually large and flat (average diameter 
3cm) with an irregular border and multiple shades of colour. These are generally 
more aggressive in their behaviour. 
 
1.5.5 DESMOPLASTIC MELANOMA 
 1% of cases are desmoplastic. This rare variation presents as an innocuous 
amelanotic lesion of the head and neck. It tends to perineural invasion.  
 
1.5.6 AMELANOTIC MELANOMA 
 There is no identifiable pigment to amelanotic melanoma and hence 
immunohistochemistry is required to diagnose these tumours. They tend to be in the 
vertical growth phase by the time of diagnosis and mimic other cutaneous 
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malignancies [20]. 
  
Figure 3, Superficial Spreading Melanoma (A), Nodular Melanoma (B), 
Lentigo Maligna Melanoma (C), Acral Lentiginous Melanoma (D) 
 (Photos by the author) 
 
 
!
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1.6 PROGNOSIS 
1.6.1 DEPTH OF TUMOUR INVASION 
 At present, the most widely cited prognostic indicator for recurrence or 
metastatic spread of melanoma is the thickness of the primary lesion. This was first 
described by Breslow in 1970 and still remains one of the most accurate 
microstaging techniques [47]. This measure describes the absolute thickness of the 
primary tumour, with measurements being taken from the upper granular layer of the 
epidermis, down to the deepest point of the tumour (deepest melanocyte detection). 
Tumour thickness correlates well with the 10-year survival rate (see table below).  
Approximately 92% of patients with a melanoma <0.76mm thick will survive 10 
years, compared to a 50% survival rate for patients with lesions >3mm thick [48]. 
As a result, tumours are frequently categorized and defined as thick (>4.0mm thick), 
intermediate (1.0-4.0mm) and thin (<1.0mm) [49]. This helps to easily give an 
approximate guide to outcome when giving patients prognostic information. 
 
 Although thin melanomas are considered to be of very low metastatic risk, 
15% of thin lesions still go on to nodal metastasis, and there are no prognostic 
indicators to predict which patients this will affect [10]. At the other extreme, 
there are no prognostic indicators available to predict which of the 30% of 
patients with a thick melanoma will remain disease free at 5 years [50](Heaton 
et al., 1998).  
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 As the degree of penetration through the skin layers by the primary lesion, as 
well as the absolute [47] thickness, became associated with metastatic potential, the 
histological level of invasion also become part of routine determination of 
melanoma prognosis [51]. This work determined that the histological level of 
invasion into the skin is an important factor in determining prognosis. A 
classification system which involved determining which of the five anatomical 
levels of the skin are involved in the invasion of the tumour was developed, which 
clearly correlated increasing invasion of the skin with decreasing patient survival 
[51].  
 Tumours occupying just the epidermis with no signs of invasion of the 
basement membrane (i.e. in situ melanomas), are described as Clark level I. Once 
tumours have extended into the papillary dermis or adventitial dermis around skin 
appendages, they are described as level II. Further progression to fill the papillary 
dermis is described as Clark’s level III, with spread into the reticular dermis 
representing Clark’s level IV and finally invasion into subcutaneous fat representing 
Clark’s level V (See figure 4). Despite these clear divisions in histological invasion, 
within each Clark’s level, tumours still present with wide ranging values for absolute 
thickness (for example, the thickness of the dermis varies throughout the body), and 
also within each level, differing tumours can show differing metastatic potential 
independent of the Clark’s level [52] It is interesting to note that the most recent UK 
melanoma guidelines no longer utilise Clarks’ as part of the minimum data set [53]. 
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Level I 
In situ. All the tumour cells are above the basement 
membrane - i.e. the tumour is confined entirely to the 
epidermis. 
Level II 
Papillary dermis level. Tumour cells have broken through 
the basement membrane and extended into the papillary 
dermis, but have not reached the reticular dermis for the 
most part. Only an occasional cell or small nest of cells 
may extend to the reticular dermis. 
Level III 
Papillary-reticular dermis level. Tumour cells are widely 
impinging upon, but not invading the reticular dermis. 
Level IV 
Reticular dermis level. Melanoma cells have invaded the 
reticular dermis, and tumour cells can be seen between 
collagen bundles. 
Level V 
Subcutaneous level. Tumour has invaded the subcutaneous 
tissue. 
 
Figure 4 Clark's Level- Clark’s level provides a means of classifying penetration of 
the primary lesion through the skin according to five anatomical levels of invasion. 
Clark’s level 1-V. Figure adapted from McGovern et al. 1973 and Anderson 2000. 
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1.6.2 PRESENCE OF ULCERATION 
 The presence of ulceration has also been described as a marker of poor 
prognosis, which is independent of the extent of the invasion through the skin layers 
by the primary lesion in both patients presenting with and without nodal metastases 
[48, 54, 55]. Balch et al., (1985) reported that in a cohort of clinically and 
histologically matched patients, the presence of horizontal ulceration of greater than 
3mm reduced 10-year survival from 78% to 50% compared to patients free from any 
ulceration [56]. However the presence of ulceration is still only indicative of poorer 
outcome, correlating with reduced 10 year survival rates rather than offering a firm 
marker that a patient will later develop metastases. The most recent melanoma 
guidelines recommend that the presence of ulceration ‘upstages’ patients for every 
‘T’ stage (see section 1.6.3.1.) below [53]. 
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1.6.3 STAGING OF MALIGNANCIES 
It is widely recognized that accurate classification and staging of cancer is an 
invaluable aid to ensuring that patients receive optimum treatment in accordance 
with the characteristics of their disease in progress. Established staging criteria 
permit physicians to stratify their patients accurately and deliver the most effective 
therapies in accordance with the best available medical evidence across a broad 
range of disease types and states. In addition to providing a useful guide for 
determining treatments and prognoses, cancer staging serves as a common, 
international language that facilitates standardisation and design of clinical trials and 
interpretation of study results.  Thus, it is to the benefit of all that oncology 
researchers and clinicians alike maintain a thorough understanding of this unique 
language of cancer care.  Cancer staging is used initially to describe the anatomic 
extent of primary disease at diagnosis, before definitive treatment, and subsequent 
response to therapeutic intervention or disease progression.  This achieves many 
purposes:  
 
1. The extent of disease at a particular time in its progression can be described 
briefly and accurately to other physicians.  
 
2. Cancers at different stages in their natural history have been found to respond 
differently to the same treatment; thus, treatments are selected according to cancer 
stage.  If current data demonstrate that a given cancer at a certain stage does not 
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respond to a particular therapy, the patient is spared the consequences of enduring 
unnecessary treatment.  
 
3. Post-treatment staging can be compared to pre-treatment staging to determine 
efficacy.   
 
1.6.3.1 STAGING NOTATION  
Staging taxonomy is a form of shorthand that reveals important disease 
characteristics at a glance.  Most physicians use guidelines developed by the 
American Joint Committee on Cancer (AJCC) to determine cancer stage [57]. The 
AJCC uses three factors to describe the most significant events in the history of a 
cancer; local tumour growth (T), spread to regional lymph nodes (N), and distant 
metastasis (M). The characteristics of these three parameters determine the overall 
disease stage; Stages I – IV. This system is commonly referred to as the TNM 
staging method.   
 
Step 1: T classification  
T classification describes the size of primary tumour.  The exact 
classification is specified in more detail according to primary site (i.e., skin, lung, 
breast, oesophagus, etc.), but in general, the notation is as follows:  
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TX: The extension of tumour cannot be determined or was not documented in 
patient records.  
T0: No evidence of primary tumour  
Tis (in situ): The tumour is non-invasive (has not spread to surrounding 
layers/structures)  
T1-T4: Extent of invasion into surrounding layers/structures; the higher the number, 
the further the invasion.   
 
 Step 2: N classification  
N classification describes extent of spread to nearby (regional) lymph nodes. 
Whether or not a lymph node is regional is defined by primary tumour site.  
 
NX: Extent of spread to regional lymph nodes cannot be determined, or was not 
documented in patient records.   
N0: No spread to regional lymph nodes  
N1: Cancer has spread to regional lymph nodes.  
Depending on the primary tumour site, the number can proceed upward to N4 
(reflecting the location and number of affected lymph nodes).  
 
Step 3: M classification  
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M classification describes the extent of spread to distant organs (distant 
metastasis).  
MX: Extent of distant metastasis cannot be determined, or was not documented in 
patient records.  
M0: No distant metastasis  
M1: Distant metastasis is present.  
 
Step 4: Stage classification  
Finally, the stage number is assigned depending on the specific permutation 
of T, N, and M classifications.  The stage number ranges from Stage I to IV (Roman 
numerals are used when designating cancer stage), with Stage I cancer being the 
least advanced.  Stage can also be further grouped into subcategories; however, 
upper-case letters are used (i.e., Stage IIA, Stage IIIB, etc.).  When sub 
classifications are available and the correct subset cannot be determined, NOS (not 
otherwise specified) is used.  
 
1.6.3.2   METHODS OF STAGING  
 
Two primary methods are used to evaluate staging; clinical and pathological.   
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Clinical staging relies on an assessment by the oncologist based on history, physical 
examination, imaging tests to determine potential extent of the disease (i.e., 
magnetic resonance imaging [MRI], computed tomography [CT] scan, plain films, 
etc.), and laboratory tests.  The pathologist usually determines pathologic staging, 
and it is based on the biopsied sample of the tumour. 
 
Despite the flaws which exist in Breslow and Clark’s systems in accurately 
determining prognosis and potential of a tumour, Breslow thickness, these two 
parameters as well as the presence of ulceration currently form the basis of 
prognosis and melanoma staging. 
The AJCC published staging guidelines in 2001 and further revised them in 
2002 and then, most recently 2009 [53] (see Table 1 below which highlights the 
differences with each revision). The most recent melanoma staging 
recommendations were made on the basis of a multivariate analysis of 30,946 
patients with stages I, II, and III melanoma and 7,972 patients with stage IV 
melanoma to revise and clarify TNM classifications and stage grouping criteria. 
 
Findings and new definitions included the following:  
 
(1) In patients with localised melanoma, tumour thickness, mitotic rate 
(histologically defined as mitoses/mm2), and ulceration were the most dominant 
prognostic factors[53].  
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(2) Mitotic rate replaces level of invasion as a primary criterion for defining T1b 
melanomas.  
 
(3) Among the 3,307 patients with regional metastases, components that defined the 
N category were the number of metastatic nodes, tumour burden, and ulceration of 
the primary melanoma.  
 
(4) For staging purposes, all patients with microscopic nodal metastases, regardless 
of extent of tumour burden, are classified as stage III. Micrometastases detected by 
immunohistochemistry are specifically included.  
 
(5) On the basis of a multivariate analysis of patients with distant metastases, the 
two dominant components in defining the M category continue to be the site of 
distant metastases (nonvisceral v lung v all other visceral metastatic sites) and an 
elevated serum lactate dehydrogenase level.  
 40 
 
Table 1 AJCC editions and their evolvement (Adapted from Marsden et al. 
2010) 
 
Although this system is widely used and accepted in the UK, it does not 
provide an accurate means of predicting which patients will later develop nodal or 
distant metastases if at initial diagnosis they are metastasis free. For example, 
patients classified as IA, i.e. with a primary tumour of <1mm thick, Clark’s level 
II/III, no signs of ulceration and no metastases who should expect the best prognosis 
according to the staging system, will still show a 12% mortality rate at 10 years [58]. 
Therefore it is apparent that a significant proportion (over 1 in 10) of patients who 
we see as clinicians, and often reassure that they are in the best subset of melanoma 
patients in terms of prognosis, will still develop further disease, either in the nodal 
10/11/2014 17:47Melanoma Molecular Map Project
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Table 2: Differences between the previous (6th edition, 2001) and the
current (7th edition, 2010) AJCC TNM staging systems.
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basin or distant disease to other organs. We have no way of knowing at present 
which patients this will affect. 
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 Other factors that have been described to affect prognosis in melanoma 
patients are; age, sex and anatomical site affected (though much to a lesser extent). 
Despite differing distribution of sites affected, women appear to have better 
prognosis and overall survival seems to be better (despite higher incidence levels in 
some age categories). Women are also at an advantage that they are more likely to 
display low-level invasion and no ulceration, perhaps reflecting better self-
examination and vigilance. In the case of anatomic site, extremity melanomas seem 
to predict better survival than axial lesions, whilst primary tumours of the head and 
neck seem to predict poorer outcomes [48, 55, 59, 60].  
 
1.7 MELANOMA METASTASIS 
 The tumour begins with a horizontal growth phase (Breslow vertical tumour 
thickness <0.75mm) that has a low metastatic potential, and it is the progression to 
vertical growth (Breslow vertical tumour thickness >0.75mm) that heralds a distinct 
change in tumour behaviour and the invasion of the lymphatic bed [61-63].  From 
this stage, melanoma has a distinct pattern of spread from a primary tumour, to 
regional lymph nodes and on to distant sites [64].  
 As early as 1907, William Sampson Handley recommended regional lymph 
node dissection as part of routine melanoma treatment, following recognition of the 
importance of the lymphatics in dissemination of these tumours [20]. The presence 
of lymph node metastasis reduces overall survival at 10 years to only 35%, and in 
70-85% of patients, it is an indicator of distant metastases [65]. 
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 Metastases can occur at either distant sites or loco-regional areas as detailed by 
the AJCC staging system. This included satellite metastases, within 2cm of the 
primary lesion, in-transit metastases within the drainage area of the nearest regional 
lymph node, or regional lymph node metastases. The dormancy period of metastatic 
tumour cells can vary hugely, and a clear difference is seen between distant 
metastases, occurring a median of 24-25 months later, and loco-regional metastases, 
occurring 16-19 months later [66]. There is currently no way of predicting which 
patients will develop these metastases or where they will occur. 
 Haematogenous spread is spread of melanoma cells in the blood stream which 
can happen either by a tumour invading blood vessels or secondary to lymph node 
involvement[20].  Once in the blood stream, melanoma cells can travel to distant 
sites within the body and deposit. These cells can theoretically proliferate in any 
tissue but most often grow in the lungs, liver, brain and distant areas of the skin [67-
69]. It is possible that in those patients who express distant metastases without any 
evidence of prior lymph node involvement, loco-regional metastases are present but 
are present as ‘micro-metastases’, which could be missed by histopathological 
sampling. Recent studies have shown in nearly half of all patients, the first 
demonstrated site of metastasis is the regional lymph node [70] and this is the 
pattern of metastasis that has formed the foundations for the wide spread belief that 
melanoma undergoes dissemination via the lymphatic vasculature [71]. 
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1.8 RELEVANCE OF LYMPHANGIOGENESIS AND ANGIOGENESIS: 
WHY IS IT IMPORTANT TO LOOK MORE CLOSELY AT LYMPHATICS AND 
BLOOD VESSELS IN THE ROLE OF TUMOUR GROWTH AND SPREAD?  
 
1.8.1 ANGIOGENESIS 
 
Mammalian cells require oxygen and nutrients for their survival and are 
therefore located within 100 to 200µm of blood vessels (the diffusion limit for 
oxygen). For multi-cellular organisms to grow beyond this size, they must recruit 
new blood vessels by angiogenesis [72]. The observation that angiogenesis occurs 
around tumours was made over 100 years ago [73]. The hypothesis that tumours 
produce a diffusible ‘angiogenic’ substance was put forward in 1968 [74, 75]. In 
1971, Folkman proposed that tumour growth and metastasis are angiogenesis-
dependent, and hence, blocking angiogenesis could be a strategy to arrest tumour 
growth [76]. This possibility stimulated an intensive search for pro- and anti-
angiogenic molecules[72].  
In 1978, Gullino showed that cells in pre-cancerous tissue acquire angiogenic 
capacity on their way to becoming cancerous [77], and he proposed that this concept 
could be used to design strategies to prevent cancer.  
Vascular Endothelial Growth Factor (VEGF) is a potent stimulator of 
angiogenesis and lymphangiogenesis. VEGF has been found to be present in high 
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levels in almost all types of solid cancer. The traditional forms of VEGF are all pro-
angiogenic, however a novel group of sister isoforms have been found which cause 
VEGF to work in the opposite way and inhibit angiogenesis and therefore tumour 
progression [78]. In malignant melanoma it has recently been demonstrated that 
increased expression of anti-angiogenic isoforms of VEGF correlates with reduced 
spread of the disease and increased survival[79] (see section 1.9 below). Inhibition 
of VEGF with the use of monoclonal antibodies has been shown to be effective in 
increasing the median survival in metastatic colorectal cancer when combined with 
chemotherapy [80]. One such licensed drug is bevacizumab. At time of writing, the 
AVAST-M trial interim results were made available by Corrie et. al 2014[81]. 
Bevacizumab is a monoclonal antibody that targets VEGF and was used to treat 
patients with resected melanoma (AJCC stage IIb and above) who were at high risk 
of recurrence in this multicentre randomised controlled trial across 48 centres in the 
UK between 2007 and 2012. 1343 patients were recruited and randomised either to 
bevacizumab treatment every 3 weeks for 1 year (n=671) or observation alone 
(n=672). Although 5 year follow up results are still awaited, the interim results were 
published with a median follow up time of 25 months for both groups. End points 
examined were overall survival, disease free survival, distant metastases interval and 
quality of life. No significant differences between the groups were noted with regard 
to overall survival, distant metastases free interval or quality of life. A significant 
improvement was noticed in the AVAST-M group with regard to disease free 
survival and overall the treatment was well toleratied with only 3 adverse drug 
reactions being reported. Interpretation of these interim findings suggest that 
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Bevacizumab has promising tolerability and a longer follow up is needed to identify 
any effect on overall survival.  
 
1.8.2 LYMPHATIC VESSEL DENSITIES 
Lymphatic density, Breslow thickness and the presence or absence of 
lymphatic invasion combined has been proposed previously by Shields et al to be a 
prognostic indicator of metastasis[82]. The authors recognised that in the samples of 
a small cohort of 21 patients, there was a clear difference in the patterns of 
lymphatic vessel density (LVD) surrounding primary malignant melanomas which 
developed lymphatic metastases versus those tumours which did not metastasise. 
The authors developed a prognostic index which considered the variables of tumour 
thickness, LVD and lymphatic invasion to generate a more efficient predictor. Using 
this Shields’ Index, it was possible to differentiate tumours which metastasised from 
those which did not. Emmett et al. undertook a retrospective analysis of 102 
malignant melanomas from patients with more than 5 years follow up to evaluate the 
Shields’ on a larger scale and to compare with existing indicators[83]. It was found 
that the Shields’ index accurately predicted outcome in 90% of patients with 
metastases and 84% of patients without metastases. For these, Shields’ index was 
more predictive than Breslow thickness or LVD. This non invasive analysis was 
concluded to be a simple and useful prognostic tool in determining onward spread 
and therefore prognosis. More recently Buzrla et al. investigated density of 
intratumoural and peritumoural lymphatic vessels in primary cutaneous melanomas 
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and assessed their correlation with SLN status and VEGF expression within the 
tumour and stroma[84]. There were 20 SLN positive patients and 20 SLN negative 
patients and  results showed that the density of lymphangiogenesis and the intensity 
of VEGF expression were unreliable predictors of melanoma metastasis to the SLN 
however ulceration and lymphatic invasion was seen in the small sub-cohort of 4 
patients where a trend was noted that these factors may predict the potential for 
metastasis[84]. 
1.8.3 VEGF MOLECULAR AND BIOLOGICAL PROPERTIES 
VEGF is a regulator of both physiological and pathological angiogenesis.   
Physiological activity of VEGF is a crucial element of embryonic development, (the 
loss of even a single VEGF allele is lethal to the embryo) and in pathological states, 
is implicated in every leading cause of mortality in the Western world-heart disease, 
cancer, stroke, and diabetes[85].   
The human VEGF gene is located on chromosome 6p21.3 with a coding 
region spanning approximately 14kb [86]. It is a mitogen for vascular endothelial 
cells from arteries, veins and lymphatics.  Activity in other cell types is significantly 
reduced.   The activity of VEGF is not limited to angiogenesis alone.  It is also 
responsible for increased vessel permeability [87].  Increased calcium influx leads to 
altered hydraulic conductivity [88]. The induced plasma protein leakage results in 
the formation of an extravascular fibronectin gel-which forms an ideal environment 
for endothelial and tumour cell growth. 
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VEGF is specific to endothelial cells and exists in at least 7 forms/families-
VEGF A, B, C, D, E and Placental Growth Factor (PlGF).  VEGF-A comprises two 
families of VEGF made up of both cell associated and soluble isoforms, regulated 
by splicing during transcription from 8 exons, to result in mRNAs encoding a large 
variety proteins which are termed according to the amino acid number in their 
composition: VEGF121, VEGF145,VEGF165 (the dominant isoform), 
VEGF189,VEGF206 [87]. Bates et al.[78] have reported the previously unknown 
existence of splice variants that are antiangiogenic in their behaviour. These variants 
are formed by the use of a distal splice acceptor site in the terminal exon 8 of the 
VEGF-A gene encoding a second open reading frame of identical length to the 
classical, proximally spliced isoforms, and resulting in proteins of the same length, 
but with an alternate C-terminus. The mRNA encoding this isoforms is termed 
VEGF165b [78] (Figure 5), has been demonstrated in renal cortical tissue, and almost 
all other normal tissues examined.  
Subsequent work has identified other isoforms using this distal splice site 
(DSS), including VEGF121b, VEGF189b and VEGF145b in normal human tissues [89, 
90]. This alternative family of isoforms is termed the VEGFxxxb family, in contrast 
with the VEGFxxx family where xxx again denotes the amino-acid number [90]. 
Expression of VEGF165b mRNA was down-regulated in renal cell carcinoma [78], 
prostate cancer [89], and the vitreous of patients with diabetic retinopathy [90], all 
angiogenic conditions. This provides a credible explanation for tumour behaviour 
that by down regulating this ‘gate-keeper’ of angiogenic behaviour, the tumour is 
free to grow, invade and metastasise.  
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This new family of sister isoforms and their specific relevance to malignant 
melanoma will be discussed in more detail below in section 1.9. Further general 
relevant properties of these isoforms are as follows. The larger variants have affinity 
for heparin sulphate proteoglycans by virtue of a heparin binding domain. A 
proteoglycan is a heavily glycosylated protein (polysaccharide-protein conjugate) 
present usually in connective tissue and cartilage, consisting of a polypeptide 
backbone to which many glycosaminoglycan chains are covalently linked; they form 
the ground substance in the extracellular matrix of connective tissue and also have 
lubricant and support functions. The variant isoforms also bind to the co-receptors 
neuropilin-1 and neuropilin –2. Neuropilin receptors are proteins that in humans are 
encoded by the NRP1 and NRP2 genes [91].  
NRP1 and NRP2 are a membrane-bound co-receptor to a tyrosine kinase 
receptor for both VEGF and semaphorin (a class of secreted and membrane proteins 
that act as axonal growth cone guidance molecules) family members.  Of the VEGF-
A isoforms VEGF165 and VEGF121 are the most potent proangiogenic isoforms[92].  
Native VEGF165 is a basic, heparin-binding, homodimeric glycoprotein of 
45kDa [92]. The members of the VEGF family utilize one or more of three receptors 
of the tyrosine kinase family, VEFGR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR-3 
(Flt-4). VEGF-A is a ligand for receptors VEGFR-1 and VEGFR-2 and induces 
endothelial cells to proliferate in vitro, produce tissue factor, ultimately leading to 
the conversion of fibrinogen to fibrin, and induce expression of proteases[85]. 
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Figure 5 Angiogenic and Anti-angiogenic isoforms of VEGF-A. Selection of 
either the proximal or distal splice site results in two sister families of VEGF-A 
isoforms, only differing in the last six amino acids. Adapted from Woolard et 
al., 2004 
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1.9 VEGF AND MELANOMA 
 
The role of VEGF in melanoma is not as straightforward as has been 
demonstrated with other tumours.  The literature is littered with contradictory data 
regarding the expression of VEGF in primary and metastatic melanoma. Malignant 
melanoma is known to express increased levels of VEGF, in particular VEGF165 and 
VEGF121 [93].  These isoforms have been shown to be up-regulated in both the 
horizontal and vertical phases of melanoma growth, and lymph node metastasis [93].  
Other authors however have found it difficult to show up-regulation of VEGF 
expression in melanoma [94].   
VEGF expression appears to be related to the switch from horizontal to 
vertical growth phase when immunohistochemical analyses are employed [95], but 
neither serum nor tumour VEGF-A levels have been shown to be independent 
prognostic factors in melanoma [96-98]. In fact one study found that only 20% of 
melanomas over-express VEGF-A [99]. 
Normal skin is known to constitutively express VEGF in small amounts and 
can be difficult to detect [41].  The VEGF is found in the endothelial cells within the 
dermis and not the keratinocytes of the epidermis itself [100]. VEGF has been seen 
in the cytoplasmic staining of 32% of primary melanoma samples where no 
expression could be found in benign naevi[100].  Within those tumour samples 
showing VEGF expression, staining was seen in the inflammatory cells infiltrating 
the tumour, and tumour microvessel endothelium.  Ninety one percent of metastatic 
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melanoma samples expressed VEGF [100].  Once again all the tumour inflammatory 
cells and microvessel endothelia expressed VEGF.  Also, increased numbers of 
tumour inflammatory cells were seen [100].  This highlighted the possible role for 
the VEGF expressing tumour-infiltrating-inflammatory cell in promoting 
tumourogenesis, angiogenesis and progression. The expression of functional VEGF 
receptors on melanoma cells raised the possibility that the tumour exerts an 
autocrine effect upon itself. 
  None of these studies had recognised the inhibitory VEGFxxxb isoforms and 
hence do not make any examination of the balance of angiogenic factors [79]. 
Pritchard Jones et al. (2007) determined whether specifically VEGFxxxb isoform 
expression was altered in melanoma using PCR and immunohistochemistry of 
archived human tumour samples[79]. In normal epidermis and in a proportion of 
melanoma samples, VEGFxxxb staining was seen. Some melanomas however had 
much weaker staining. Subsequent examination of tumours and correlating this to 
metastatic outcome (defined by authors as nodal spread) revealed that expression 
was significantly reduced in primary melanoma samples (both horizontal and 
vertical growth phases) from patients who subsequently developed tumour 
metastasis compared with those who did not. This work demonstrated for the first 
time, the important role which the balance of angiogenic factors may play within 
tumour growth and metastasis but also highlight that there are certain questions such 
as the role of the lymphatic system within this relationship, which remain 
unanswered. For example, can a tumour and its relative balance of pro and anti-
angiogenic VEGF impact on the behaviour of the lymphatics? 
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1.10 THE LYMPHATIC VASCULATURE AND LYMPHANGIOGENESIS  
 
The mechanisms of angiogenesis have been studied extensively over the past 
years. The focus, however, has been almost exclusively on blood vessels, whereas 
less effort has been directed toward understanding lymphangiogenesis and the role 
of lymphatic vessels in physiology and pathology. The lymphatic system, acting in 
concert with the blood vascular system, is of fundamental importance in maintaining 
tissue homeostasis, and disorders of the lymphatic system are common, often 
resulting in chronic, disabling conditions[101]. Although structurally two distinct 
systems, the blood and lymphatic vascular system are functionally interconnected 
and act together to ensure fluid and protein balance in tissues, cell nutrition, proper 
immunologic functioning, etc[101]. In many ways the lymphatic system 
complements the blood vascular system. Thus, it is most likely that their growth and 
functions are regulated in concert. The regulatory mechanisms and structural 
elements shared by and distinct to the lymphatic versus blood vascular system are 
only beginning to be disclosed.  
The lymphatic vascular system consists of a series of blind-ending vessels 
which allow unidirectional flow of fluid and work in unison with the blood 
vasculature in order to maintain tissue homeostasis[101-103]. The lymphatic system 
is of fundamental importance for the normal maintenance of fluid balance in tissues. 
In the course of a day, 50% of the total circulating protein escapes from the blood 
vessels cannot be reabsorbed. Therefore, return of the extravasated fluid and 
macromolecules into the blood stream is crucial for the maintenance of plasma 
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volume and to prevent an increase in tissue pressure. Furthermore, consistent 
clearance of excess fluid from the interstitium assures adequate cell nutrition by 
keeping the distances between cells and capillaries to a minimum.  
The lymphatic system is also involved in the response of the organism to 
infection. Lymphatic vessels direct antigen-presenting cells to the lymph nodes and 
are thus essential for the development of cellular immunity. In the skin, lymphatic 
vessels are an important exit path for Langerhans cells. Impairment of lymphatic 
functioning, e.g., inadequate transport of fluid, macromolecules, or cells from the 
interstitium, leads to a number of diseases that are characterised by oedema, 
impaired immunity, and fibrosis[101].  
The lymphatics collect the net flux of exudates and return them to the blood 
via the thoracic duct [104]. These macromolecules include around 50% of 
circulating proteins, which are lost from the blood each day, and fat that is absorbed 
by the gastrointestinal tract.  
The lymphatic capillaries only have a single layer of lymphatic endothelial 
cells and lack both the smooth muscle cells and pericytes of the blood vasculature 
[105]. In contrast to the blood vasculature, the basement membrane is incomplete 
and tight intercellular junctions only occur focally rather than forming a continual 
boundary between adjacent cells[105]. The lymphatics are also different to blood 
vessels due to their close association with the surrounding tissues. Elastic anchoring 
fibres between the endothelial cells and the collagen fibres of the extracellular 
matrix not only provide support and structure, they are crucial to regulation of vessel 
lumen size[101]. When interstitial pressure rises around the lymphatic, these 
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anchoring filaments are put under increased strain. As a result, they pull upon the 
endothelial cells and cause the lymphatic vessel lumens to increase in diameter. The 
endothelial cells are pulled apart effectively opening intercellular valves, formed by 
overlapping of adjacent cells [105]. Therefore fluid and macromolecules enter into 
the lymphatic lumen, and when the pressure subsides again, the valves close over 
preventing any back flow [102].  
Despite knowledge that the lymphatic system is distinct from the vascular 
system in a number of ways, it is only recently that molecular markers have become 
available to distinguish lymphatic from vascular structures. The understanding of 
lymphatic biology has expanded rapidly with the discovery of the lymphangiogenic 
proteins VEGF C and D and their cognate receptor VEGF-R3[106, 107]. They are 
members of the VEGF family of growth factors, having 40% homology with VEGF-
A, and their importance in lymph vasculature biology is well demonstrated by the 
finding that VEGF-C null mice die as a result of abnormal lymphatic 
development[108]. Increasingly it has become clear that the biological role of these 
VEGF proteins have expanded beyond effects on the lymphatic endothelium alone 
to include the peri-lymphatic milieu and the investing immature vascular smooth 
muscle or pericytes[109]. Furthermore, they have now been implicated in both 
pathogenic and non-pathogenic human processes including cancer growth and 
metastasis, wound healing, and immune regulation. 
As stated above, the lymphatic endothelial cell (LEC) is distinct from blood 
vessel endothelium with respect to their biological function, structure, and protein 
repertoire. As such they represent a unique cell that may play a distinctive role in the 
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pathogenesis of human disease. It is clear that along with VEGF, pericyte-
endothelial cell interactions play an important role in modulating vascular 
biology[109]. These interactions have been termed as ‘cross-talk’ and have been 
explained by activation of the signalling intermediates such as Akt/mTOR/S6[110]. 
 
1.11 LYMPHATIC METASTASIS 
 
 There are several possible mechanisms to explain lymphatogenous metastasis. 
Firstly, tumour cells may migrate into pre-existing lymphatics that have been 
encompassed during the growth of the primary lesion. Alternatively, malignant cells 
may migrate out of the tumour to invade pre-existing epi-tumoural lymphatics 
within the normal tissue. Finally, the tumour may produce specific growth factors 
that stimulate the development of new lymphatic vessels either within the tumour or 
in the surrounding area, i.e. stimulate lymphangiogenesis [82]. When this occurs in 
the neighbouring lymphatic basin it is known as the “Seed and Soil” theory, 
whereby the microenvironment within the lymphatic basin is optomised in part by 
lymphangiogenesis. This theory is highly relevant if we begin to question whether 
the primary tumour can impact on the behaviour of the lymphatics to influence 
disease spread. 
57 
1.12  OTHER FORMS OF SPREAD 
Although the main scope of this thesis is to examine any patterns which may 
exist in the tumoural and nodal expression of VEGF, it is also worth mentioning that 
as well as nodal metastases, other modes of spread exist for this disease.  
Local recurrence is defined as a recurrence of melanoma within 2cm of the 
surgical scar of a primary melanoma. It can result from either extension of the 
primary melanoma or from spread via the lymphatic vessels. 
In-transit melanoma metastases are melanoma deposits within the lymphatic 
vessels more than 2cm from the site of the primary melanoma[20]. 
Nodal metastases have been described above. 
Finally, haematogenous spread of melanoma is spread of melanoma cells in 
the blood stream which occurs either because of the tumour invading blood vessels 
or secondary to lymph node involvement. Once in the blood stream, melanoma cells 
are able to deposit anywhere in the body but as mentioned above, show a 
predilection for lungs, liver, brain and skin[81].  
1.13 ADJUVANT THERAPIES 
 Local recurrences and in-transit metastases are most effectively treated by 
surgical excision, whilst surgery or radiotherapy are useful in selected patients with 
oligometastatic disease[111]. In general distant metastatic melanoma patients have a 
poor prognosis with a median survival of 6-10 months after diagnosis of distant 
metastatic disease. However, this may improve in forthcoming trial data as newly 
approved agents become more widely used [112-114]. As aforementioned, as part of 
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haematogenous spread, melanoma has a tendency to metastasise to the brain, 
whereupon the already poor prognosis worsens.  
Until recently, UK patients with unresectable metastatic spread had very few 
systemic treatment options. Despite no current demonstrable survival benefit, 
chemotherapy is widely used for patients with unresectable stage III or IV disease, 
and this remains the case for those not eligible for targeted therapy with dacarbazine 
(approved) or temozolomide (off label) being standard first line agents[115, 116]. 
The most current UK melanoma guidance states that stage IV patients should be 
considered for entry into clinical trials[117].  
Recently, two agents with different mechanisms of action have improved 
survival in phase III studies of patients with advanced melanoma[112, 113]. 
Ipilimumab, a fully human monoclonal antibody against cytotoxic T lymphocyte-
associated antigen-4, was approved by the European Union in July 2011 for the 
treatment of advanced (unresectable or metastatic) melanoma in adults who have 
received prior therapy. Vemurafenib, an inhibitor of BRAF (serine/threonine-protein 
kinase B-Raf), was approved for the treatment of adult patients with BRAF V600 
mutation-positive unresectable or metastatic melanoma by the European Union in 
February 2012, alongside a test to identify the BRAF V600 mutation[118]. 
A recent article has published the effects of combined therapy of the anti-
angiogenic bevacizumab with ipilimumab in patients with metastatic melanoma. In 
this small study, patients were treated with a combination of the above therapies 
with encouraging results and the authors called for further investigation of the dual 
roles of antiangiogenesis agents and immune checkpoint blockade[119]. 
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1.14 THE SEED AND SOIL THEORY 
 
 Stephen Paget made an important observation in 1889, that breast cancer 
patients had a predilection for metastasis to the liver. Paget perceived this as unusual 
as other organs such as the spleen could have been equally affected as they receive 
the same amount of blood as the liver. This enduring finding prompted Paget to 
develop the theory of “Seed and Soil”. He hypothesized that certain tumour cells 
(seeds) colonise selectively distant organs (soil) with a favourable environment 
facilitating survival of tumour cells[120]: “When a plant goes to seed, its seeds are 
carried in all directions, but they can only live and grow if they fall on congenial 
soil”. Certain organs must therefore provide appropriate conditions for development 
of organ specific metastases, contributing to the organ selectivity [121]. 
 The theory had not been experimentally challenged until Sugarbaker (1952) 
and later Kinsey (1960) retested Paget’s hypothesis by ectopically transplanting 
various organ tissues in syngenic mice and injecting them from different routes with 
melanoma S91 cloudman strain [122, 123]. They reported that tumour cells 
metastasised specifically to lungs but not to any other of the organs transplanted. A 
similar observation reported by Hart and Fidler [124] confirmed the idea that organ 
specific stimuli must permit new tumour growth. 
 More recently, further work has sought to investigate specifically at the role of 
the lymphatic system within tumour metastasis and the “seed and soil” theory, it has 
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been known for decades that the regional lymph nodes draining tumour areas may be 
enlarged, without any other evidence of lymph node metastasis. This is known as 
“tumour-reactive lymphadenopathy” [125].  
 The phenomenon of tumour-reactive lymphadenopathy in SLNs has been 
observed for many years, but alterations of the lymphatic channels and vasculature 
by the process of angiogenesis and lymphangiogenesis in these nodes before the 
arrival of metastatic tumour cells remained relatively unexplored (see figure 6). 
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Figure 6 Schematic to represent the "Seed and Soil" Theory. Adapted from 
Fokas et al. 2007 
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Figure 1-5: Schematic to represent the “Seed and Soil” Theory. Adapted from 
Fokas et al. 2007[106].  
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In 2006, Qian et al., explored the theory that alterations in the lymphatic and 
vascular channels of these tumour-reactive enlarged lymph nodes may be correlated 
with the weight of the primary tumour. Using animal models, the authors showed 
that long before the establishment of metastasis within the sentinel lymph node, 
there were re-organisations of the lymphatic channels and the vasculature. The 
sentinel node became a functional blood vessel enriched and lymph vessel/sinus 
enriched organ before lymph node metastasis. This was a process that appeared to be 
dependent on the primary tumour on analysis of mouse models [125]. A further 
study used transgenic mice that over expressed VEGF-C and green fluorescent 
protein (GFP) specifically in the skin [126]. The effects of chemically induced skin 
carcinogenesis in these models were studied. VEGF-C in these models was found to 
induce expansion of lymphatic networks within sentinel lymph nodes. Again, a 
process that was directly observed before the detection of metastatic cells within the 
sentinel node. Once metastatic cells had arrived at the sentinel node, the extent of 
lymphangiogenesis increased further. Of additional note, in mice with metastasis 
containing sentinel nodes, tumours that expressed VEGF-C were more likely to 
metastasise to additional organs such as distal lymph nodes and lungs. This work 
added to the theory that VEGF-C may be important in the promotion of cancer 
metastasis not only to the sentinel lymph node, but also beyond the sentinel node to 
further sites. The work to date to investigate this “Seed and Soil” theory is clinically 
relevant as debates continue into the pros and cons of sentinel lymph node biopsy 
and completion lymphadenectomy.  
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1.15 THE SENTINEL LYMPH NODE BIOPSY 
 Sentinel lymph node biopsy (SLNB) was introduced as a less invasive 
alternative to allow evaluation of the “sentinel” lymph node (SLN), i.e., the first 
node or nodes draining the primary melanoma along its lymphatic pathway [127]. 
The status of the SLN has been shown to be the most important predictor of 
recurrence and survival for patients with malignant melanoma. The proportion of 
patients who have had a negative SLNB and who are free of disease at three years is 
88.5% compared with 55.8% of patients with a positive biopsy; these groups have 
overall survival rates of 93% and 67%, respectively[128, 129]. 
The thickness of the tumour and whether there is ulceration remain important 
prognostic discriminators in patients with a negative biopsy[128], however, as 
detailed above these indicators are also not entirely reliable. 
Several reasons have been presented in the literature to justify the use of 
SLNB. Firstly, it is cheaper and caused less morbidity than elective lymph node 
dissection. In 2005, a group of plastic surgeons from the Royal Free Hospital in 
London estimated the cost of conducting sentinel node biopsy in the UK at £1550 
per patient plus £2915 for each patient who had completion lymphadectomy. It was 
however mentioned that there was also “a significant cost in setting up a sentinel 
node service, including nuclear medicine staffing and probe costs.”[130]. 
Because only 20% of patients with a primary melanoma of intermediate 
thickness are expected to have metastases in their regional nodes, 80% of those 
undergoing elective lymph node dissection are risking complications without benefit 
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(wound infection, seroma, deep venous thrombosis, and potential life-long 
lymphedema). Although these advantages of SLNB may be applicable in the United 
States and Australia, elective lymph node dissection has never been widely practiced 
in the United Kingdom, where observation and therapeutic lymph node dissection 
for patients who develop nodal metastasis have been preferred[131]. 
A second argument for SLNB is that it can be used to select patients for 
adjuvant therapy and although previously, no postsurgical therapy was effective in 
prolonging survival of these patients [132], lately incorporation of emerging and 
encouraging biological therapy regimes have been found to be beneficial in some 
groups of patients and trials continue in this area (see above). Furthermore, when the 
next adjuvant treatment is defined the subsequent controlled trials are likely to prefer 
to recruit patients at clinical stage III to provide a quicker result. SLN is the only 
method (in the absence of palpable lymph nodes) which upstages patients from 
clinical stage II to stage III. Nevertheless, the use of SLNB to determine nodal status 
would be useful in excluding low risk patients with negative sentinel node biopsies 
from such studies of adjuvant treatments. 
Thirdly, the use of SLNB is justified as a method for selecting patients for 
completion node dissection on the assumption that clearing the regional node basin 
in patients who have had positive biopsies of sentinel nodes improves survival. This 
was also the justification given for elective lymph node dissection, but the results of 
randomised, prospective clinical trials and several historically controlled trials have 
found no survival advantage [133-137].  
One randomised controlled trial did show that there was some survival 
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benefit among a small subset of patients who were under 60 years of age and who 
had melanomas 1 mm to 2 mm in thickness without ulceration [138].  
A multinational, randomised clinical trial, the multicentre selective 
lymphadenectomy trial (MSLT-1), validated the therapeutic efficacy of sentinel node 
biopsy using survival as an endpoint [139]. The preliminary findings of the trial 
represent the first randomised prospective clinical study to show a potential survival 
advantage to performing sentinel lymph node biopsy in patients with melanoma 
[140]. The study included 1269 patients with intermediate thickness (1.2-3.5mm) 
primary melanomas randomised to either a wide local excision and observation of 
regional lymph nodes with lymph node dissection if nodal relapse occurred (n=500) 
or to a wide local excision and SLNB with immediate regional lymphadenectomy if 
nodal micrometastases were found (n=769).   
Initially, there was no difference in overall 5-year melanoma-specific survival rate; 
87.1% for the SLNB and 86.6% in the control arm. However, the study did show 
improved disease-free survival in those patients who underwent the SLNB compared 
to those in the nodal observation arm group; the 5-year survival rate for node 
positive melanoma was 72.3 ± 4.6% and 90.2 ± 1.3% in the node negative group 
(hazard ratio for death, 2.48; 95% confidence interval, 1.54 to 3.98; P < 0.001).    
The incidence of sentinel-node micrometastases was 16.0% and the rate of nodal 
relapse in the observation group was 15.6%. The corresponding mean number of 
tumour-involved nodes was 1.4 in the biopsy group and 3.3 in the observation group 
(P<0.001), indicating disease progression during observation. Among patients with 
nodal metastases, the 5-year survival rate was higher among those who underwent 
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immediate lymphadenectomy than among those in whom lymphadenectomy was 
delayed (72.3+/-4.6% vs. 52.4+/-5.9%; hazard ratio for death, 0.51; 95% confidence 
interval, 0.32 to 0.81; P=0.004)[140]. The study authors concluded that the staging 
of intermediate-thickness (1.2 to 3.5 mm) primary melanomas according to the 
results of SLNB provided important prognostic information. However, the study did 
not show a clear survival advantage associated with SLNB.  Further subset analysis 
from MSLT-1 comparing patients with a positive SLNB + immediate 
lymphadenectomy versus those in the nodal observation group showed that there 
was significant progression to more advanced nodal disease in the nodal observation 
group and more importantly that there was a significant survival advantage in those 
undergoing immediate lymphadenectomy. More recently, further data from this 
study has become available. With results and follow up now spanning two decades, 
ten year follow up results for the same study have become available and further 
analysis of outcomes have recently been published. Mean (±SE) 10-year disease-free 
survival rates were significantly improved in the biopsy group, as compared with the 
observation group, among patients with intermediate-thickness melanomas, (defined 
in this study as 1.20 to 3.50 mm) (71.3±1.8% vs. 64.7±2.3%; hazard ratio for 
recurrence or metastasis, 0.76; P = 0.01), and those with thick melanomas, defined 
as >3.50 mm (50.7±4.0% vs. 40.5±4.7%; hazard ratio, 0.70; P = 0.03). Among 
patients with intermediate-thickness melanomas, the 10-year melanoma-specific 
survival rate was 62.1±4.8% among those with metastasis versus 85.1±1.5% for 
those without metastasis[141]. 
As until recently there was a paucity of evidence to support the long term 
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value with regard to survival for melanoma patients, there is some literature 
available which has examined the drawbacks and risks associated with this 
technique. 
A potential risk of SLNB is the entrapment of melanoma cells at the time of 
surgery, causing a higher incidence of in transit metastasis (deposits of tumour 
occurring between the primary tumour site and the regional node basin) [142]. A 
retrospective study combined the data from two national centres on local and in-
transit disease in 972 melanoma patients who underwent SLNB procedure over 6.5 
years period. In total, 77 patients (7.9%) developed loco-regional recurrence: 41 
(4.2%) local recurrence only and 36 patients (3.7%) in-transit metastases during a 
mean follow-up of 42 months. Patients with positive sentinel lymph node were three 
times more likely to develop loco-regional metastases than those with no nodal 
disease (17 vs. 5.6%). Over one third of all recurrences developed following 
excision of thick (Breslow thickness over 4mm) primary tumours. In both centres 
age and Breslow thickness were found to be significantly higher in the recurrence 
group (p<0.001 for both). This study revealed a strong association between 
increased risk of loco-regional metastases and aggressive tumour biology and 
adverse patients factors. No conclusive evidence however was found to support an 
increased incidence in patients undergoing SLNB and CLND compared to that 
published for patients undergoing wide local excision alone[77].  
It is clear that there are reported flaws to the SLNB technique. In addition to 
those listed above, there is also the possibility of false negative results, which 
introduces the argument that patients who have had negative sentinel node biopsies 
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must be kept under review. The immediate false negative rate, as determined by 
elective lymphadenectomy performed concomitantly with sentinel node biopsy, is 
consistently less than 4% [128]. However, when defined as a recurrence developing 
in the nodal basin after negative sentinel node biopsy (without completion 
lymphadenectomy) the false negative rate varies from 0% to 25%, depending on the 
length of follow up and whether immunohistochemistry was used in the initial 
pathological analysis of the specimen [129, 143, 144]. It has been suggested that 
pathological analysis needs to include routine immunohistochemical staining of both 
sentinel and non-sentinel nodes because histology alone misses up to 14% of occult 
micrometastases [145]. Other reasons a false negative SNLB can occur because of 
deficiencies in nuclear medicine, surgery failure (i.e. removal of a non sentinel 
lymph node) [146], or physiological reasons, i.e., circulating tumour cells had not 
arrived at the SLN at time of removal [147] or past straight through. 
As previously mentioned, all positive sentinel lymph nodes are assumed to 
inevitably progress to palpable nodal recurrence if not removed in the SLNB 
procedure. There are concerns that some deposits of melanoma within the SLN are 
destined for dormancy or destruction and are not prognostically significant [148]. 
This phenomenon is referred to as prognostic false positivity. Spanknebel et al. 
concluded that the prognosis for patients with micrometastases that could only be 
detected with immunohostochemical techniques is similar to that of patients with 
negative sentinel lymph nodes [149]. Similarly, van Akkooi et al. stated that patients 
with micrometastases smaller than 0.1mm in diameter should be judged to have 
negative sentinel lymph nodes [150]. These observations are however based on 
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removing the SLN for histology, which could be construed as contributing to a 
therapeutic effect [148]. 
There is also the paradox that younger patients with melanoma have a 
significantly better prognosis than older patients despite having a higher incidence of 
positive SLNB [151, 152]. On all continents, mortality from melanoma rises steeply 
with advancing age [153]. Despite this observation, Chao et al. reported that in a 
study of 3,076 patients, that the incidence of positive sentinel lymph nodes declines 
with increasing decades of age, being 23.1% in patients younger than 30 years and 
only 12% on patients aged between 61 and 70 years (p<0.001)[152], and suggested 
that younger patients might have generally a more competent  system that eliminates 
small micrometastases before they manifest clinically. Statius-Muller et al. found 
that the incidence of positive SLNB was 37% amongst patients aged between 18-30 
years and 17% amongst patients aged 71-84 years [151]. It is possible that a 
fundamental assumption may therefore be contested and there is some evidence that 
a positive SLNB might have no adverse prognostic relevance in certain patients. 
Such patients may be incorrectly upstaged, given inaccurate prognostic information 
and may even undergo unnecessary completion lymphadenectomy and adjuvant 
therapy. 
Other clinical problems relating to the use of SLNB is that it is also important 
to select patients carefully using sound clinical judgment. In general, sentinel node 
biopsy is recommended for patients with an estimated risk of nodal metastasis of 
10% or more; these patients include those with melanomas of 1 mm or graded as 
Clark level IV [128]. Clark level IV is defined as invasion into the reticular dermis 
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but not into the subcutaneous tissue (see earlier). This distinction is important when 
skin thickness is thin and a melanoma may be <1 mm in thickness but still Clark 
level IV [145]. 
 
Evidence supporting the use SLNB as shown above is not entirely encouraging 
or readily available. It is important to recognise that regional lymph node 
involvement may simply be a marker for more widespread disease. If survival 
advantages shown for sentinel node biopsy have been interpreted with caution and 
completion lymph node dissection has been largely found to confer no survival 
benefit, it is clear that until further supportive studies are available, alternatives or 
adjuncts to investigation could be offered to these patients. 
 
1.16 AIMS OF MY WORK 
 
1.16.1 DOES THE EXPRESSION OF VEGF IN THE PRIMARY MELANOMA 
CORRELATE WITH THE SENTINEL NODE ? 
 
 This study will determine whether there is any link between the balance of 
VEGFxxx and VEGFxxxb and VEGF-C expression in the primary melanoma, and its 
corresponding SLN as a mechanism to facilitate metastasis. This would, establish a 
role for tumour expressed pro- and anti-angiogenic factors in preparing the body for 
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metastasis via the lymphatic system and add to what is known about this subject 
already. We hope to demonstrate that the angiogenic environment of the SLN may 
be an important consideration in predicting overall patient survival. A recent study 
has disproved the theory that lymphatic densities within or around the tumour can 
aid in SLN status prediction[84]. If a pattern may be determined when examining 
VEGF expression, this would not only provide a means of identifying the patients 
for whom SLN biopsy may be of greatest advantage but would also provide a better 
understanding of the mechanisms underlying the process of lymphatic metastases.   
 If a relationship can be determined, this  could be used to predict the status of 
the SLN and even the surrounding lymph node basin, thus identifying a subgroup of 
patients for whom SLNB is unnecessary, thereby minimizing unnecessary surgical 
procedures and their associated risks and also allow us to predict the significant false 
negative and false positive subgroups. 
 
1.16.2  DO POSITIVE SENTINEL NODES SHOW ANY EVIDENCE OF AN 
ALTERED NODAL MICROENVIRONMENT? 
 
 Although VEGF expression has been demonstrated to predict nodal metastasis 
in malignant melanoma, the mechanisms underlying this are still unclear. There is 
growing evidence that growth factors expressed by the primary lesion are able to 
impact directly upon the SLN to induce proliferation of the vasculature and 
effectively prepare the node to be a more hospitable environment into which tumour 
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cells can then seed i.e. the “seed and soil” hypothesis. Immunohistochemistry of the 
corresponding SLNB from (i) will be investigated for their expression of both pro- 
and anti-angiogenic isoforms of VEGF. This will then be correlated with the primary 
tumour, results of the SLNB, completion lymphadenectomy and patient survival. 
Hence, we aim to determine whether these growth factors are affecting patient 
outcome by directly influencing the mechanisms underlying nodal metastasis.   
 Additionally, I will determine the precise vasculature within the SLNB 
samples, (lymphatic and blood). Can any additional patterns be demonstrated by 
looking at the ‘false negative cohort’ of patients? 
 
 On review of the literature as part of writing early aspects of this work and 
analysing our cohort of patients, it became apparent to us that we would expect to 
find some patients who initially had a negative sentinel lymph node biopsy and who 
subsequently developed lymph node metastases. It will be interesting to access the 
primary tumour of these patients as well as the SLN in question to perform the 
above analyses on these as part of a separate chapter. There is little information of 
the clinical outcome of these patients and so it would be interesting not only to 
perform experimental work but also examine their demographics more closely. 
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2 CHAPTER TWO 
MATERIALS AND METHODS 
 
 74 
 
 
2.1 CHEMICALS AND SOLUTIONS 
 
All chemicals and solutions were provided by Fisher Scientific Limited 
(Peterborough, UK), unless otherwise stated. 
 
2.2 PATIENT SELECTION 
 
In accordance with ethical approval from Liverpool (Adult) Research Ethics 
Committee (08/H1005/115), all patients included in this study were coded at 
Whiston Hospital at the point of sample preparation and the detail of the coding kept 
by Dr. Kate Nelson. As a result samples remained anonymous throughout the study 
and were further kept blinded until final analysis was completed. In compliance with 
the Human Tissue Act (section 7, subsections 1 and 3), samples were excised prior 
to 1st Sept 2006 and informed consent was not a requirement. 
In order to select suitable patients for inclusion in our study, patient lists were 
accessed via the Cancer Registry Services (St Helens’ and Knowsley Trust), 
providing a complete list of all patients who had undergone a SLNB at Whiston 
Hospital between the years of 1999-2004 for the main cohort of interest, a total of 
241 patients. All samples would therefore have at least 5 years of follow-up 
information potentially available including mortality and recurrence status. A 
colleague not directly related to the research project, Dr Kate Nelson, examined 
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these patient lists and identified a total of 34 patients, 15 which were SLN positive 
and 19 which were SLN negative, for whom tissue from both the primary melanoma 
and corresponding SLN was available at Whiston Hospital, with each group 
matched for age, sex, Breslow thickness and location of primary lesion. Patients 
were excluded if their primary tumour was excised elsewhere, if more than one true 
SLN was removed and if they had occult distant metastases at time of SLNB which 
was later discovered. 
A further group of ‘false negative’ patients (i.e. a group of patients who were 
initially thought to be lymph node disease free as identified by a negative SLNB, but 
subsequently developed lymph node disease), were identified as an important group 
of interest as they are effectively under-staged. Therefore, through the Cancer 
Registry Services (St Helens’ and Knowsley Trust) list of patients that underwent 
SLNB at Whiston Hospital between 1999-2005. The period of interest was extended 
by a year as it was one year after starting this study that this small group emerged as 
a possible area of interest, (therefore we were still able to have 5 year follow up on 
this group but maximise numbers in the group as much as possible. Dr Kate Nelson 
identified a total of 16 ‘false negative’ patients from the patients that underwent 
SLNB between 1999-2005 at Whiston Hospital. SLNB samples were available for 
14 of theses patients along with 11 corresponding primary melanomas.  
We were therefore able to categorise suitable patients for inclusion into 3 
separate categories, true positive, true negative and false negative patients, with each 
group being examined separately for any identifiable patterns.  
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A limitation of the work was that although details were sought (if available) of 
whether each patient received any adjuvant therapies, no deeper analysis on patients 
who received these therapies was carried out. This was because in the time period in 
question of 1999-2004 effects of these therapies where not found to affect survival 
[8] and as no patient at the time of tumour and nodal sampling was receiving any 
adjuvant therapy, data collected was not adjusted to account for this information. 
This data was collected before the emergence of the more successful immune 
modulators and antibody therapies which were detailed in Chapter 1. 
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Figure 7 Flow chart to illustrate categories of patients and subsequent selection 
 
Melanoma 
diagnosis and 
excision 
SLN biopsy 
performed 
Positive SLN 
biopsy 
Negative SLN 
biopsy 
Completion 
lymphadenectomy 
Clear of 
metastases 
No later 
metastases 
Later 
metastases 
No further 
metastases 
Later metastases 
(False Negative?) 
Figure 2-1 Patient Selection 
Flow chart to illustrate the categorising of patients and 
subsequent selection. 
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Demographic data on this group was also assessed by reviewing case note records 
held at St Helens’ and Knowsley Trust. This group (of melanoma patients) has not 
been subject to any detailed study in the available literature. 
 
After excision of a primary melanoma, samples are routinely fixed in formalin 
before embedding in paraffin blocks and sectioning for routine histopathological 
diagnosis. As this study was aimed at determining absence or presence of disease 
based on usual clinical practice, normal practice at the hospital trust where these 
sections were analysed is to examine the node histologically in 4 different depth 
levels to detect any evidence of spread of disease. These tissues are then archived 
and stored and so available for analysis. Serial sections of 4µm thick were cut from 
these tissue blocks of excised primary melanomas and corresponding SLNs at the 
Histopathology Department, Whiston Hospital, with a microtome Thermo Shandon 
Finesse® ME+ Microtome, LEICA RM2135 Microtome and LEICA RM2145 
Microtome) and mounted on SuperFrost Plus glass slides (Menzel-Glaser, Fisher 
Scientific, Peterborough, UK) before baking for 16-24 hours at 60ºC. 
 
2.3  IMMUNOHISTOCHEMISTRY 
 
Immunohistochemical analysis of this archival primary melanoma and 
corresponding SLN tissue was used to determine the expression of pro- and anti-
angiogenic VEGF, and lymphangiogenic VEGF-C, with primary antibodies specific 
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for all VEGF isoforms, mouse anti-human VEGF; 7µg/ml  (M7273, Clone VG1, 
Dako), anti-angiogenic VEGF, mouse anti-human VEGFxxxb; 12µg/ml (Ab14994 
[MVRL 56/1], Abcam) and VEGF-C goat anti-human VEGF-C; 1.14µg/ml (sc-
7133, Santa-Cruz). Furthermore, the vasculature within the excised SLN was 
examined through immunohistochemical analysis with the vasculature specific 
marker PECAM-1 (CD31); 8µg/ml (sc-1506, Santa Cruz) and the lymphatic specific 
marker polyclonal goat anti-human LYVE-1; 15µg/ml (AF2089, R&D Systems, 
UK)  
These primary antibodies were then detected with corresponding secondary 
antibodies (Goat IgG 1-5000, Vector Laboratories, Peterborough, UK, Mouse IgG1 
IHC solution, X0931, Inverness Medical, UK. Biotinylated horse anti-mouse IgG 
secondary antibody; 2µg/ml (BA-2000, Vector Laboratories, Peterborough, UK), 
biotinylated horse anti-goat IgG secondary antibody; 2µg/ml (BA-9500, Vector 
Laboratories, Peterborough, UK). 
 
2.3.1 VESSEL IMMUNOHISTOCHEMISTRY 
In order to examine the microrenvironment of the sentinel lymph nodes 
removed at biopsy, the vascular marker PECAM-1 and lymphatic specific marker 
LYVE-1 were used to identify vessels within the lymph node for detailed analysis. 
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2.3.1.1 LYVE-1 AND PECAM-1 IMMUNOHISTOCHEMISTRY 
DAY ONE  
First paired 4!m sections were dewaxed with Xylene for 15 minutes before 
rehydration in graded alcohols. The sections were incubated for 2 minutes each in 
100%, 90% and 70% ethanol respectively before being twice washed in distilled 
water for 5 minutes. Then follows two 5 minute washes in 1x Phosphate Buffered 
Saline (PBS). (1x PBS is made by dilution of 10" PBS (137mM NaCl, 2.68mM 
KCl, 10mM Na2HPO4, 1.76mM KH2PO4, pH 7.4) in distilled water).  
Next followed the antigen retrieval step. The demonstration of many antigens 
can be significantly improved by the pre-treatment with the antigen retrieval reagent 
that break the protein cross-links formed by formalin fixation and thereby uncover 
hidden antigenic sites. Sections were therefore transferred to a plastic tub containing 
a total of 400ml (to ensure all slides are covered) of 0.1mM Tris-HCl/2mM Ethylene 
Diamine Tetraacetic Acid (EDTA) buffer, pH 9.0. The fluid level was marked on the 
outside of the tub prior to placing in a microwave oven and the sections subjected to 
microwave treatment at 600W for 2 treatments each lasting 4 minutes with no 
formal rest period in between but where any evaporated losses were replaced with 
distilled water. This was to prevent any significant change/alteration in solution 
molarity. Following treatment, the tub and sections rested at room temperature for at 
least 30 minutes before the sections were twice washed in distilled water.  
An endogenous peroxidase-blocking step was performed whereby the 
sections were defined using a hydrophobic pen to avoid liquid running off the slide, 
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immersed in 3% hydrogen peroxide (Sigma-Aldrich, UK) for 5 minutes before being 
twice washed in 1xPBS. This was followed by a non-immune blocking step. 
Sections were incubated with 1.5% normal horse serum as this is the normal serum 
from which the secondary antibody was raised. (The secondary antibody in this 
instance is horse anti-goat). (Normal horse serum, S2000, Vector Laboratories, 
Peterborough, UK) (75!l/5ml 1xPBS) applied for 30 minutes in a humid chamber at 
room temperature.   
Slides were then incubated with primary PECAM-1 or LYVE-1 antibody 
diluted in blocking solution, with a total of 40!l added per slide.  For each treated 
slide, a corresponding negative control received a matched concentration of normal 
immunoglobulins diluted in blocking solution as a negative control. The primary 
antibody (Santa Cruz Biotechnology SC 1506 goat anti-human endothelia (PECAM-
1)) stock is 200!g/ml. This is diluted 1:25 to produce a final concentration of 
8!g/ml. Control IgG stock is 100!g/ml and hence is diluted 1:12.5.  
The slides are mounted with 22x50 mm cover slips and incubated in a humid 
chamber at 4°C overnight.  
 
For LYVE-1, both the primary antibody LYVE-1 and control IgG stocks are 
434!g/ml. These were diluted 1:217 in 1xPBS to produce a working solution of 
2!g/ml and 40!l added per slide. The slides were again mounted with 22x50mm 
cover slips and incubated in a humid chamber at 4°C overnight.  
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DAY TWO  
The cover slips were removed by bathing in a solution of 1x PBS-Tween 
(PBS-T) keeping the negative controls separate and twice washed in PBS/T for 5 
minutes. A non-immune blocking step of incubation with 1.5% normal horse serum, 
for 30 minutes at room temperature in a humid chamber was then repeated. This was 
followed by the addition of the secondary antibody (biotinylated horse anti-goat 
IgG; 1.5mg/ml, details of who it’s from) diluted in blocking solution 1:750 to 
produce a working solution of 2!g/ml. Sections were incubated in a humid chamber 
at room temperature for 30 minutes.  During this incubation the avidin biotinylated 
enzyme complex (ABC) was prepared with the Vector Elite Kit (Vector PK- 400, 
Vector Laboratories, Peterbourough, UK) adding 1 drop of solutions A and B in 5ml 
1x PBS (10!l/ml), at least 30 minutes before use to allow complexes to form. 
Following incubation in secondary antibody sections were twice washed for 5 
minutes in 1xPBS/T before incubation with ABC in a humid chamber for 30 minutes 
at room temperature. There then followed two 1xPBS/T washes each of 5 minutes 
before the addition of the visualising diaminobenzidine (DAB) substrate (SK-4100, 
Vector Laboratories, Peterborough, UK). To prepare it, 5ml of distilled water was 
added 2 drops of buffer stock, 4 drops of DAB and 2 drops of hydrogen peroxide. 
This was made up immediately before use. Sections were treated with DAB for up to 
15 minutes or until colour was visualised. If a colour change became apparent with 
the naked eye, matched slides were removed at the same time into distilled water. 
Once all sections were in this phase they were twice washed with distilled water for 
5 minutes. Sections were counterstained in Mayers’ haematoxylin (Sigma-Aldrich, 
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UK) for 5 minutes before being gently washed under running tap water for at least 5 
minutes to allow ‘blueing’.  
The sections were the dehydrated in graded alcohols (70, 90 and 100% 
ethanol) for two minutes each before final clearing in xylene for 15 minutes before 
mounting with DPX mountant (Sigma-Aldrich, UK) and 22x50mm glass cover slips. 
 
2.3.2 VEGF IMMUNOHISTOCHEMISTRY  
 
All primary melanoma sections and SLNs were stained 
immunohistochemically with antibodies specific for pan-VEGF, VEGFxxxb, and 
VEGF-C to quantify isoform expression. 
 Immunohistochemistry experiments were run over two or three days to 
allow the primary antibody to bathe the sections overnight. The secondary antibody 
incubation period was overnight for Pan-VEGF and VEGFxxxb and therefore these 
protocols were three days long.  
 
DAY ONE  
First paired 4!m sections were dewaxed using Xylene for 15 minutes before 
rehydration in graded alcohols took place. The sections incubated for 2 minutes in 
100%, 90% and 70% ethanol respectively before finally being twice washed in 
distilled water for 5 minutes each time. Next, were two 5 minute washes in 1xPBS 
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before antigen retrieval. This was undertaken in 0.01M Sodium citrate buffer (8ml 
of 0.5M stock in 392ml water) pH 6.0, and were subjected to microwave treatment 
for 14 minutes at 600W with the lid half off. (Recipe for 0.5M stock of Sodium 
Citrate Buffer- dissolve 7.35g of trisodium citrate in 40 mls of distilled water. Add 
citric acid until pH 6.0. Make up to 50ml using distilled water.) 
Following treatment the sections rested at room temperature for 30 minutes 
to allow to cool before the sections were twice washed in distilled water.  
There followed an endogenous peroxidase blocking step whereby the 
sections were immersed in 3% hydrogen peroxide (Sigma-Aldrich, UK) for 5 
minutes. They were then twice washed in 1xPBS.  
The non-immune blocking step saw the sections incubated in 1.5% normal 
horse serum (Vector Laboratories) (75!l/5ml 1xPBS) for 30 minutes in a humid 
chamber at room temperature.   
The primary antibody was diluted in blocking solution, and 40 !l added per 
slide and incubated at room temperature overnight in a humid chamber.  For each 
treated slide, the control receives a matched concentration of normal goat 
immunoglobulin diluted in blocking solution as a negative control.  
The slides were mounted with 22x50mm coverslips and incubated in a humid 
chamber at 4°C overnight.  
 
 DAY TWO  
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The coverslips were soaked off in PBS with added Tween-20 (0.5ml/L-
PBS/T), keeping the negative controls separate before being twice washed in PBS/T 
for 5 minutes. For VEGFxxxb detection, the secondary antibody (biotinylated horse 
anti mouse IgG (Vector BA-2000)) was diluted in blocking solution to produce a 
working solution of 2!g/ml (pan VEGF) and 8!g/ml (VEGFxxxb). Sections were 
mounted with 22x50mm coverslips and incubated in a humid chamber at room 
temperature overnight.   
 
DAY THREE 
Avidin biotinylated enzyme complex (ABC Elite PK 6100 Vector 
Laboratories, California, USA) was prepared at least 30 minutes before use as 
follows. Vector Elite Kit utilises 2 drops of solutions A and B in 5ml 1x PBS 
(20!l/ml).  
Following incubation in secondary antibody sections were twice washed for 
5 minutes in PBS/T before incubation with ABC in a humid chamber for 45 minutes 
at room temperature. There then followed two PBS/T washes each of 5 minutes 
before the addition of the visualising DAB substrate. To 5ml of distilled water  was 
added 2 drops of buffer stock, 4 drops of DAB and 2 drops of H2O2. This was made 
up immediately before use. Sections were treated with DAB for up to 15 minutes or 
until colour was visualised. Once seen, matched slides were removed at the same 
time into distilled water. Once all sections were in this phase they were twice 
washed with distilled water for 5 minutes. Sections were counterstained in 
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Haematoxylin for 5 minutes before being gently washed under running tap water for 
5 minutes.  
Then sections were dehydrated in graded alcohols (70, 90 and 100% ethanol) 
for two minutes each before final clearing in xylene for 15 minutes before mounting 
with DPX and glass coverslips. Slides dried overnight before light microscopy 
examination of the results.   
 
2.4 ANALYSIS OF PAN-VEGF, VEGFXXXB AND VEGF-C 
IMMUNOHISTOCHEMISTRY 
 
Three assessors, who were blinded to the outcome of the patient in question, 
independently scored each of the slides. Assessors were myself, Dr. Maxine 
Emmett, a postdoctoral researcher and Mr. Pritchard-Jones who was supervising the 
work and familiar with this scoring method as part of his previous research. Training 
was supplied by a pathologist at the Royal Liverpool University Hospital (where all 
assessment of results took place). Concordance between raters was checked with test 
slides provided by the department, as was ability to identify key components within 
tumours and nodes. There was no formal inter/intra rater statistical reliabilities 
performed as this technique for scoring of staining has previously been described 
and validated for use following appropriate familiarisation with staining of slides[79, 
99, 154]. Staining was scored for both intensity, on a scale of 0-3 (Table 2) and 
percentage of cells expressing awarding a score accordingly on a scale of 0-4 (Table 
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3), scoring both normal skin and tumour for pan-VEGF and VEGFxxxb and just 
primary lesion for VEGF-C. Similarly, SLNs were scored for both intensity of 
staining in the capsule and node. 
 
 
Score Percentage Stained 
0 0 
1 <10 
2 10-50 
3 50-90 
4 90-100 
Score Intensity 
0 No Stain 
1 Weak Stain 
2 Stronger Stain 
3 Strongest Stain 
Table 2 Qualitative Assessment of staining intensity 
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Table 3 Qualitative Assessment of Staining Percentage 
 
2.5 ANALYSIS OF VESSEL IMMUNOHISTOCHEMISTRY 
 
The PECAM-1 (CD31) and LYVE-1 staining of SLNs was assessed using 
again Nikon NIS Elements software. In keeping with similar analysis and the current 
literature, each image was further captured in the following manner: 
For each slide, three vessel ‘hotspots’ were identified at 40x magnification. These 
were areas of concentrated staining. For each ‘hotspot’ the following analysis was 
undertaken,  
• Total vessel number i.e. number of vessels within ‘hotspot’ 
• Vessel diameters  
• Vessel areas 
 
This method was in keeping with methods used by Qian et al., [125] in their similar 
analysis of breast cancer patients’ lymph nodes. The Eclipse Net software package 
has been previously calibrated with the microscope, such that it can be used to 
accurately measure specific lengths i.e. diameters and specifically demarked areas of 
interest i.e. vessel areas. 
 
89 
2.5.1 EXAMPLES OF VESSEL IMMUNOHISTOCHEMISTRY 
 
Figure 8 Example of calculation of vessel number 
 
This is a SLN stained for CD31 in a 51 year-old male who had a 3.5mm 
Breslow thickness Malignant Melanoma excised from his back. This particular SLN 
was negative. The red arrows indicate vessels which were counted (n=9) 
Figure 2-2 This is a SLN stained for CD31 in a 51 year-old male who had a 
3.5mm Breslow thickness Malignant Melanoma excised from his back. This 
particular SLN was negative. The red arrows indicate vessels which were counted 
(n=9)  
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Figure 9 Example of calculation of vessel diameter 
This is a SLN stained for CD31 in a 51 year-old male who had a 3.5mm 
Breslow thickness Malignant Melanoma excised from his back. This particular SLN 
was negative. The green lines indicate vessel diameters, which are measured in 
microns. 
 
Figure 2-3: Example of Calculation of Vessel Diameters 
This is a SLN stain d for CD31 in a 51 year-old m le who had a 3.5mm Breslow 
thickness Malignant Melanoma excised from his back. This particular SLN was 
negative. The green lines indicate vessel diameters, which are measured in 
microns. 
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Figure 10 Example of calculation of vessel area 
This is a SLN which has been stained for CD31 in a 51 year-old male who had 
a 3.5mm Breslow thickness Malignant Melanoma excised from his back. This 
particular SLN was negative. The pink areas indicate vessel areas, which are 
measured in microns.  
  
Figure 2-4: Example of Calculation of Vessel Areas 
This is a SLN whic  has been st ined for CD31 in 51 year-old ale who had a 
3.5mm Breslow thickness Malignant Melanoma excised from his back. This 
particular SLN  negative. The pink are s indicate vessel ar as, which are 
measured in microns.  
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2.6 ‘FALSE NEGATIVE’ PATIENTS 
 
There are several possible mechanisms by which ‘false negative’ results can 
occur.  
1. Metastatic disease from the primary site had not reached the SLN at the time 
of the procedure. 
2. Microscopic disease was not detected using current pathological examination 
protocols. 
3. Technical issue, i.e the surgeon may have removed a non-sentinel node. 
 
To confirm that these nodes were not missed during their initial 
histopathological examination using standard laboratory protocols with 
haematoxylin and eosin staining, further immunohistochemical analysis of these 
SLNs was undertaken by Miss Natalie Rimmer at the Histopathology Department, 
Whiston Hospital, staining with the melanoma specific markers Melan-A and S100 
(Dako, Cambridgeshire, UK)(Protocol available in appendix). Melan-A is a protein 
antigen found on melanocytes. Antibodies against the antigen are used in the 
medical specialty of anatomic pathology in order to recognise cells of melanocytic 
differentiation, useful for the diagnosis of a melanoma [155, 156]. Furthermore, 
several members of the S-100 protein family are useful as markers for certain 
tumours and epidermal differentiation. It is regularly used as a reliable marker in 
melanoma[157].  
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All 14 patients for whom SLN tissue was available were re-examined. 
This was done according to the standard protocol supplied from St. Helens’ and 
Knowsley Trust included in appendix 1. 
A representative node from all 14 ‘false negative’ patients for whom tissue 
was available were then immunohistochemically stained for VEGF expression with 
antibodies specific for pan-VEGF, VEGFxxxb, VEGF-C, along with the vessel 
markers PECAM-1 and LYVE-1. This was all undertaken and assessed as described 
above.. A further 11 corresponding primary melanomas from these patients were 
further stained for pan-VEGF, VEGFxxxb and VEGF-C and scored accordingly. 
These samples were analysed alone and in comparison to the main cohort. 
 
2.7 STATISTICAL ANALYSIS 
All data is expressed as mean ± standard error of the mean (SEM). Appropriate 
statistical analyses were undertaken including t test, one-way ANOVA followed by 
a Bonferroni post test where p<0.05 overall or Kruskal-Wallis, followed by a 
Dunn’s post test where p<0.05 overall. Correlations were assessed using the 
Spearman or Pearson test for correlation. A power calculation was performed 
whereby the scoring system of 0-3 was incorporated. To demonstrate a difference 
between scores (i.e. a drop or increase of 1 point) with 80% power and alpha 5% 
then 15 patients would be needed in each group. This would allow us to make 
conclusions with accuracy for the main cohort of patients (true negative versus true 
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positive). For the false negative cohort as 14 patients were examined and compared 
with larger groups, as this was only one patient short of a 80% powered study this 
remained a statistically viable comparison, and the 11 tumour sample within this 
cohort were recommended to be included to identify any trends if present. 
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3 CHAPTER 3 
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3.1 INTRODUCTION 
3.1.1 ANTI-ANGIOGENIC ISOFORMS OF VEGF AND THEIR RELEVANCE TO 
MALIGNANT MELANOMA 
As discussed in Chapter 1, VEGF exists as a family of isoforms that result 
from splicing of mRNA to generate a series of proteins each of differing amino acid 
length, after which they are named (VEGF189, VEGF165, VEGF121 etc, Fig.3-1) 
[158]. For over 10 years, VEGF has been accepted as a molecule that stimulates 
vasodilatation, angiogenesis (endothelial cell proliferation and migration) and 
increased microvascular permeability.   
However, this dogma has been turned on its head by the description of a 
family of almost identical sister isoforms named VEGFxxxb where the ‘xxx’ prefix is 
amino acid number (VEGF189b, VEGF165b etc, Fig. 3-1) that appear to do exactly the 
opposite [78]. VEGF165b does not stimulate vasodilatation, endothelial cell 
migration or proliferation and furthermore inhibits the VEGF165-dependent 
mediation of these responses [78]. These new inhibitory molecules only differ in the 
final six amino acids at their C- terminus, and it is this small change that confers 
these radically different properties.   
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Figure 11 Angiogenic and anti-angiogenic isoforms of VEGF-A. Selection of 
either the proximal or distal splice site results in two sister families of VEGF-A 
isoforms, only differing in the last six amino acids. Adapted from Woolard et al. 
2004 
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VEGF165b has so far been shown to be down-regulated in primary melanoma, colon 
cancer, renal cell carcinoma and prostate cancer in contrast to all other isoforms of 
VEGF [78]. When dominant in archival malignant melanoma, these anti-angiogenic 
isoforms appear to confer a protective anti-metastatic effect. Work published by 
Pritchard Jones et al., has demonstrated that the balance of VEGFxxxb expression can 
be used to predict metastatic spread to sentinel lymph nodes, suggesting the 
expression of the two isoforms of VEGF has a mechanistic role in patient outcome 
[79]. To determine whether VEGFxxxb expression was altered in melanoma, PCR 
and immunohistochemistry of archived human tumour samples were used. In normal 
epidermis and in a proportion of melanoma samples, VEGFxxxb staining was seen. 
Some melanomas had much weaker staining of this alternative isoform. Subsequent 
examination revealed that expression was significantly reduced in primary 
melanoma samples (both horizontal and vertical growth phases) from patients who 
subsequently developed tumour metastasis compared with those who did not, 
irrespective of tumour thickness, while the surrounding epidermis showed no 
difference in expression. Staining for total VEGF expression showed staining in 
metastatic and nonmetastatic melanomas, and normal epidermis. An absence of 
VEGFxxxb expression appeared to predict metastatic spread to lymph nodes in 
patients with primary melanoma. The results may suggest that there could be a 
switch in splicing as part of the metastatic process, from anti-angiogenic to pro-
angiogenic VEGF isoforms.  
As a consequence of the cumulative work in this area to date in the 
malignancies named above, anti-angiogenic agents provide a novel class of anti- 
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tumour therapy and are now termed the fourth cancer treatment modality. Indeed, 
anti-angiogenic therapy is becoming of growing importance in skin cancer 
management with the anti-angiogenic agent “Avastin” clinical trials which have 
recently been running in melanoma patients across the UK (AVAST-M, CRUK) 
with encouraging interim results published in 2014, as discussed in chapter 1[81]. 
 
An area of interest that remains relatively unexplored in human melanoma 
samples is whether the relative expression of the angiogenic or anti-angiogenic 
isoforms of VEGF in the primary tumour allows prediction of the sentinel lymph 
node status. As suggested by Pritchard Jones et al., it may be possible to predict 
metastatic potential by examination of the relative expression of VEGF within the 
tumour[79], but is there a pattern which could be found which may help us to predict 
the SLN status? This could be helpful as the SLNB is a technique that continues to 
be controversial in many ways. 
 
3.1.2 THE SENTINEL LYMPH NODE BIOPSY DEBATE 
 
 Melanoma is believed to metastasise via the lymphatics with tumour cells 
migrating along the same pathways as draining fluid and thus first arriving at the 
sentinel lymph node (SLN), the first node encountered by lymph draining from a 
particular site [70, 71].  As highlighted in Chapter 1, as the incidence of malignant 
melanoma continues to rise at an alarming rate, the importance of diagnosing nodal 
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metastatic disease has impacted significantly on the accurate staging and 
stratification of melanoma patients[53, 159] 
 
 Another prevalent disease which is similarly rising in incidence in the 
population and bears some resemblance to malignant melanoma in its mechanism of 
spread is carcinoma of the breast[160]. Axillary lymph node dissection (ALND) has 
long been an integral part of the management of breast carcinoma. Initially, like 
SLN in the management of malignant melanoma, its purpose was to remove the 
likely first area of tumour spread from the primary lesion in the breast, with the 
thought that a higher cure rate would result than if only mastectomy were 
performed[42]. Subsequent clinical trials, however, showed that ALND contributed 
little to overall survival, despite a relatively high pathologic frequency of axillary 
nodal involvement in clinically node-negative patients[161]. The concept evolved 
that positive axillary lymph nodes were primarily a marker for a high risk of occult 
systemic spread, rather than a source of systemic metastases. With the advent of 
adjuvant systemic therapy, ALND came to be viewed primarily as a staging 
procedure: it conveyed prognostic information and guided decisions regarding 
adjuvant systemic therapy[162]. 
The SLNB as a technique in malignant melanoma patients was similarly 
investigated as part of a multinational, randomised clinical trial, the multicentre 
selective lymphadenectomy trial (MSLT-1). This aimed to validate the therapeutic 
efficacy of sentinel node biopsy in malignant melanoma patients using survival as an 
endpoint[139]. The study included 1269 patients with intermediate thickness (1.2-
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3.5mm) primary melanomas randomised to either a wide local excision and 
observation of regional lymph nodes with lymph node dissection if nodal relapse 
occurred (n=500) or to a wide local excision and SLNB with immediate regional 
lymphadenectomy if nodal micrometastases were found (n=769).   
There was no difference in overall 5-year melanoma-specific survival rate; 87.1% 
for the SLNB and 86.6% in the control arm. However, the study did show improved 
disease-free survival in those patients who underwent the SLNB compared to those 
in the nodal observation arm group; the 5-year survival rate for node positive 
melanoma was 72.3 ± 4.6% and 90.2 ± 1.3% in the node negative group (hazard 
ratio for death, 2.48; 95% confidence interval, 1.54 to 3.98; P < 0.001). The 
incidence of sentinel-node micrometastases was 16.0% and the rate of nodal relapse 
in the observation group was 15.6%. The corresponding mean number of tumour-
involved nodes was 1.4 in the biopsy group and 3.3 in the observation group 
(P<0.001), indicating disease progression during observation. Among patients with 
nodal metastases, the 5-year survival rate was higher among those who underwent 
immediate lymphadenectomy than among those in whom lymphadenectomy was 
delayed (72.3+/-4.6% vs. 52.4+/-5.9%; hazard ratio for death, 0.51; 95% confidence 
interval, 0.32 to 0.81; P=0.004)[140]. The study authors concluded that the staging 
of intermediate-thickness (1.2 to 3.5 mm) primary melanomas according to the 
results of SLNB provided important prognostic information. However, the study did 
not show a clear survival advantage associated with SLNB.  Further subset analysis 
from MSLT-1 comparing patients with a positive SLNB + immediate 
lymphadenectomy versus those in the nodal observation group showed that there 
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was significant progression to more advanced nodal disease in the nodal observation 
group and more importantly that there was a significant survival advantage in those 
undergoing immediate lymphadenectomy. More recently, the ten year follow up data 
for MSLT-1 has become available for this study[141]. This has helped to clarify 
matters to some extent by concluding that amongst patients with intermediate-
thickness melanomas (defined as those between 1.20-3.50 in this study), the 10-year 
melanoma-specific survival rate was 62.1±4.8% among those with lymph node 
metastasis versus 85.1±1.5% for those without metastasis. However, overall 10 year 
melanoma specific survival across all groups was unchanged. Furthermore, another 
significant finding within the study was that biopsy-based management prolongs 
disease-free survival for all patient subgroups, regardless of melanoma thickness.  
 
 Presently other than the updated recently available MSLT-1 results, there is no 
other robust evidence to show that SLNB results in a significant improvement in the 
rate of recurrence or spread of the melanoma[140]. However, clinical practice and 
current melanoma guidelines dictate that the SLN status remains an important part 
of the management of melanoma patients until there is further clarification on its 
role[53]. SLN negative melanoma patients have a 15% 5-year mortality, compared 
with 53% mortality for SLN positive patients[163]. It is clear therefore that SLNB 
may be a useful indicator of likelihood of recurrence[164], although it is has been 
proposed that it is insensitive for 18-22% of patients (incorrectly predicts as disease 
free therefore false negative)[165], and non-specific for up to 47% of patients 
(incorrectly identifies them as likely to die from recurrence therefore false positive) 
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if 5-year survival statistics are used as an endpoint[163]. In addition to the above, 
the process of SLNB can require significant pre-operative planning with injection of 
radioisotope in the radiology department and theatre time to perform the procedure. 
SLNB can be a cause of morbidity in a proportion of patients, so there is still 
discussion in the literature of its value and cost effectiveness given that questions 
exist regarding its validity and the interpretation of its status[166]. 
 
3.1.3 LYMPHATICS AND TUMOURS 
 
[122]In 1652, Thomas Bartholin published the first full description of the 
human lymphatic system. This followed on from Jean Pecquet’s work in 1651 which 
noted the lymphatic system in animals and his discovery of the thoracic duct[101]. 
In 1874, Sappey investigated the relatively unexplored area of lymphatic drainage of 
the skin. By injecting mercury into the interstitial tissues and lymphatic vessels of 
cadavers, he produced an extensive lymphatic atlas which contained highly detailed 
anatomical drawings[167]. He claimed that lymphatic drainage from the skin of the 
trunk was symmetric between the two sides of the body, never crossing the vertical 
midline of the body or a theoretical horizontal line drawn around the waist. These 
lines were termed “Sappey’s Lines” and defined four zones of skin on the trunk 
from which Sappey claimed that lymphatic drainage would occur to the 
corresponding axillary or groin node field. Uren et al. and Sugarbaker & McBride 
built upon Sappey’s concepts in the 1970’s when his theories were expanded further 
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[109,203]. These studies showed that lymphatic drainage was unpredictable from a 
strip of skin 2.5cm wide on either side of Sappey’s lines. Subsequent studies 
expanded the area of ambiguous drainage to include the head and neck and a much 
larger area of skin on the trunk, up to 11cm on either side of Sappey’s lines. This 
may be relevant in a clinical context, as it is still widely accepted that melanomas 
which affect the trunk are amongst those which carry the worst prognosis[53]. 
Further guidance regarding the patterns of lymphatic drainage of skin and associated 
tumours would be helpful to help us to delineate any clinically relevant patterns. 
Tissues in close proximity to the surface of the body usually have a high 
density of lymphatic vessels, including the skin or respiratory tract[101]. Although 
vessels are usually collapsed and non-functional, as a tumour grows it develops a 
high interstitial pressure at the centre which results in a fluid flow towards the 
periphery and may prompt opening of intercellular valves in lymphatics around the 
tumour[101]. This would increase the chances of malignant cells crossing into the 
lumen of the vessels and therefore increase the chances of nodal metastasis. In 2002, 
Padera et al. demonstrated that the intra-tumoural lymphatics are indeed non-
functional, however, there are functional lymphatics at the tumour margin which are 
sufficient for metastasis[168]. The adaptive characteristics of the lymphatic vessels, 
which make them ideal for the passage of antigen-presenting cells across the 
endothelial layer, may also increase the ease with which melanoma cells can 
metastasise via the lymphatics.    
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There are several possible mechanisms to explain lymphatogenous 
metastasis. Firstly, tumour cells may migrate into pre-existing lymphatics that have 
been encompassed during the growth of the primary lesion. Alternatively, malignant 
cells may migrate out of the tumour to invade pre-existing epi-tumoural lymphatics 
within the normal tissue.  Finally, the tumour may produce specific growth factors 
that stimulate the development of new lymphatic vessels either within the tumour or 
in the surrounding area, i.e. stimulate lymphangiogenesis [82]. Several animal 
models have been used to demonstrate that expression of the lymphatic specific 
growth factors, VEGF-C [169-171] and VEGF-D [172, 173], lead to an increase in 
both lymphangiogenesis and metastasis. The VEGF family represents highly potent 
growth factors, which as discussed are already known to play an important role in 
tumour angiogenesis. This is primarily mediated by VEGF-A through the tyrosine 
kinase receptor VEGF receptor-2[158].  VEGF-C and VEGF-D, however, are both 
lymphatic specific growth factors, which induce lymphangiogenesis through VEGF 
receptor-3[108]. This tyrosine kinase receptor undergoes homodimerisation and 
transphosphorylation on ligand binding and so induces a series of intracellular 
signalling pathways that are not fully understood [174]. The fully processed forms of 
both growth factors will also stimulate VEGF receptor-2 and so can influence blood 
endothelial cells. As a result they can cause angiogenesis as well as 
lymphangiogenesis, through different degrees of processing. VEGF-D is known to 
be secreted by developing melanocytes and fibroblasts, though its precise role is still 
unclear[175]. 
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Animal models which involved over expression of VEGF-C in transfected 
MCF-7 (human breast cancer) cells stimulated in vivo tumour growth in 
xenotransplanted mice demonstrated notable lymphangiogenesis and an increased 
rate of nodal metastasis[169, 171]. A link has also been indicated between increased 
expression of lymphatic specific growth factors and melanoma progression[176]. 
This work suggests that it would be of value to examine the expression of VEGF-C 
both in the melanoma samples in my cohort as well as their corresponding SLNs.  
 
3.1.4  AIMS AND REASONING 
 
It would be useful for us to examine VEGF expression in the primary tumour 
and see if a pattern emerges which allows us to predict nodal status. We have 
already presented that SLNB as a technique is not always accurate and several 
controversies still exist regarding its use. As presented above, we have some 
evidence that VEGF expression may help us to predict which tumours metastasise to 
the nodal basin, but at present it has not been attempted to predict nodal status by 
examining the primary tumour. Expression of high levels of VEGF by the primary 
tumour has been shown to induce endothelial proliferation in the SLN long before 
any metastatic tumour cells are even present [125, 126, 177]. These growth factors 
may prime the SLN for the arrival of metastatic cells optimising the environment for 
tumour survival, thus the “seed and soil” theory (see chapter 4)[125].   
 It may be possible to use VEGF expression for example as an aide to help us 
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decide which tumours are likely to have higher metastatic potential and/or chance of 
nodal spread and perhaps use VEGF expression as a marker for further disease 
potential. 
 
This chapter will examine whether there is a direct link between the balance 
of VEGFxxx and VEGFxxxb and VEGF-C expression in the primary tumour, and its 
SLN as a mechanism to facilitate nodal metastasis. This would establish a role for 
tumour expressed pro- and anti-angiogenic and pro-lymphangiogenic factors in 
preparing the body for metastasis.  
This relationship could be used to predict the status of the SLN and even the 
surrounding lymph node basin, thus identifying a subgroup of patients for whom 
SLNB is unnecessary, thereby minimising unnecessary surgical procedures and their 
associated risks. Furthermore, as highlighted in Chapter 1, the technique of staging 
patients and delivering prognostic information is currently suboptimal in several 
ways and if information can be identified from the primary tumour, which may 
further contribute to improving therapeutics and perhaps prevention strategies 
towards lymph node metastasis. Which would be ideal due to its rapidly rising 
incidence 
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METHOD 
3.1.5 PATIENT COHORT 
A total of 34 patients were investigated as part of this chapter of work. These 
were identified from the St. Helen’s and Knowsley Cancer Registry and had been 
treated for malignant melanoma between the years of 1999 and 2004. Five-year 
follow up data was therefore available on each patient. A colleague not directly 
related to the research project, Dr Kate Nelson, examined these patient lists and 
identified a total of 34 patients, 15 which were SLN positive and 19 which were 
SLN negative, for whom tissue from both the primary melanoma and corresponding 
SLN was available at Whiston Hospital, with each group matched for age, sex, 
Breslow thickness and location of primary lesion.  
 
3.1.6 ANALYSIS 
Archival melanoma tissues were sectioned and subsequently stained 
immunohistochemically for VEGFxxxb and Pan VEGF and finally VEGF-C. 
• Pan VEGF (detects all isoforms of VEGF) 
• VEGFxxxb (antiangiogenic isoforms only) 
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Immunohistochemistry methods used were as per those described in Chapter 
Two section 2.3. These samples were analysed as per Chapter 2 sections 2.5 and 
2.7.  
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3.2 RESULTS 
3.2.1 EPITUMOURAL EPIDERMIS 
Epitumoural and intratumoural staining patterns of VEGFxxxb and panVEGF 
were compared to begin with to see whether our samples showed similarities with 
patterns which have already been found by Pritchard-Jones et al[79].  Figure 12 
demonstrates at 4x magnification staining of normal epidermis adjacent to a stained 
malignant melanoma.  
 
 To compare pan VEGF staining of epi-tumoural epidermis and staining 
within the tumour with VEGFxxxb staining, a total of 34 sections of malignant 
melanoma, underwent immunohistochemically for pan VEGF and then VEGFxxxb. 
 
Figure 12 Section at x4 magnification demonstrating stained normal epidermis 
adjacent to a stained tumour 
 
111 
This staining was scored by three independent assessors on a scale of 0-3 (with 3 
being the strongest staining) both intratumourally and also in the normal epitumoural 
tissue for A) intensity of staining, and also the B) percentage of cells expressing. 
These scores were then combined to give an overall C) combined score. 
 
 
Figure 13 illustrates VEGF expression in normal skin and its corresponding tumour. 
We can see a significant reduction of VEGFxxxb in the tumour as compared with the 
epi-tumoural epidermis as well as a significant increase of the angiogenic pan VEGF 
in the tumour when compared with epi-tumoural epidermis. These were not 
surprising findings based on our knowledge of tumour related angiogenesis, already 
described in Chapter 1[72].  
Next, based on the discussion of the value of SLNB above, I proceeded to 
assess staining of VEGF within the tumour and compare this to SLN status to 
Figure 13 VEGF expression in normal skin and corresponding primary lesions 
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establish whether a relationship could be delineated which may allow prediction of 
SLN status based on VEGF expression. 
 
3.2.2 TUMOUR STAINING COMPARED WITH SENTINEL LYMPH NODE 
OUTCOME 
 
A total of 34 primary tumours were stained immunohistochemically for pan 
VEGF and VEGFxxxb. This staining was scored by three independent assessors both 
in the epi-tumoural epidermis and intratumourally for A) intensity of staining, and 
also the B) percentage of cells expressing. These scores were then combined to give 
an overall C) combined score. The graphs in Figure 14 and 15 represent mean ± 
SEM displayed as error bars.  
Staining intensity was first examined (intratumoural 1.31±0.25, epi-tumoural 
0.74±0.16 in SLN positive nodes versus intratumoural 1.30±0.18, epi-tumoural 
0.61±0.17 in SLN negative nodes) 
Percentage of cells stained was next looked at (intratumoural 1.67±0.31, epi-
tumoural 0.86±0.22 in SLN positive nodes versus intratumoural 1.57±0.21, epi-
tumoural 0.76±0.21 in SLN negative nodes)  
Finally, a combined score was looked at (intratumoural 3.02±0.50, epi-
tumoural 1.60±0.34 in SLN positive nodes versus intratumoural 2.87±0.36, epi-
tumoural 1.37±0.35 in SLN negative nodes) 
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There was no significant difference in any of the parameters above used to 
measure expression of pan VEGF staining (SLN positive n=15, SLN negative n=18, 
one-way ANOVA, p>0.05), see graphs below.  
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Figure 3-4 Expression of pan VEGF within Primary Lesions 
A total of 33 primary tumours were stained immunohistochemically for Pan 
VEGF. This staining was scored by three independent assessors both 
intratumourally and also in the normal epitumoural tissue for A) intensity of 
staining, and also the B) percentage of cells expressing. These scores were then 
combined to give an overall C) combined score. Graphs represent mean ± SEM. 
There was no significant difference in pan VEGF expression intratumourally or 
epitumourally between those tumours that were found to be SLN positive (n=15) 
or SLN negative (n=18) (one-way ANOVA, p>0.05). 
Figure 14 Expression of Pan VEGF within primary tumours 
Similarly, there was no significant difference in expression of VEGFxxxb 
staining intensity (intratumoural 1.53±0.23, epi-tumoural 2.07±0.20 in SLN positive 
nodes versus intratumoural 1.49±0.20, epi-tumoural 2.16±0.20 in SLN negative 
nodes) 
Percentage of cells stained was again next looked at (intratumoural 
2.43±0.27, epi-tumoural 3.10±0.27 in SLN positive nodes versus intratumoural 
1.98±0.26, epi-tumoural 3.02±0.18 in SLN negative nodes)  
Finally, as above, total combined score was looked at (intratumoural 
4.07±0.43, epi-tumoural 5.19±0.27 in SLN positive nodes versus intratumoural 
3.43±0.41, epi-tumoural 4.87±0.34 in SLN negative nodes) 
There was no significant difference in any of the parameters above used to 
measure expression of VEGFxxxb staining (SLN positive n=15, SLN negative n=19, 
one-way ANOVA, p>0.05), see graphs below.  
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Figure 3-5 Expression of VEGFxxxb within Primary Lesions 
A total of 33 primary tumours were stained immunohistochemically for VEGFxxxb. 
This staining was scored by three independent assessors both intratumourally and 
also in the normal epitumoural tissue for A) intensity of staining, and also the B) 
percentage of cells expressing. These scores were then combined to give an 
overall C) combined score. Graphs represent mean ± SEM. There was no 
significant difference in VEGFxxxb expression intratumourally or epitumourally 
between those tumours that were found to be SLN positive (n=15) or SLN 
negative (n=18) (one-way ANOVA, p>0.05). 
Staining Intensity Percentage Staining 
Score 
Combined Score 
Figure 15 Expression of Antiangiogenic VEGF within primary tumours 
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Clearly no pattern has been defined so far by looking at these tumour 
staining patterns, except what was already expected within normal skin staining. The 
nodal status apparently does no reveal any significant VEGF staining patterns within 
my cohort of tumour samples and their corresponding adjacent epidermis. There 
may be many explanations for this, which will be discussed below. 
I then proceeded based on the known findings by Pritchard-Jones et al. [79] 
to examine whether any relationship could be determined in our cohort by dividing 
the patients into two groups based on the metastatic status where available, 
(metastasis vs. non-metastasis of tumour). 
 
3.2.3 TUMOUR STAINING COMPARED WITH DISTANT METASTATIC 
OUTCOME 
Next, having divided my patients into two groups based on whether their 
tumour metastasised to a distant site (i.e. distant organs as opposed to lymphatic 
basin) (n=8) or not (n=13), VEGF staining was compared based on this parameter. 
As the hospital where we accessed our tumours from is a tertiary referral unit, all 
aspects of care were not carried out at this hospital in every case. Therefore 
metastatic outcome was not known in 13 patients within my cohort, Scoring 
methods were consistent and as described above.  
Again, the graphs in Figure 16 and 17 represent mean ± SEM displayed as 
error bars. A total of 21 primary tumours were stained immunohistochemically for 
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pan VEGF and VEGFxxxb. This staining was scored by the same three independent 
assessors both in the epi-tumoural epidermis and intratumourally as above.  
Pan VEGF staining was examined first. Staining intensity was first examined 
(intratumoural 1.13±0.19, epi-tumoural 0.70±0.19, in tumours which metastasised to 
a distant site versus intratumoural 1.39±0.21, epi-tumoural 0.90±0.29 in tumours 
which did not metastasise) 
Percentage of cells stained was next looked at (intratumoural 1.37±0.24, epi-
tumoural 0.90±0.29 in tumours which metastasised to a distant site versus 
intratumoural 1.81±0.25, epi-tumoural 0.77±0.20 in tumours which did not 
metastasise) 
Finally, a combined score was looked at (intratumoural 2.47±0.38, epi-
tumoural 1.60±0.44 in tumours which metastasised to a distant site versus 
intratumoural 3.24±0.41, epi-tumoural 1.42±0.34 in tumours which did not 
metastasise). 
Next VEGFxxxb staining was examined. As above, staining intensity was first 
examined (intratumoural 1.47±0.26, epi-tumoural 1.67±0.35 in tumours which 
metastasised to a distant site versus intratumoural 1.57±0.20, epi-tumoural 
2.32±0.13 in tumours which did not metastasise) 
Percentage of cells stained was next looked at (intratumoural 2.00±0.30, epi-
tumoural 3.10±0.39 in tumours which metastasised to a distant site versus 
intratumoural 2.25±0.26, epi-tumoural 3.13±0.16 in tumours which did not 
metastasise) 
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Finally, a combined score was looked at (intratumoural 3.47±0.49, epi-
tumoural 4.77±0.68 in tumours which metastasised to a distant site versus 
intratumoural 3.83±0.42, epi-tumoural 5.22±0.29 in tumours which did not 
metastasise) 
 
There was no significant difference in any of the parameters above used to 
measure expression of pan VEGF or VEGFxxxb staining (patients who metastasised 
to a distant site n=8, patients who did not metastasise n=13, one-way ANOVA, 
p>0.05), see graphs below.  
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Figure 3-6 Expression of pan VEGF in tumours sorted by Metastatic Status 
A total of 21 primary tumours were stained immunohistochemically for VEGFxxxb. 
This staining was scored by three independent assessors both intratumourally and 
also in the normal epitumoural tissue for A) intensity of staining, and also the B) 
percentage of cells expressing. These scores were then combined to give an overall 
C) combined score. Graphs represent mean ± SEM. There was no significant 
difference in VEGFxxxb expression intratumourally or epitumourally between those 
tumours that were found to be metastatic (n=8) or non metastatic (n=13) (one-way 
ANOVA, p>0.05). 
Figure 16 Expression of pan VEGF in tumours sorted by metastatic status 
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Figure 3-7 Expression of VEGFxxxb in tumours sorted by Metastatic Status 
A total of 21 primary tumours were stained immunohistochemically for VEGFxxxb. 
This staining was scored by three independent assessors both intratumourally and 
also in the normal epitumoural tissue for A) intensity of staining, and also the B) 
percentage of cells expressing. These scores were then combined to give an overall 
C) combined score. Graphs represent mean ± SEM. There was no significant 
difference in VEGFxxxb expression intratumourally or epitumourally between those 
tumours that were found to be metastatic (n=8) or non metastatic (n=13) (one-way 
ANOVA, p>0.05). 
Figure 17 Expression of antiangiogenic VEGF in tumours sorted by metastatic 
status 
 3.2.4 VEGF-C STAINING 
VEGF-C expression in the primary tumour was next analysed using the same 
methods as above. As mentioned in section 1.1.3, a link has been indicated between 
increased expression of lymphatic specific growth factors and melanoma 
progression[176]. Hence, I next evaluated VEGF-C expression using the same 
immunohistochemistry techniques described above to determine whether a pattern 
might be established based on nodal status. Following examination of the emerging 
staining patterns, in conjunction with the histopathology department of St. Helens’ 
and Knowsley Trust, it became clear that both the capsular element and the 
intranodal element of the SLN was subject to differing intensities of staining. Figure 
18 depicts a stained SLN with VEGF-C. 
 
 Figure 18 VEGF-C expression within a positive SLN (control slide inset). Note 
deeper intensity of staining intranodally and light brown staining of capsule 
As seen in figures 19 and 20 below, I was unable to predict SLN status by 
examining VEGF-C levels within the primary tumour. Staining intensity was 
measured at 0.76±0.23 in SLN positive patients versus 1.11±0.23 in SLN negative 
patients. Percentage of cells stained was measured at 0.85±0.27 in SLN positive 
patients versus 0.94±0.21 in SLN negative patients. Combined staining scores were 
measured at 1.61±0.49 in SLN positive patients versus 2.05±0.42 in SLN negative 
patients. (SLN positive n=15, SLN negative n=18, one-way ANOVA, p>0.05), see 
graph in Figure 19 below.  
 
The levels also did not allow prediction of distant metastatic status in this cohort of 
patients. Staining intensity was measured at 1.10±0.35 in patients who metastasised 
to a distant site versus 1.00±0.20 in those patients who did not metastasise. 
Percentage of cells stained was measured at 0.70±0.21 in patients who metastasised 
to a distant site versus 0.89±0.24 in those who did not metastasise. Combined 
staining scores were measured at 1.80±0.56 in those patients who metastasised to a 
distant site versus 2.11±0.43 in those patients who did not metastasise. (Patients who 
metastasised n=8, patients who did not metastasise n=13, one-way ANOVA, 
p>0.05), see graph in Figure 20 below. 
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Figure 3-9 Expression of VEGF-C within Primary Lesions 
A total of 33 primary tumours were stained immunohistochemically for  
VEGF-C. This staining was scored by three independent assessors 
intratumourally for A) intensity of staining, and also the B) percentage of 
cells expressing. These scores were then combined to give an overall C) 
combined score. Graphs represent mean ± SEM. There was no significant 
difference in VEGF-C expression intratumourally between those tumours 
that were found to be SLN positive (n=15) or SLN negative (n=18) (one-
way ANOVA, p>0.05). 
Figure 19 Expression of VEGF-C within primary lesions 
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Figure 3-10 Expression of VEGF-C in tumours sorted by metastatic status 
A total of 33 primary tumours were stained immunohistochemically for  VEGF-C. 
This staining was scored by three independent assessors intratumourally for A) 
intensity of staining, and also the B) percentage of cells expressing. These scores 
were then combined to give an overall C) combined score. Graphs represent mean 
± SEM. There was no significant difference in VEGF-C expression 
intratumourally between those tumours that were found to have metastasised (n=8) 
or not metastasised (n=13) (one-way ANOVA, p>0.05). 
Figure 20 Expression of VEGF-C in tumours sorted by metastatic status 
 
!! "#$!
 
Taking account of the staining patterns depicted in figure 18, if I looked 
specifically at capsular versus intranodal staining of VEGF-C and compared 
SLN positive patients with SLN negative patients, this is depicted in figure 21.  
 SLN positive nodes capsular combined scoring was 1.42±0.22 versus 
1.23±0.16 in node negative patients, a non significant difference. SLN positive 
nodes intranodal score was 3.91±0.49 versus 2.63±0.43 in node negative 
patients. This was a significant difference (p<0.01 Bonferroni). Intranodal 
VEGF-C expression was significantly higher in SLN positive patients when 
compared with SLN negative patients. This suggests, therefore, that either 
tumour cells expressing VEGF-C are most likely to successfully spread to the 
lymphatic system (but as our results show, there is little evidence of this from our 
set of experiments with no significant difference being found between 
intratumoural VEGF-C staining of tumours which spread to the nodes and those 
which did not), or that tumour cells arriving in SLNs may need to express 
VEGF-C to survive.  This will be discussed in more detail below. 
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Figure 21 Expression of VEGF-C in the sentinel lymph node, capsular vs intranodal staining 
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3.3 DISCUSSION 
3.3.1 INTERPRETATION OF RESULTS 
Epitumoural and intratumoural staining patterns of VEGFxxxb and pan 
VEGF were compared to begin with to see whether our samples showed 
similarities with patterns which have already been found by Pritchard-Jones et 
al[79]. I found a significant reduction of VEGFxxxb in the tumour as compared 
with the corresponding epi-tumoural epidermis as well as a significant increase 
of the angiogenic pan VEGF in the tumour when compared with epi-tumoural 
epidermis. These were not surprising findings based on our knowledge of tumour 
related angiogenesis, already described in Chapter 1[72]. The concurrent 
reduction in VEGFxxxb within the tumour with an increase in pan VEGF (hence 
pro-angiogenic isoforms) may represent not only a pro-angiogenic tumour, but 
also a switch away from anti-angiogenic isoforms expression. This supports the 
notion that there is a switch in splicing as part of the metastatic process, from 
anti-angiogenic to pro-angiogenic VEGF isoforms[79]. See section 1.3.2, “The 
Angiogenic Switch”.  
Next, in response to the arguments presented above that SLNB as a 
technique has its limitations, I proceeded to stain tumours with pan VEGF, 
VEGFxxxb and VEGF-C to attempt to predict SLN status by examining relative 
expression of these factors. No significant patterns were found. Reasons were 
sought in the current literature to try to explain these findings. Much data exists 
regarding the validity of SLN as a technique and this may help to explain my 
findings. See section 1.33 below “The Value of Sentinel Lymph Node Biopsy” 
with subsequent subsections detailing the notions of “False Positivity”, 
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discussing in more detail the already introduced MSLT-1 trial and further 
detailing the concept of “Burden of disease” in the SLN. 
 
Further patterns were sought when SLN status did not reveal any 
significant patterns. Dividing the patients by distant metastatic outcome again did 
not allow any significant patterns to be determined. Numbers of patients whose 
distant metastatic outcome could be reliably determined however were low as not 
all patients received all care at the hospital trust which we had access to, and may 
have moved on to see physicians at a more local unit to them following their 
melanoma surgery. With regard to predicting metastatic outcome, despite low 
numbers, our results are not unexpected and are subject to further discussion. A 
number of studies have attempted to investigate angiogenic growth factors to 
determine whether they can predict distant metastasis, but these studies have 
shown a poor correlation between the most potent angiogenic factor VEGF-A 
and metastatic spread[99, 154].  This is discussed further below in section 1.3.4 
“Predicting Metastatic Status by the Expression of VEGF” 
 
As staining for VEGF-C was examined within the lymph nodes, a 
staining pattern emerged whereby capsular staining and intranodal staining 
differed within SLNs. Therefore scoring methods were adjusted accordingly to 
take account of this. By dividing the capsular and intranodal scoring and sorting 
the patients into SLN positive versus negative, a statistically significant rise in 
VEGF-C was apparent in the intranodal component of positive nodes when 
compared with negative nodes. This suggests, therefore, that either tumour cells 
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expressing VEGF-C are most likely to successfully spread to the lymphatic 
system (but we have found little supportive evidence for this as no difference 
was found in intratumoural staining between those tumours which metastasised 
to the lymph node and those which did not), or that tumour cells arriving in 
SLNs may need to express VEGF-C to survive.  This will be discussed in more 
detail below in section 3.3.5. 
 
3.3.2 THE ANGIOGENIC SWITCH 
 
 The “Angiogenic Switch” is the tumour’s ability to break free of the 
normal physiological controls of angiogenesis and can be triggered by various 
signals. This is essential for tumour progression. Triggers include metabolic 
stress (Low pO2, low pH, or hypoglycaemia), mechanical stress (pressure from 
proliferating cells), an inflammatory response (infiltrating inflammatory cells) 
and genetic mutations (oncogene activation, tumour suppressor gene 
inactivation)[72]. VEGF expression appears to be related to the switch from 
horizontal to vertical growth phase when immunohistochemical analyses are 
employed[95]. This 1997 study helps to explain the staining patterns which we 
see in normal skin versus tumours. The study involved assessing the role of 
VEGF in the angiogenic process in primary cutaneous melanoma, mean vascular 
density and the presence of VEGF protein was determined in human melanomas. 
Results were compared with normal uninvolved skin from the same patient. 
Mean vascular density was shown to rise with melanoma progression, transition 
from horizontal to vertical growth phase was accompanied by an induction of 
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VEGF and accumulation of the this factor in the stroma. This would explain my 
results as shown in figure 3.3. I saw a rise in pan VEGF but not VEGFxxxb from 
epi-tumoural skin compared with intratumoural levels. Similarly our results were 
consistent with the staining patterns found by Pritchard Jones et al. [79] where 
expression was significantly reduced in primary melanoma samples (both 
horizontal and vertical growth phases) from patients who subsequently 
developed nodal metastasis compared with those who did not (analysis of 
variance (ANOVA) P<0.001 metastatic vs. nonmetastatic), irrespective of 
tumour thickness, while the surrounding epidermis showed no difference in 
expression.  
 
3.3.3 THE VALUE OF SENTINEL LYMPH NODE BIOPSY 
 
 As previously mentioned, SLNB is growing in importance in the 
management of melanoma patients, with many centres now utilising it as part of 
routine staging, providing both prognostic information and identifying subgroups 
of patients who may benefit from completion lymphadenectomy (CL).  There is 
however a growing debate on performing SLNB and there is literature available 
which disputes the value of SLNB and this may be relevant to explain why we 
were unable to find any discernible patterns of VEGF expression in positive or 
negative nodes.  
 Work by Thomas disputes that all positive SLN biopsies will progress to 
nodal disease if not removed[178]. In this work, the author describes his theories 
that some deposits of melanoma within the sentinel nodes are destined for 
dormancy or destruction and are not prognostically relevant. Although studies 
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have concluded that SLN status is the most important prognostic factor for 
recurrence and survival when compared with other prognostic factors 
individually[128, 140], it has also been demonstrated that algorithms of other 
prognostic factors might be almost as powerful prognostic indicators as sentinel 
node status alone[179]. Kruger at al performed a study recruiting 682 patients 
with primary vertical growth phase (VGP) melanoma and no clinical evidence of 
metastatic disease who underwent SLN biopsy (1995-2003). Logistic regression 
and classification tree analyses were used to investigate the association between 
SLN positivity and Breslow thickness, Clark level, tumour infiltrating 
lymphocytes (TIL), ulceration, mitotic rate (MR), lesion site, gender, and age. 
The authors concluded that their analysis indicated that by incorporating 
biologically based variables such as VGP, TIL, and MR along with thickness 
into a prognostic model, both patients at high risk and minimal risk for SLN 
positivity can be identified. 
 
 As evidence grows that SLNB as a prognostic indicator is suboptimal, the 
use of ultrasound has heightened the debate. Ultrasound techniques with or 
without the use of Doppler have been found to accurately image lymph-node 
basins even for micrometastases, and there is growing evidence that the use of 
non-invasive ultrasound techniques are more superior to both clinical 
examination alone or SLNB in terms of accuracy and sensitivity to detecting 
micrometastases with fewer associated risks[180-182]. 
 Deposits of melanoma as small as 4 mm in the groin and neck, and 4.5 mm 
in the axilla, which may remain undetected by SLNB alone, can be identified 
according to morphological criteria and the diagnosis proven by ultrasound-
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guided biopsy. This approach identifies 24% of patients who are eventually 
proven to have positive sentinel nodes[183]. Deposits of this size represent 
occult clinical disease and if undetected by SLNB would fail to upstage a patient, 
but are still defined as micrometastases and classified as N1a or N2a (see 
Chapter 1). For this reason it has been recommended that the at-risk nodal basins 
should be screened by ultrasonography before proceeding to SLNB[178]. 
 Contributing to the debate of the value of SLNB is the SLN, which is 
negative at time of sampling but where the patient later develops lymph node 
metastasis. ‘False negative’ SLNB has previously been described in the literature 
and a cohort of ‘false negative’ patients are addressed in my own work as part of 
Chapter 5. Up to 14% of patients with negative SLNB will develop tumour 
recurrence by 3 years[128, 184, 185]. Clearly this is a concern for patients who 
attend for accurate prognostic information at the worrying time of diagnosis of 
the primary tumour and equally for clinicians who would wish to deliver the 
most accurate prognostic information to their patients. 
 The above collection of works calls into question the true validity of the 
SLN and its clinical impact. Furthermore, there is work which exists which states 
that not all positive nodes will progress to cause clinically significant disease and 
this is termed the concept of “false positivity”. 
 
3.3.3.1 “FALSE POSITIVITY OF THE SENTINEL LYMPH NODE” 
 The relatively unexplored concept of ‘false positivity’ has also been 
introduced by the work of Thomas[178]. Thomas  “there are concerns that some 
deposits of melanoma within the sentinel nodes are destined for dormancy or 
destruction and are not prognostically relevant”. These theories may also 
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contribute to why the analysed lymph nodes in my study regardless of status or 
metastatic outcome, did not show any significantly different staining patterns.  
 The evidence for prognostic false positivity comes from several sources, all 
of which contribute to the growing body of evidence that contribute to the 
debates regarding the prognostic value of SLNB. Such patients can be wrongly 
up-staged, might be given inaccurate prognostic information, and might undergo 
unnecessary lymphadenectomy and possibly unnecessary adjuvant therapy, all 
with their associated and considerable risks and side effects. 
 Identifying which patients are at risk of being “falsely positive” is possible, 
according to Thomas[178], based on previous work. Firstly, it is inferred that if a 
tumour is below a certain size, a melanoma micrometastasis in a sentinel node is 
of no adverse prognostic importance, but there is no agreement about the cut-off 
point with respect to size[149, 150, 186-188]. Spanknebel et al.[149] concluded 
that the prognosis for patients with micrometastases that can be detected only by 
immunohistochemistry is similar to that of patients with negative sentinel nodes. 
Similarly, van Akkooi et al.[150] state that patients with micrometastases smaller 
than 0.1 mm diameter in the sentinel nodes should be judged to have negative 
sentinel nodes. These observations, however, depend on the sentinel nodes being 
removed for histology, which could be construed as contributing to any 
therapeutic benefit[178]. 
 Another explanation for prognostic false positivity is the apparent paradox 
that exists that younger patients with melanoma have a significantly better 
prognosis than older patients despite having a higher incidence of positive 
sentinel nodes[151, 152]. Chao et al.[152] report in their study of 3,076 patients 
that the incidence of positive sentinel nodes declines with increasing decades of 
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age, being 23.1% in patients younger than 30 years and only 12% in patients 
aged between 61 and 70 years (P <0.001). Statius Muller et al.[151] found that 
the incidence of positive sentinel nodes was 37% among patients aged 18–30 
years and 17% among patients aged 71–84 years. One possible explanation is 
that in the absence of evidence that melanoma spreads more commonly by the 
bloodstream in older patients, Chao and coauthors suggest that younger patients 
may have a generally more competent immune system that eliminates small 
micrometastases before they manifest clinically[152]. Despite these findings, 
work conducted by Thompson et al.[189] and Sondak et al.[190] recommends 
that the increased incidence of positive SLNB in young patients (those under 35 
years) should be one of the prognostic factors that justifies routine performance 
of SLNB in young people[190] even when the tumour thickness is less than 1 
mm[183].  
 
 Work done by Thomas[178] details also how prognostic false- positivity in 
the patients with positive SLNB is the most likely explanation of why the results 
of two well known retrospective studies indicated that early lymphadenectomy in 
patients with positive sentinel nodes would result in a survival advantage [145, 
191]. Both studies compared the survival of patients who had positive sentinel 
nodes and who underwent early lymphadenectomy with that of patients who had 
delayed lymphadenectomy for palpable nodal recurrence. Kretschmer et al.[191] 
a 12% survival advantage at 5 years whereas Morton et al.[145], who did a 
matched pair analysis, claimed a survival advantage of 22%, 32% and 37% at 5, 
10 and 15 years, respectively, in favour of early lymphadenectomy.  
 Clarification in this field of work was clearly called for and the first Multi-
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center Selective Lymphadenectomy Trial (MSLT-1) was conducted to evaluate 
the safety, efficacy and therapeutic impact of lymph node dissection as directed 
by SLN biopsy. 
 
3.3.3.2 THE “MULTICENTER SELECTIVE LYMPHADENECTOMY TRIAL” 
(MSLT-1) AND ITS RELEVANCE  
 
 The only large-scale randomised multicentre trial that has been done for the 
evaluation of SLNB benefit in melanoma is the “Multicenter Selective 
Lymphadenectomy Trial” (MSLT-1)[140]. Recently, 10 year follow up data has 
become available based on the work of the initial study[141]. This trial entered 
2,001 patients who were randomized (40% versus 60%) either to WLE of the 
primary tumour with delayed lymphadenectomy if and when metastatic regional 
nodes became palpable (the observation arm) or to WLE and SLNB with 
immediate (early) lymphadenectomy if the sentinel node or nodes contained 
metastatic melanoma (the biopsy arm). The initially published results however 
refer only to 1,269 patients with intermediate-thickness tumours (1.2–3.5 mm). 
There was no difference in melanoma-specific survival at 5 years (87% versus 
86%) and only a small difference of 5.2% in disease-free survival (DFS) at 5 
years, in favour of early lymphadenectomy. No survival or other data are 
available on the 732 patients with tumours that were less than 1.2 mm or more 
than 3.5 mm thick, who were entered and randomized into MSLT-1 but excluded 
from this publication. The ten year follow up data as described previously, found 
a melanoma-specific survival advantage in the intermediate thickness group 
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only, (62.1±4.8% among those with metastasis versus 85.1±1.5% for those 
without metastasis). SLNB based management also was found to prolong 
disease-free survival for all patients but overall survival across all melanoma 
thicknesses in the SLN group was unchanged when compared with the 
observation group. 
 Further work by Thomas critiques the arguments presented by Morton[140] 
and Thompson,[183] which argues that it is valid and legitimate within the 
MSLT-I to compare the survival of patients in the control arm (wide local 
excision and observation) who developed palpable nodal recurrence, with 
patients in the test arm (wide local excision, SLNB with or without complete 
lymphadenectomy) who are SLN-positive. In other words, making the 
assumption that “most if not all occult SN-metastases will eventually become 
palpable nodal recurrences” meaning that these two groups of patients are 
biologically comparable. Thomas argues that this is almost certainly not the case 
and furthermore, a survival comparison of the two groups of patients in question 
is statistically invalid. In a randomised controlled trial, survival comparisons 
must be made on an intention-to-treat basis and from the point of random 
assignment. Patients can be identified and stratified before random assignment. 
Within MSLT-I, for example, this could apply to prognostic factors such as 
primary tumour thickness and site. However, it was not known before random 
assignment which patients would develop palpable nodal recurrences and which 
patients would be SLN-positive. Therefore, these patients represent selected 
subgroups, which invalidate any statistical comparison. Thomas argues that this 
error is an elementary and fundamental misunderstanding of the rules of 
statistical methodology which might account for the lengthy delay in publishing 
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the results of the 10-year follow-up of MSLT-1. Furthermore, the above critique 
of MSLT-1 undermines the rationale for MSLT-2 (which at was coming to the 
end of the recruitment process worldwide prior to the ten year results of MSLT-1 
being published) as this is predicated on the assumption that selective 
lymphadenectomy confers a survival benefit. 
 
3.3.3.3 BURDEN OF DISEASE IN THE SENTINEL NODE 
 
Another controversy that surrounds SLNB is that there is no consensus on 
the benefit of a completion dissection in melanoma patients with a small tumour 
burden in their sentinel node. The micromorphometric S-classification described 
by Starz et al. can guide the decision whether to perform completion 
dissection[188, 192]. This system is based on the depth of penetration of the 
metastasis from the surrounding capsule into the node. Patients categorised as S-I  
(0.3 mm invasion depth) and S-II (0.31–1.0 mm invasion depth) has a relatively 
small risk of additional lymph node disease[188, 193]. S-III metastases are 
defined by an invasion depth of more than 1.0 mm, which has been reported to 
imply a more than 50% risk of additional lymph node metastases in the 
basin[188]. 
In a study performed by van der Ploeg et al.[194], 79 patients with SLN 
metastases were studied. 20 patients with an S-I or S-II classification were spared 
further surgery and 50 S-III patients underwent completion dissection. The 
median follow-up time for all groups was 33 months. No lymph node recurrences 
were detected in the 20 S-I, II patients. 6/50 S-III patients (12%) had additional 
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involved nodes in the dissection specimen. In these patients no recurrences 
developed in the cleared regional basins. Overall 3-year survival was 100% in 
the S-I, II patients and 80% in the S-III patients (P = 0.04).  
Two interesting points relevant to our results can be drawn from this 
work. Firstly, almost a quarter of cases from the sample size of 79 had a very low 
burden of disease (S-1 or 11), which prognostically did not alter their chance of 
further lymph node recurrence or survival. This may be relevant to our work and 
may indicate that a proportion of our samples may have had microscopic disease 
present. Secondly, this may explain why our immunohistochemical techniques 
were unable to detect a significant difference in VEGF expression regardless of 
nodal status. Perhaps some of the SLN which we were sampling displayed such 
microscopic levels of disease that our staining techniques were unable to detect 
any significant differences in positive or negative nodes based on the low levels 
of disease in the nodes.   
Furthermore, although the term ‘micrometastases’ is widely used in 
malignant melanoma, the literature highlights the need for further clarification of 
this term. In the breast cancer staging system, tumour deposits with a size of 0.2 
to 2.0 mm are defined as micrometastases and when smaller than 0.2 mm as 
submicrometastases[195]. 
It is widely accepted that completion axillary dissection can be safely 
omitted in patients with submicrometastases in the sentinel node. In melanoma, 
the term micrometastasis has been formally defined as a metastasis that is 
“diagnosed after sentinel node biopsy or elective lymphadenectomy.”[53]. This 
definition implies that any nonpalpable metastasis is a micrometastasis. There is 
thus no defined upper diameter and a micrometastasis may be quite sizeable 
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depending on factors that are not associated with the actual tumour deposit such 
as patient size. For instance, a lymph node metastasis in an obese patient will 
generally be larger before it becomes palpable compared with a slim patient. The 
micromorphometric S-classification introduced by Starz et al. is an attempt to 
formally establish what size metastasis constitutes a ‘micrometastasis’, and 
suggests that melanoma patients with an S-I, II sentinel node metastasis can be 
spared a lymph node dissection, while an S-III metastasis implies a need for 
completion dissection[188, 192]. These findings are supported by the MSLT-1 
results as finding disease early in the patients recruited did not improve 
outcomes[140].  
 
Linking this with our results, it is becoming apparent that finding positive 
nodal disease may not change clinical outcomes. Data to support its use with 
regard to improving survival is lacking. I found no evidence that expression of 
VEGF isoforms could predict the nodal status within my cohort. Although many 
arguments have been presented above as to why disease in the SLN may not be 
as clinically relevant as initially thought, it is also worth bearing in mind that this 
may reflect the unpredictable nature of malignant melanoma which highlights the 
need for continued research in this area so that we can select with surety those 
patients who would benefit from completion lymphadenectomy so that their will 
be a definite improvement in their outcomes.  
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3.3.4 PREDICTING METASTATIC STATUS BY EXAMINING VEGF 
EXPRESSION 
 
Unlike previous work done by Pritchard Jones et al. on human 
melanoma[79], I was unable to predict the distant metastatic status of the patient 
by examining the relative expression of VEGF in primary tumours.  As 
previously mentioned, this may be due to my low sample size as many patients 
within my cohort had an unknown metastatic status due to receiving onward care 
after SLN and subsequent surgery at a more local hospital rather than our tertiary 
care centre. From my cohort of 34 patients, I was able to ascertain only 21 
patients’ metastatic status. My inability to find any discernible patterns however, 
do support the findings of some other authors. 
A study by Erhard et al. [95] which investigated the role of VEGF in 
primary cutaneous melanoma involved determining the mean vascular density 
and the presence of VEGF protein in biopsies of human lesions. The results were 
compared with those found in normal skin or uninvolved skin from melanoma 
patients. They showed that the mean vascular density gradually rose along with 
melanoma progression. As mentioned above, they also demonstrated that 
transition of horizontal to vertical growth phase melanoma is accompanied by 
induction of VEGF protein expression and accumulation of this factor in the 
stroma, Interestingly, they found that vertical growth phase melanoma is often 
organised in nodules separated by septa containing blood vessels, but without 
lymphatics, and that blood vessel lumina in the vertical growth phase are 
separated from tumour nodules by two basal lamina containing collagen type IV 
 
141 
and the endothelium shows activated morphology and focal expression of the 
adhesion molecule E-selectin. The findings indicated that although VEGF is a 
prominent angiogenic factor in human melanoma angiogenesis, the effect of 
VEGF on the incidence of metastasis is probably indirect. 
Similarly, a 2003 study by Potti et al. [99] the role of VEGF in transition 
of melanoma cells from radial to vertical growth phase was investigated to 
determine its possible diagnostic and prognostic implications. The authors 
analysed if there was the presence of over expression of VEGF in 202 archived 
cases of human melanoma where the patient outcome was known. IHC 
techniques were used. Of the 202 melanoma specimens, 42 (20.8%) showed 
evidence of VEGF over expression on IHC testing. Multivariate analysis 
performed using Cox proportional hazards method did not show a statistically 
significant survival difference between the VEGF-positive and negative groups 
(p = 0.25). It was concluded that although of no significant prognostic value, 
VEGF might have critical therapeutic implications as a molecular target since it 
is expressed in about 20% of melanomas.  
 The fact that metastatic cancer cells can easily replace all of the 
lymphocytes and other normal cells in the lymph node but retain the preexisting 
vascular system for a longer time also strongly implies that the 
microenvironment in lymph node is favourable for the expansion of metastatic 
tumours [196] but perhaps with little change in its own cell profile whilst these 
changes ensue.  Although this pattern has not been previously defined in 
melanoma, this may also help to explain why we saw no relationship between 
melanoma VEGF expression in those tumours, which metastasised to the nodal 
basin, and those which did not.  
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3.3.5 THE RELEVANCE OF VEGF-C AND MELANOMA 
 
Much recent work has sought to investigate the prognostic significance of 
VEGF-C and the promotion of lymphatic spread. Recent work by Watanabe et 
al.[197] examined the role of VEGF-C in SCC of the oral region.  Having 
recognised that SCC of the head and neck often metastasises to the cervical 
lymph nodes, the authors investigated whether the risk of cervical lymph node 
metastasis is predictable through lymphatic vessel density (LVD) and VEGF-C 
expression. Immunohistochemical techniques were employed. 109 patients with 
SCC of the head and neck were included in the study and clinico-pathological 
factors such as lymph node metastasis, histological grade and disease stage were 
examined with regard to their association with LVD and also the expression of 
VEGF-C. Results specific to VEGF-C were that in SCC of the lip, significantly 
higher levels of expression of VEGF-C in the tumour were associated with larger 
lymph node metastases (p=0.02).  
Yin et al. found that in 120 rectal cancer patients’ samples, VEGF-C 
levels were positively correlated in patients with larger tumours, advancing TNM 
stage and tumour differentiation (all p<0.05)[198]. Rectal cancer patients with 
low expression of VEGF-C had significantly longer survival than those with high 
levels of expression of VEGF-C (p=0.014). 
An argument appears to be emerging that high VEGF-C levels expressed 
within the tumour may promote the growth and spread of certain cancers perhaps 
providing evidence to assess prognosis of patients. Although I found no evidence 
of this within my cohort, I did find that intranodal expression within SLN 
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positive patients was significantly higher than expression in SLN negative 
patients. Liu et al. identified that the prognostic significance of VEGF-C, and 
lymphangiogenesis, lymph node metastasis and prognosis in melanoma patients 
remained controversial and therefore planned a study to investigate this 
further[199]. The expressions of VEGF-C, VEGF-D, and their receptor 
(VEGFR-3) were detected by IHC and reverse transcriptase-polymerase chain 
reaction. The expression of both VEGF-C and VEGF-D proteins were also 
detected in the cytoplasm of the malignant cells. VEGF-C and VEGF-D 
expressions were associated with VEGFR-3 expression and were significantly 
correlated with both peritumoral lymphangiogenesis and lymph node metastasis. 
The incidence of peritumoral lymphatic vessels was significantly higher in lymph 
node metastatic melanomas than that in nonmetastatic melanomas. Univariate 
and multivariate analyses indicated that VEGF-C and VEGF-D were independent 
prognostic factors for overall survival and disease-free survival in patients with 
malignant melanoma. The study suggested that both VEGF-C and VEGF- D are 
involved in peritumoral lymphangiogenesis and lymphatic metastasis.  
My results as shown in figure 21 as well as the above findings by Liu et 
al.[199] support the notion that VEGF-C and VEGF-D expression may be 
clinically useful indicators for prognostic evaluation in patients with cutaneous 
malignant melanoma. Cutaneous melanoma prognosis is currently based 
predominantly on tumour thickness although variables such as presence of 
ulceration, mitotic index and patient sex have also been identified to be the most 
relevant[53]. Breslow thickness remains to have the most important prognostic 
value however as highlighted in Chapter 1, a considerable number of patients 
with thin melanomas die of metastatic disease, whereas many of those with thick 
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tumours experience long-term survival. A study by Cianfarani et al. [69] which 
was published in 2012 involved a cohort of 36 node SLN positive patients and 26 
SLN negative patients. Similar techniques as detailed above in my method were 
employed to investigate VEGF-C expression within the tumour and correlations 
were performed depending on nodal outcome. VEGF-C expression in primary 
melanoma specimens was significantly associated with SLN-positive (p < 0.001), 
particularly in thin melanomas[200]. A similar trend was demonstrated by Massi 
et. al their 2006 case control study of 45 patients[201]. Boone et. al demonstrated 
in their 2008 study that VEGF-C immunohistochemical staining on melanoma 
tissues of 113 patients with known sentinel lymph node status showed high 
VEGF-C expression in melanoma cells was positively associated with the 
presence of a positive sentinel lymph node[202]. We were unable to show this 
trend as mentioned above, however our work was slightly different as a 
difference in nodal staining patterns was deciphered and therefore incorporated 
into the staining scores.  
Based on the evidence above, there is an urgent need for new and more 
effective prognostic indicators of metastasis in patients with malignant 
melanomas. In summary, my work demonstrated that VEGF-C staining within 
the lymph nodes might play important roles in lymphatic spread. Thus, the 
determination of VEGF-C expression could further enhance the accuracy of 
prognostic evaluation in patients with malignant melanoma. Prospective clinical 
trials are needed to further validate the prognostic value of VEGF-C expression 
within the sentinel lymph node to examine for patterns of metastasis and patient 
survival in malignant melanoma. Given the argument presented regarding the 
concept of “false positivity” and the burden of disease, it would be interesting to 
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evaluate the significance of VEGF-C staining depending on the burden of disease 
within the SLN and this is something which has not been addressed by the 
current literature. 
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4 CHAPTER 4 
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4.1 INTRODUCTION 
4.1.1 THE “SEED AND SOIL” THEORY 
Stephen Paget made an important observation in 1889, that breast cancer 
patients had a predilection for metastasis to the liver. Paget perceived this as 
unusual as other organs such as the spleen could have been equally affected as 
they receive the same amount of blood as the liver. This enduring finding 
prompted Paget to develop the theory of “Seed and Soil”. He hypothesised that 
certain tumour cells (seeds) colonise selectively distant organs (soil) with a 
favourable environment facilitating survival of tumour cells[120]: “When a plant 
goes to seed, its seeds are carried in all directions, but they can only live and 
grow if they fall on congenial soil”. Certain organs must therefore provide 
appropriate conditions for development of organ specific metastases, 
contributing to the organ selectivity[121]. 
 
The theory had not been experimentally challenged until Sugarbaker 
(1952) and later Kinsey (1960) retested Paget’s hypothesis by ectopically 
transplanting various organ tissues in syngenic mice and injecting them from 
different routes with melanoma S91 cloudman strain[122, 123]. They reported 
that tumour cells metastasised specifically to lungs but not to any other of the 
organs transplanted. A similar observation reported by Hart and Fidler [124] 
confirmed the idea that organ specific stimuli must permit new tumour growth 
and metastasis. 
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More recently, and relevant to my work on melanoma metastasis, further 
work has sought to investigate specifically at the role of the lymphatic system 
within tumour metastasis and the “seed and soil” theory, it has been known for 
decades that the regional lymph nodes draining tumour areas may be enlarged, 
without any evidence of actual lymph node metastasis. This is known as 
“tumour-reactive lymphadenopathy” [125].  
The phenomenon of tumour-reactive lymphadenopathy in SLNs has been 
observed for many years, but alterations of the lymphatic channels and 
vasculature by the process of angiogenesis and lymphangiogenesis in these nodes 
before the arrival of metastatic tumour cells remained relatively unexplored (see 
figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Schematic to represent the Seed and Soil Theory. Adapted from Fokas 
et al. (1) 
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In 2006, Qian et al., explored the theory that alterations in the lymphatic 
and vascular channels of these tumour-reactive enlarged lymph nodes may be 
correlated with the weight of the primary tumour. The authors used mouse 
models injected with the human nasopharageal carcinoma cell line NPC CNE-2 
(nasopharangeal carcinoma has the highest incidence rate of lymph node 
metastasis amongst the head and neck carcinomas[125]). Knowing that breast 
cancer spreads via lymphatics, they also used the murine breast cancer cell line 
DA3. Tumour cells were injected into the left hind leg of each nude mouse. The 
premetastatic alterations of the sentinel lymph node, which received direct 
lymphatic drainage from the tumour lesion were analysed. By using real time 
quantatitive PCR, ultrasonography to assess blood flow in the popliteal sentinel 
lymph node, immunohistochemistry and immunofluorescent staining, the authors 
were able to show that long before the establishment of metastasis within the 
sentinel lymph node, there were re-organisations of the lymphatic channels and 
the vasculature. The sentinel node became a functional blood vessel enriched and 
lymph vessel/sinus enriched organ before metastasis. This was a process that 
appeared to be dependent on the primary tumour[125].  
A further study in 2007 by Hirakawa et al., used transgenic mice that 
over expressed VEGF-C and green fluorescent protein (GFP) specifically in the 
skin [126]. Recognising that transgenic overexpression of VEGF-C in the skin of 
mice promotes cutaneous lymphangiogenesis and that in VEGF-C null mice, 
early lymphatic endothelial cells fail to migrate away from cardinal veins and to 
form lymphatic vessels, the authors indicated that VEGF-C is an important 
regulator of lymphangiogenesis. The authors created mice that expressed GFP, 
specifically in the skin, under the transcriptional control of the keratin 14 
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promoter. These mice were then crossed with those that specifically expressed 
VEGF-C in the skin, under the control of the same promoter. The offspring of 
this cross were subjected to a chemically-induced multistep regimen of skin 
carcinogenesis. Using this approach, the effects of VEGF-C on skin tumour 
formation and progression was investigated using ELISA, computer assisted 
morphometric vessel analyses, flow cytometry to detect GFP expression and real 
time PCR. It was found that in contrast to known skin-specific expression of 
VEGF-A[79], expression of VEGF-C does not increase the rate of primary 
tumour growth. However, VEGF-C–expressing primary tumours of the skin 
formed expanded lymphatic networks within sentinel lymph nodes, even before 
lymphatic metastasis occurred. Tumours of VEGF-C transgenic mice also spread 
to the sentinel lymph nodes with increased frequency. Tumours that had spread 
to the sentinel lymph nodes of VEGF-C transgenic mice were also more likely to 
continue metastasising, to distal lymph nodes and to the lungs, than controls. 
These findings identify VEGF-C–induced lymph node lymphangiogenesis as a 
novel mechanism by which tumour cells mediate their metastatic spread to the 
lymph nodes, and then on to other organs. Lymph node lymphangiogenesis 
therefore represents a novel target for the treatment or the prevention of 
metastasis.  
The work to date to investigate this “Seed and Soil” theory is clinically 
relevant as debates continue into the pros and cons of sentinel lymph node biopsy 
and completion lymphadenectomy. It is perhaps supportive of the “Seed and 
Soil” theory that in Chapter 3 I found that intranodal expression of VEGF-C 
within SLN positive patients was significantly higher than expression in SLN 
negative patients. This would imply that the lymphatics in the SLN or the 
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microenvironment around it are increased in tumours that are destined for 
lymphatic spread. It is unclear from these findings however whether this is due to 
the tumour over expressing VEGF-C prior to dissemination of metastatic cells or 
whether the arrival of tumour within the SLN leads to perhaps an upregulating of 
VEGF-C. These findings could support the “Seed and Soil” theory but warrants 
further investigation and experimental techniques. 
 
4.1.2 AIM OF CHAPTER 
 
“Do positive SLNB specimens show evidence of an altered microenvironment”?  
Although VEGF expression has been demonstrated to predict lymphatic 
metastasis in malignant melanoma, the mechanisms underlying this are still 
unclear. There is growing evidence presented above, that growth factors 
expressed by the primary lesion are able to impact directly upon the SLN to 
induce proliferation of the vasculature and effectively prepare the node to be a 
more hospitable environment into which tumour cells can then seed i.e. the “seed 
and soil” hypothesis. 
Immunohistochemistry techniques will be used to assess pro and anti-
angiogenic isoforms of VEGF as previously completed on tumour samples in 
Chapter 3. This will then be correlated with the expression within the primary 
tumour to determine whether VEGF expression within the tumour may go on to 
affect the microenvironment around the SLN, therefore perhaps influencing 
lymph node metastasis. The precise vasculature within the SLNB samples, 
(lymphatic and blood) will also be ascertained using immunohistochemistry and 
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again findings will be correlated to expression within the primary tumour. If the 
status of these lymph nodes (positive or negative for disease spread) shows any 
pattern with regards to vessel presence, this will be an additional novel finding in 
human melanoma.  
 
4.2 METHODS 
4.2.1 PATIENT COHORT 
A total of 34 patients were investigated as part of this chapter of work. 
These were identified from the St. Helen’s and Knowsley Cancer Registry and 
had been treated for malignant melanoma between the years of 1999 and 2004. 
Five-year follow up data was therefore available on each patient. As detailed in 
Chapter 2 section 2.2 patients were selected for inclusion and a total of 34 
patients were identified, 15 which were SLN positive and 19 which were SLN 
negative, for whom tissue from both the primary melanoma and corresponding 
SLN was available at Whiston Hospital, with each group matched for age, sex, 
Breslow thickness and location of primary lesion.  
 
4.2.2 IMMUNOHISTOCHEMISTRY 
Archival sentinel lymph node biopsy tissue was sectioned and subsequently 
stained immunohistochemically for Pan VEGF, VEGFxxxb, VEGF-C, LYVE-1 
and CD31. 
• !"#$%&'($)*+,+-,.$"//$0.12134.$12$%&'(5$
• %&'(6667$)"#,0"#8018+#0-$0.12134.$1#/95$
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• !"#$%&'()*+*,+-'./012345675*46,'6-78790-'78'!"#$:'
• ;<!"%='(./0123+6,'-1*,686,'039>*9:'
• &?@='(*4)7+2*.63.'-1*,686,'039>*9'
Immunohistochemistry methods used were as per those described in Chapter 
Two section 2.3 but on SLN specifically.   
4.2.3 ANALYSIS 
These samples were analysed as per the methods previously described in 
Chapter 2, sections 2.4 and 2.5 and analysed as per Chapter 2 section 2.7. As the 
same cohort was used in this chapter as Chapter 3, this set of experiments were 
powered at 80%.   
4.3 RESULTS 
4.3.1 VEGF IMMUNOHISTOCHEMISTRY 
Work completed in Chapter 3 investigated the pro and anti-angiogenic 
VEGF expression within tumours. No relationship between this expression and 
nodal status was determined. Next, it is possible to investigate the expression of 
these factors within the SLN itself to ascertain whether alterations in the pro or 
anti-angiogenic environment of the lymph node can be attributed to tumour 
spread and perhaps contribute to the “Seed and Soil” theory. 
A total of 34 SLNs were stained immunohistochemically for pan VEGF 
and VEGFxxxb and VEGF-C. This staining was scored by three independent 
assessors for A) intensity of staining, and also the B) percentage of cells 
expressing. These scores were then combined to give an overall C) combined 
score. The graphs below represent mean±SEM. 
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4.3.1.1 PRO AND ANTI-ANGIOGENIC STAINING OF THE SLN 
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Pan VEGF staining intensity was first examined (1.31±0.19 in SLN 
positive nodes versus 1.31±0.19 in SLN negative nodes). Percentage of cells 
stained were then assessed (1.82±0.28 in SLN positive nodes versus 1.53±0.23 in 
SLN negative nodes). Finally, a combined score was derived (3.00±0.38 in SLN 
positive nodes versus 2.92±0.32 in SLN negative nodes). There was no 
significant difference between positive or negative SLNs staining of pan VEGF 
(SLN positive n=15, negative n=19, one-way ANOVA, p>0.05).  
I next tried to determine whether the microenvironment around and 
within the SLN may be influenced by the nodal expression of VEGFxxxb. As 
above VEGFxxxb staining intensity was first examined (1.40±0.22 in SLN 
positive nodes versus 1.05±0.24 in SLN negative nodes). Percentage of cells 
stained were then assessed (1.36±0.22 in SLN positive nodes versus 0.98±0.23 in 
SLN negative nodes). Finally, a combined score was derived (2.81±0.36 in SLN 
positive nodes versus 2.04±0.23 in SLN negative nodes). There was no 
significant difference between positive or negative SLNs staining of VEGFxxxb 
(SLN positive n=15, negative n=19, one-way ANOVA, p>0.05).  
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The microenvironment appears to be uninfluenced by the nodal expression of pro 
or anti angiogenic VEGF. To examine the theory of the tumour controlling the 
micro-environment around the SLN further, I next correlated VEGF expression 
within the tumour with VEGF expression in the corresponding SLN.  
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Figure 26 Graph to investigate correlation between intratumoural VEGFxxxb 
expression and SLN expression 
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Figure 25 Graph to investigate correlation between intratumoural pan VEGF 
expression and SLN expression 
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No significant correlation was found between either pan VEGF expression 
within the tumour and pan VEGF expression within the corresponding SLN 
(p>0.05 R
2
=0.0007). Similarly , no correlation was found between VEGFxxxb 
expression within the tumour and VEGFxxxb expression within the SLN (p>0.05 
R
2
=0.06).  
With no convincing evidence that pro and anti-angiogenic isoforms 
expression of VEGF within the tumour influence nodal microenvironment, I next 
looked at VEGF-C in a similar set of experiments. 
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4.3.1.2 VEGF-C STAINING  
Firstly using techniques described above, I stained the primary tumours 
for VEGF-C  and sorted them by nodal status.  
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As above VEGF-C staining intensity was first examined (0.77±0.23 in 
SLN positive nodes versus 1.11±0.23 in SLN negative nodes). Percentage of 
cells stained were then assessed (0.85±0.27 in SLN positive nodes versus 
0.94±0.21 in SLN negative nodes). Finally, a combined score was derived 
(2.06±0.42 in SLN positive nodes versus 2.04±0.23 in SLN negative nodes). 
There was no significant difference between positive or negative SLNs 
staining of VEGF-C (SLN positive n=15, negative n=19, one-way ANOVA, 
p>0.05).  
Next, to investigate the nodal lymphatics staining, SLN staining was 
carried out. As previously discussed in Chapter 3, it became apparent that 
staining within the capsule of the SLN and the intranodal element of the SLN 
differed, see figure 28 therefore, staining was scored separately for these two 
areas and is illustrated below. 
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 As detailed in Chapter 3, taking account of the staining patterns depicted 
in figure 28, I looked specifically at capsular versus intranodal staining of 
VEGF-C and compared SLN positive patients with SLN negative patients. 
Intranodal VEGF-C expression was significantly higher in SLN positive patients 
when compared with SLN negative patients. This suggests, therefore, that either 
tumour cells expressing VEGF-C are most likely to successfully spread to the 
lymphatic system perhaps due to “Seed and Soil” (but as mentioned above we 
have found no evidence for this to be the case), or that tumour cells arriving in 
SLNs may need to express VEGF-C to survive. 
 
 
Figure 28 Example of VEGF-C staining within capsular and intranodal 
elements of the SLN (control slide inset) 
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SLN positive nodes capsular combined scoring was 1.42±0.22 versus 
1.23±0.16 in node negative patients, a non significant difference. SLN positive 
nodes intranodal score was 3.91±0.49 versus 2.63±0.43 in node negative 
patients. This was a significant difference (p<0.01 Bonferroni). 
Again, as above, to investigate whether the tumour appeared to be controlling the 
microenvironment around the SLN, next, tumour expression of VEGF-C was 
correlated with nodal expression of VEGF-C.  
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No correlation was found between expression within the primary tumour and 
VEGF-C expression within the SLN (p>0.05, R
2
=0.07).  
With no evidence to show that the tumour expression of VEGF-C is 
related to nodal environment expression of VEGF-C i.e. to support the “Seed and 
Soil” theory, I next examined the expression of lymphatic vessel markers within 
the SLN to examine whether any further patterns could be established. 
 
4.3.2 LYMPHATIC MARKER STAINING OF THE SLN 
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Figure 31 Expression of LYVE-1 within the SLN 
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A total of 34 SLNs were stained immunohistochemically with LYVE-1. For each 
slide, three vessel ‘hotspots’ were identified at 40x magnification. These were 
areas of concentrated staining. For each ‘hotspot’ the following analysis was 
undertaken,  
• Total vessel number i.e. number of vessels within ‘hotspot’ 
• Vessel diameters  
• Vessel areas 
The graphs below represent mean±SEM. The trend identified in the expression is 
the opposite to what I would have expected. It appears that negative nodes have 
larger numbers of vessels with greater diameters and vessel areas. Vessel counts 
in three hotspots as detailed above were examined (6.93±0.81 in SLN positive 
patients versus 12.1±2.22 in SLN negative patients). Diameters of vessels within 
the three hotspots were then measured (34.5±3.03 in SLN positive patients 
versus 35.9±5.52 in SLN negative patients). Next vessel lumen areas were 
calculated (36083.47±5618.34 in SLN positive patients versus 
46666.00±19924.77). Finally a combined score was given (36124.91±5618.34 in 
SLN positive patients versus 46714.00±19924.77 in SLN negative patients. 
There was no significant difference between positive or negative SLNs staining 
of LYVE-1 (SLN positive n=15, negative n=19, one-way ANOVA, p>0.05).  
As my only significant finding so far is that in SLN positive patients, 
intranodal staining of VEGF-C is significantly higher than SLN negative 
patients, it would be useful to try and ascertain whether this raised expression of 
VEGF-C (a lymphatic endothelial marker) could perhaps be due to the tumour 
preparing the nodal environment to receive a metastasis. This can be done by 
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correlating VEGF-C expression in the tumour to LYVE-1 expression in positive 
SLN, thereby trying to establish whether the tumour’s expression of VEGF-C 
could perhaps be controlling lymphatics in the nodal basin.  
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Figure 32 VEGF-C Expression in the Tumour vs Lymphatics in Positive SLN 
 168 
A correlation was found between VEGF-C expression in the tumour and mean 
vessel area within positive SLN but no correlation was found between VEGF-C 
expression in the tumour and numbers of vessels and vessel diameter within 
positive SLN. With poor evidence to support the “Seed and Soil” theory so far, 
knowing that as well as lymphatics, blood vessels must be involved to facilitate 
the process of metastasis, I next examined for the presence of blood vessels in 
the SLN.   
 
4.3.3 BLOOD VESSEL MARKER STAINING OF THE SLN 
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A total of 34 SLNs were stained immunohistochemically with CD31 antibody 
using the methods described above. For each slide, three vessel ‘hotspots’ were 
identified at 40x magnification. These were areas of concentrated staining. For 
each ‘hotspot’ the following analysis was undertaken,  
• Total vessel number i.e. number of vessels within ‘hotspot’ 
• Vessel diameters  
• Vessel areas 
The graphs below represent mean±SEM.. Vessel counts in three hotspots 
as detailed above were examined (5.87±0.76 in SLN positive patients versus 
8.63±1.02 in SLN negative patients). Diameters of vessels within the three 
hotspots were then measured (43.64±5.08 in SLN positive patients versus 
37.18±9.61 in SLN negative patients). Next vessel lumen areas were calculated 
(44066.19±4814.31 in SLN positive patients versus 84682.28±44206.82 in SLN 
negative patients). Finally a combined score was given (44115.70± 4814.15 in 
SLN positive patients versus 84728.10±44215.83 in SLN negative patients. 
There was no significant difference between positive or negative SLNs staining 
of CD31 (SLN positive n=15, negative n=19, one-way ANOVA, p>0.05).  In the 
previous section I was able to explore lymphatics in the tumour and node further 
by correlating VEGF-C tumour expression with LYVE-1 lymphatic marker 
expression in the positive SLN cohort. As I did not assess tumour vascularity as 
part of my work, I am unable to correlate the presence of tumour blood vessels 
with blood vessels in the positive SLN. 
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4.4 DISCUSSION 
4.4.1 INTRODUCTION TO DISCUSSION 
In summary I have found little evidence to support the “Seed and Soil” 
theory. My previous finding in Chapter 3 of significantly increased intranodal 
expression of VEGF-C within positive SLNs appears unrelated to expression of 
VEGF-C within the tumour with no correlation found between the two. 
Therefore the tumour does not appear to control the nodal microenvironment by 
its expression of VEGF-C. The significantly increased mean vessel areas in 
positive nodes when stained with LYVE-1 also appear to be independent of 
expression of growth factors from the primary tumour on the correlations which I 
have performed.  
 
4.4.2 ARGUMENTS FOR AND AGAINST PRO AND ANTI-ANGIOGENIC 
ISOFORM TUMOUR EXPRESSION AND ITS POTENTIAL 
RELATIONSHIP WITH THE NODAL MICROENVIRONMENT 
 
As mentioned above, no significant difference was found between the 
expression of pro or anti-angiogenic isoforms of VEGF in positive or negative 
nodes. Furthermore, when correlating expression within the primary tumour to 
expression within the SLN, there was no significant correlation of pro or anti-
angiogenic VEGF. Therefore, my results did not support the theory that the 
tumour might begin preparing for its future metastatic site by producing 
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lymphangiogenic factors that mediate efficient transport to the sentinel lymph 
node of metastatic cells.  
Some of the available literature would imply the opposite to my findings. 
Hirakawa et al. [177] found that targeted overexpression of VEGF-A in 
transgenic mice, potently induced tumour lymphangiogenesis in cutaneous 
squamous cell carcinoma (SCC) and promoted tumour metastasis to sentinel 
lymph nodes. VEGF-A expressing tumour cells maintained their 
lymphangiogenic activity after metastasis to lymph nodes. VEGF-A over-
expressing cutaneous SCC showed evidence of lymphangiogenesis in SLNs, 
even before the tumours had metastasised to these tissues. The authors concluded 
that together, these results identify VEGF-A as a novel tumour 
lymphangiogenesis factor. They also indicated that VEGF-A induced lymph 
node lymphangiogenesis, promotes lymph node metastasis, and therefore, is an 
important target for the treatment of advanced cancer and the prevention of 
metastasis. Although the study demonstrated that once a tumour is present, 
overexpression of VEGF-A enhanced its onward spread, it is worth noting that 
there was no increased incidence of tumour formation as a consequence of 
overexpression of VEGF-A. Therefore we can not conclude from this work that 
large amounts of VEGF-A are oncogenic, but may perhaps be a fuel to onward 
progression. Furthermore, VEGF-A is vastly overexpressed over a naturally 
metastatic cell lines’ normal level in the murine model used in this study. As we 
know, cutaneous SCC are able to metastasise to the lymphatic system[203]. 
Rates are quoted at differing values depending on tumour location but are quoted 
to be between 1.9-5.15% with the highest levels being within tumours of the 
head and neck [204, 205] Perhaps the overexpression of these tumours (which 
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were induced on the ear) is the reason why such a convincing argument for 
“Seed and Soil” has been found by the authors of this paper. 
The concept of increasing melanoma “tumour burden” is found to be 
increasingly relevant in the onward spread even of positive SLNs [206].  No such 
work exists looking specifically at SCC and this may be relevant to the findings 
of this paper, for example, the overexpression of VEGF-A may have caused a 
larger tumour burden than normally expected within the SLN, not typical of that 
expected within a human melanoma. This may in turn have affected the SLN 
microenvironment in the way in which the authors demonstrated. 
As previously discussed, VEGF-A acts via VEGFR-1 and VEGFR-2 to 
act on endothelial cells of blood vessels stimulating angiogenesis[72]. This study 
seems to imply that by overexpressing VEGF-A, this may also stimulate the 
lymphatic endothelium, which I have mentioned displays the differing VEGFR-
3[107]. This paradox can be explained by the phenomenon of “Cross Talk”. This 
theory implies that due to unsuspected feedback loops and cross-talk between 
different signalling pathways both receptor systems may be stimulated[207]. 
This effect would be expected to be amplified when there in a model of 
overexpression involved.  
Lastly, the authors of this study allowed the SLNs to have the time to 
become enlarged whereas in the clinical setting, it is recommended that in 
patients they would be removed at the first detected sign of change, whether that 
be on result of routine biopsy alone or a biopsy spurred on by clinical or patient 
detection[53]. Perhaps we have not found any evidence for the “Seed and Soil” 
because the SLNs in my cohort were removed long before they were able to start 
responding to any tumoural influences, unlike the ones in the model in the above 
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work which were allowed time to respond to overexpression of VEGF-A which 
is unrealistic in the clinical setting. 
 
4.4.3 ARGUMENTS FOR AND AGAINST VEGF-C TUMOUR EXPRESSION 
AND ITS POTENTIAL RELATIONSHIP WITH THE NODAL 
MICROENVIRONMENT 
In Hirakawa’s 2007 paper, as discussed above, the authors used 
transgenic mice that over expressed VEGF-C and green fluorescent protein 
(GFP) specifically in the skin [126]. The authors created mice that expressed 
GFP under the transcriptional control of the keratin 14 promoter. These mice 
were then crossed with those that specifically overexpressed VEGF-C in the skin, 
under the control of the same promoter. The offspring of this cross were 
subjected to a chemically-induced multistep regimen of skin carcinogenesis. 
Using this approach, the effects of VEGF-C on skin tumour formation and 
progression was investigated using ELISA, computer assisted morphometric 
vessel analyses, flow cytometry to detect GFP expression and real time PCR. It 
was found that in contrast to known skin-specific expression of VEGF-A[79], 
expression of VEGF-C does not increase the rate of primary tumour growth. 
However, VEGF-C–expressing primary tumours of the skin formed expanded 
lymphatic networks within SLNs, even before lymph node metastasis occurred. 
Tumours of VEGF-C transgenic mice also spread to the SLNs with increased 
frequency. Tumours that had spread to the sentinel lymph nodes of VEGF-C 
transgenic mice were also more likely to continue metastasising, to distal lymph 
nodes and to the lungs, than controls. The authors stated that these findings 
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identified VEGF-C–induced lymph node lymphangiogenesis as a novel 
mechanism by which tumour cells mediate their metastatic spread to the lymph 
nodes, and then on to other organs. They concluded that lymph node 
lymphangiogenesis therefore represents a novel target for the treatment or the 
prevention of nodal metastasis.  
The authors have demonstrated in their VEGF-C overexpressing model 
that the number of LYVE-1 positive vessels in SLNs which were found to 
contain metastases was significantly increased. In nodes examined without 
metastases in the same model (but with skin tumours again overexpressing 
VEGF-C), they found significantly enlarged vessel areas. It is possible that the 
enlarged vessel areas, (detected with LYVE-1 staining) seen to correlate with 
VEGF-C expression in tumour bearing nodes by myself, is a smaller scale 
version of the same effect in a human non over-expressing clinical scenario. As 
my patient cohort were not overexpressing to the levels of the animal model, 
perhaps my results indicate that in a clinical scenario, it is a more subtle change 
that may be detected but perhaps one which is equally important as those found 
by Hirakawa et al.. 
Again, other differences between my work and this study included 
differences in the skin carcinoma. This was a chemically-induced multistep 
regimen of skin carcinogenesis which resulted in SCC , Mice were euthanised 
and analysed at either 35 weeks post initiation of carcinogenesis, or 8 weeks after 
first detection of tumour, which again would perhaps allow greater exposure of 
the nodal microenvironment to factors released by the overexpressing induced 
carcinoma.  
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In 2006, Qian et al., explored the theory that alterations in the lymphatic 
and vascular channels of these tumour-reactive enlarged lymph nodes may be 
correlated with the weight of the primary tumour. The authors used mouse 
models injected with the human nasopharageal carcinoma cell line NPC CNE-2 
(nasopharangeal carcinoma has the highest incidence rate of lymph node 
metastasis amongst the head and neck carcinomas[125]). Knowing that breast 
cancer spreads via lymphatics, they also used the murine breast cancer cell line 
DA3. Tumour cells were injected into the left hind leg of each nude mouse. The 
premetastatic alterations of the sentinel lymph node, which received direct 
lymphatic drainage from the tumour lesion were analysed. By using real time 
quantatitive PCR, ultrasonography to assess blood flow in the popliteal sentinel 
lymph node, immunohistochemistry and immunofluorescent staining, the authors 
were able to show that long before the establishment of metastasis within the 
sentinel lymph node, there were re-organisations of the lymphatic channels and 
the vasculature. The sentinel node became a functional blood vessel enriched and 
lymph vessel/sinus enriched organ before metastasis. This was a process that 
appeared to be dependent on the primary tumour[125]. The newly emerged 
functional blood vessels develop from high endothelial venules (HEV), in which 
the proliferation rate of the endothelial cells was also significantly increased. The 
HEVs were identified using the MECA-79 antibody[125]. Important points to 
include regarding this study include that again, differences in the burden of 
disease within the SLN in SCC, breast carcinoma and melanoma is a field which 
remains relatively unexplored but we know is becoming more relevant from a 
prognostic point of view[206]. For example, if there is a high tumour burden 
within a SLN, more distinctive changes will be detected.  
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Management of human breast carcinoma dictates the removal of the 
tumour with simultaneous SLN. This is usually following confirmation of 
diagnosis using less invasive techniques[208]. However, as previously detailed in 
Chapter 1, melanoma usually requires an excision biopsy to confirm the 
diagnosis and often, the entire tumour may have been removed by the time the 
SLN is performed. An explanation for my patient cohort not showing any 
convincing evidence for the “Seed and Soil” theory could be that the removal of 
the tumour before the SLN could cause any changes to have settled back to 
normal before nodal removal and analysis took place.  
In the model used by Qian et al. they examined normal contralateral foot 
pads as a control in the mice used in the analysis. There was no injection of fluid 
into those foot pads. The influx of any fluid into the circulating lymphatic system 
may cause a reactive lymphadenopathy[105] therefore this may have caused the 
increase in nodal size, not a specific response to receptors. This was not a 
limitation which the authors took account of.  
 
4.4.4 RELEVANCE OF HIGH ENDOTHELIAL VENULES 
 
To determine if the remodelling of HEVs also occurred in human 
neoplasia, in the same paper, Qian et al. examined a series of archived axillary 
lymph node tissues[125]. They reported that “mother vessels” appeared to be 
nurturing the secondary tumour within the SLN. These mother vessels within 
secondary tumour sites were found to actually be remodelled high endothelial 
venules (HEVs), which are preexistent in normal lymphoid tissue. In the same 
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study, Qian et al. were the first to describe the transformation of HEVs from 
immune-related vessels to tumour vasculature. The transformation of HEVs in 
the SLN, coupled with the increased proliferation rate of HEV endothelial cells, 
occurs before the physical presence of metastatic tumour cells. The dilatation of 
the lymphatic channels in the SLN could also be induced by the primary tumour 
before nodal metastasis. In animal models, the dilation of lymphatic channels 
before metastasis is positively correlated with primary tumour weight. 
In a later paper, Qian et al. detail how this tumour induced phenomenon 
is co-opting normal vessels to become changed in response to VEGF-C 
expression by the primary. The authors further suggest that once the stimulus is 
removed (for example in the clinical setting, excision of the primary tumour), 
these vessels may regress back to their more normal physiological state. This 
may again support why my findings did not support the “Seed and Soil” theory. 
If the primary tumour was not present, the stimulus has been removed, therefore 
changes may be more subtle or may regress.  
 
4.4.5 POTENTIAL FOR FURTHER WORK 
As discussed above, the concept of tumour burden within the SLN is 
something which  remains unexplored with regard to SCC and was not addressed 
by any of the studies mentioned above. In fact with regard to human malignant 
melanoma and breast carcinoma, work is emerging which supports the theory 
there is a subgroup of patients with a positive SLN who may be spared CL. 
Further clarification is expected with the results of trials detailed below. 
Approximately 20% of patients who progress to CL following a positive SLN are 
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found to have further disease in their resected specimens[194, 206]. As 
mentioned before, CL carries with it the risk of morbidity and the therapeutic 
benefits remain to be clarified. Primary and SLN tumour burden parameters and 
patient comorbidities should be taken into consideration when offering CL to an 
individual patient. The Rotterdam and Dewar criteria and S-classification are 
important sentinel node tumour burden criteria to stratify melanoma patients for 
prognosis and risk of non SLN metastases[193, 209, 210]. Patients with less than 
0.1mm metastases seem to have similar prognosis as sentinel node negative 
patients, especially when located in the subcapsular area.  
With regards to melanoma, we await results of prospective studies such 
as the MSLT-II and the EORTC-1208 which will hopefully will provide answers 
to whether CLND has a therapeutic benefit and to which patients might safely be 
spared CLND.  
Qian et al. [112] discuss specifically the recruitment of HEVs and implicated 
them directly in the “Seed and Soil” theory. I looked at CD31 staining, which is 
an  endothelial vessel marker overall rather than HEVs specifically with MECA-
79. This may highlight an area of further work, especially given that my trends 
were sometimes unexpected in CD31 staining. There may be further patterns to 
be found by looking at different types of vessels.  
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5 CHAPTER 5 
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5.1 INTRODUCTION 
5.1.1 DEFINITION AND INTRODUCTION 
Despite the debate which continued until the recently published MSLT 
ten year follow up figures[141], SLNB has remained the standard of care for 
melanoma patients in the UK and is the only method for up-regulating patients 
with occult nodal disease so that their clinical care, treatment and potential entry 
to clinical trials can be tailored effectively[53]. 
Some earlier authors have concluded that the most powerful predictor of 
outcome for early-stage melanoma is the status of the sentinel lymph node[48]. 
The concepts of ‘false negativity’ and ‘false negativity rate’ are different. 
‘False negativity’ is defined as a nodal recurrence in a previously sentinel node-
negative patient. ‘False negative rate’ is calculated by dividing the number of 
false negative patients by the sum of the false negative patients + the true 
positive patients and multiplying this number by 100[211].  
Incidence of false negativity and false negativity rates have been 
investigated as part of several large series, see figure table 8 below. It is apparent 
that higher nodal recurrences and false negative rates seem to be associated with 
longer follow up periods. There are no studies to date which have investigated 
outcome data on this subset. As seen above, studies seem to suggest that this can 
be a considerable group. Therefore further information is desirable especially 
given that their outcomes may be poor. 
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Author 
(year of 
publication) 
Number of 
Patients 
Median 
Follow Up 
(months) 
Nodal Recurrence 
following negative 
SLNB (% of all 
patients) 
False Negative 
Rate 
(FN/(FN+TP) x 
100 
Chao 
(2002)[212] 
1183 16 14 (1.1%) 5.6 
Scoggins 
(2010)[213] 
2451 61 59 (3.0%) 10.8 
Testori 
(2009)[214] 
1313 54 36 (2.7%) 14.4 
Morton 
(2006)[140] 
767 60 26 (3.3%) 17.6 
Nowecki 
(2006)[215] 
1207 36 43 (3.6) 20.0 
Cascinelli 
(2006)[216] 
1108 61 47 (4.2%) 21.0 
Table 4 False Negativity in Several Large Published Series 
Demographic data has recently been published particularly for breast 
cancer patients with false positive SLN results[217, 218]. These studies 
uncovered trends in rates were associated with the calendar month and operator 
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experience as well as certain histological subtypes of breast cancer. At time of 
writing, no such study for melanoma was available to my knowledge. 
 
The causes for false negativity have been identified as  
• !"#$%&'()*'%("#+)
• ,'-./(/$%&'()*'%("#+)
• ,.01%/(/$%&'()*'%("#+)
These will each now be discussed in more detail below.  
5.1.2 SURGICAL FAILURE 
Several theories have been put forward to suggest why ‘surgical failure’ 
to remove the positive SLN may occur, therefore leading to a false negative 
result.  
The first most straightforward cause is that the surgeon may not have 
removed the correct node(s) but other than a technical failure there may be other 
reasons behind this[211]. Sondak et al. detail in their paper how the operational 
definition of a SLN is itself somewhat arbitrary, particularly in terms of the 
amount of radioactivity that can be contained within a lymph node before it is 
deemed ‘hot’ enough to remove[211]. The authors also state that just as arbitrary, 
if not more so, is the point at which a basin can be considered clear of residual 
SLNs, that is, that any residual radioactivity in the basin represents background 
or shine-through from the primary tumour site. This is usually checked prior to 
the closure of the surgical wound by the surgeon. Because of the potential for 
shine-through to mask a small retained SLN, we might well expect higher rates 
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of false-negative results the closer the primary tumour is to the sentinel node, but 
with the possible exception of upper outer quadrant breast cancer primaries, as 
far as my literature search has revealed, this has never been documented or even 
directly studied[219]. 
The SLNB procedure begins in the Nuclear Medicine department where a 
practitioner has to make sure that the injection is performed correctly with the 
Tc99 sulphur colloid injection as close to the scar or biopsy site as possible and 
in such a way that drainage from that site truly recapitulates the actual dermal 
lymphatic drainage of that particular area of skin. Deeper injection may reduce 
the accuracy of identifying true sentinel nodes, as would injection farther away 
from the biopsy site[211]. 
A study based at the Sydney Melanoma Unit was performed to check for 
reproducibility of lymphoscintigraphy (LS), Uren et al. formulated a study as 
they stated occasionally, after LS had been performed to map the location of 
SLNs in their unit, the patient was unable to proceed to SLN biopsy surgery 
within the time limit imposed by the radioactive decay of the 99mTc label 
attached to the colloid particles[220]. In this situation, the surgery was 
rescheduled and LS repeated to relabel the SLNs so that they may be accurately 
biopsied. This had happened on 21 occasions at this particular unit and the 
authors performed a retrospective analysis of the reproducibility of the LS 
results. In 19 patients, the same SLNs were shown in the same locations on the 
two studies. Two patients had discrepant results (10.5%). One showed two extra 
interval nodes on the back as well as concordant flow to SLNs in each axilla. The 
other with a leg melanoma showed the same groin SLNs but failed to re label the 
two popliteal SLNs on the second study. These results indicate that minor 
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technical variations could result in some SLNs being missed and perhaps warrant 
further investigation with larger groups of patients.  
Even if the correct node accumulates the radiotracer, ascertaining the 
location of that node (or even the basin in which it resides) may be inaccurate, 
especially in the head and neck due to the previously mentioned close proximity 
of tumour to SLN basin. Certainly, there are numerous reports to suggest that 
higher false-negative rates are associated with head and neck primary sites[221]. 
A potential solution could be the use of single-photon emission computed 
tomography with computed tomography scanning (SPECT/CT) 
lymphoscintigraphy imaging, which has been shown to increase the resolution 
and improve anatomic localisation for sentinel nodes in the head and neck. Van 
der Ploeg and colleagues showed the potential value of SPECT/CT 
lymphoscintigraphy: in a series of 85 patients who underwent both conventional 
lymphoscintigraphy and SPECT/CT imaging prior to SLNB, SPECT/CT resulted 
in a different incision in 17 patients, an incision at another site in 8, and an extra 
incision in 5 patients.7 SPECT/CT identified 12 nodes not seen on standard 
scanning (an extra 8%). Ten of these 12 nodes were harvested and 2 contained 
lymphatic metastases[222]. This provides evidence that better 
lymphoscintigraphy could lower the false-negative rate, especially for our most 
difficult sites such as the head and neck.  
 
5.1.3 PATHOLOGICAL FAILURE 
Pathological failure leading to a false negative SLNB result is due to 
cases where the correct node has been identified and removed but this is not 
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detected by the examining pathologist[211]. Routine examination of the sentinel 
node includes immunohistochemical staining techniques using a combination of 
haematoxylin and eosin (H+E) staining as well as sometimes antibodies to 
melanocyte lineage antigens, which while sensitive, are unfortunately not 
foolproof especially given the techniques employed for examining the 
node[213].  
Even with the intensive attention that the sentinel node receives, only a 
small portion of the entire lymph node is examined[211]. Hence it is possible 
that the pathologist may not see the tumour cells in a sentinel node and call it 
negative. Those patients would not undergo completion node dissection and 
hence would be at risk of onward spread in nonsentinel nodes, and these cases 
would be considered false-negative results. Evidence suggests that more 
intensive sampling of the sentinel node does indeed identify more positive nodes, 
but as yet there is no proof that this more time-consuming approach decreases 
false-negative results[223]. Furthermore, it is the intention of this study to 
examine rates within normal clinical practice, and while it may be that more 
intensive sampling of the SLN may have altered false-negative yield, this is 
beyond the scope and aims of this chapter. 
SLNB is recommended even for thin melanomas[53]. Scheri et al. 
examined the impact of micrometastases (!0.2 mm) and isolated tumour cells in 
the SLN in their 2008 study[224]. The authors found that the incidence of 
positive nonsentinel nodes in the completion node dissection specimen was 12%. 
In addition, the 5-year melanoma specific survival rate for those patients with 
isolated tumour cells or very small metastatic foci when compared with those 
who were deemed SLN negative was significantly lower (94 vs. 89%, p = 0.02). 
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Future studies on more intensive analysis of sentinel nodes, including molecular 
analysis using reverse-transcriptase polymerase chain reaction (RT-PCR) 
technology, should look at whether these techniques can decrease the false 
negative SLNB rate while also taking into account the potential risk that some of 
these techniques, especially RT-PCR, may be identifying false-positive 
cases[225]. 
 
5.1.4 PHYSIOLOGICAL FAILURE 
Finally, there could be patient-related factors that lead to false-negative 
SLNB, no matter how well every other aspect of the patient’s care has been 
provided. For example, it may be that, at time of diagnosis and SLNB, there are 
already metastatic tumour cells within the lymphatic channels that simply have 
not made it all the way to the node yet[211]. There is no actual evidence for or 
against this, and indeed the MSLT-1 trial did not find any evidence that the 
SLNB procedure increased the likelihood of in-transit metastasis[140]. However, 
there is evidence of declining lymphatic dysfunction with age, which may be a 
potential factor in some false-negative sentinel node biopsies. Conway et al. have 
shown that lymphatic function, as assessed by radiocolloid transit to and uptake 
within the sentinel node, declines with age[226]. This age-related lymphatic 
dysfunction could be due to limitations of transit of lymph from the primary site 
to the node, or it could be due to diminished filtration function of the aging 
lymph node, with greater pass-through to second-echelon nodes. Either of these, 
but particularly the latter, could increase false-negative sentinel node biopsy rates 
in older patients. In work supportive of this theory, Scoggins et al. found that 
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older patients were more likely to have false-negative results than younger 
patients[213]. 
 
The physiological failure subset may be identifiable by applying the seed 
and soil theory, previously discussed in Chapter 4, If the theory is applicable to 
human melanoma, we would assume that tumoural influences would alter the 
nodal microenvironment, making it more hospitable to receiving and growing a 
successful metastasis, Chapter 4 did not reveal any significant supportive 
evidence for seed and soil based on markers which I used specifically for 
angiogenesis and lymphangiogenesis. A further area of interest, which links 
Chapters 4 and 5 of my work together is the theory by comparing nodal 
environment of postive SLN and false negative SLN, if the seed and soil theory 
can be applicable to human melanoma patients, you would expect to see that the 
there is greater expression of growth factors in those nodes which received a 
metastasis when compared with those that did not. This may be an interesting 
concept to explore further and is listed beneath as one of the aims of the work in 
this chapter. 
 
5.1.5 WHY FURTHER WORK IN THIS AREA IS WARRANTED 
 
As mentioned above, incidence of false negativity and false negativity 
rates have been investigated as part of several large series, (see table 5-1). 
Outcome of this subset remains unclear. Further information is desirable 
especially given that their outcomes may be poor. A review of the literature and 
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the reasons behind a false negative SLN suggests that false-negative SLNB 
results are likely to be a problem for clinicians, even if our patients’ care is 
maximised in every possible way. What requires further investigation is what the 
consequences are for these patients. Are they worse off having a false-negative 
SLNB than if they had not undergone the procedure at all? The MSLT- 1 trial 
allowed for a comparison between patients with a false-negative biopsy, with a 
68.4% relapse rate at 3 years, and those in the observation group who relapsed in 
the nodes without a prior sentinel node biopsy (64.9% at 3 years, p = 0.60)[140]. 
The Sunbelt Melanoma Trial results reported in this issue, which did not have a 
nodal observation arm, the overall survival of patients with false-negative SLNB 
results was not statistically significantly worse than those with true-positive 
sentinel nodes[5]. 3 basins were seen after excisional biopsy was performed. 
However, in two cases, nodal basins initially identified as draining the primary 
site were not seen on the post excision scan. Although there were no false-
negative cases reported by those authors, their data does provide evidence that 
clinically appropriate and necessary biopsies may at times disrupt lymphatic 
channels sufficiently to influence the accuracy of SLNB, and further studies are 
warranted to identify which, if any, primary melanomas should best be diagnosed 
by nonexcisional biopsy procedures to minimise this effect. This is encouraging 
news that should reassure that small percentage of patients who do return with a 
palpable node months or years after a negative sentinel node biopsy.  
However, is there anything we can or should be doing to detect 
recurrences earlier in patients at highest risk? First, who are these patients? 
Certainly, patients with thick, ulcerated, and/or high-mitotic-rate primaries are at 
high risk for false-negative results, because they are at high risk of having a 
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positive node in the first place[213]. Furthermore, it seems that older patients, 
patients with head and neck primaries, and patients undergoing sentinel node 
biopsy after prior wide excision are groups at increased risk of false-negative 
biopsy[213]. Perhaps we can even include patients with discordant results 
between their lymphoscintigraphy and the findings at sentinel node biopsy (e.g. 
those in whom the scan shows three nodes but the sentinel node procedure only 
yields two) in this group, although that is speculative at this point. So what, if 
anything, should we do to monitor high-risk patients? The MSLT-2 trial is 
prospectively evaluating whether nodal ultrasound can help monitor nodal basins 
that are known to be sentinel node positive but that do not undergo complete 
dissection. If so, nodal ultrasound for surveillance of patients considered at risk 
of false-negative sentinel node biopsy results would potentially make sense. 
Prospective evaluation is warranted before this approach is widely adopted.  
Lastly, in the mouse model used by Pritchard Jones et al., VEGFxxxb was found 
to be protective[79]. As we are looking at levels of VEGFxxxb throughout this 
work, can I show same pattern in false negative SLN’s. I have shown no such 
association in my main cohort of patients, but does this false negative group give 
us any further data or identifiable patterns? For example can we show that there 
is an increased expression of VEGFxxxb in those patients who survived longer if 
mortality statistics were to be accessed? Bearing all these potential areas of 
further work in mind, I have formulated aims of this chapter (see below) 
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5.1.6 AIMS 
 
Aim 1: Can we use angiogenic and lymphangiogenic growth factors to identify 
patients whose nodes are best equipped to support successful metastasis? i.e the 
physiological subset? Is there any connection to the ‘Seed and Soil’ theory that 
can be drawn here? 
 
Aim 2: Can we show a pattern between the balance of pro and anti-angiogenic 
growth factors released and survival? This has previously found to be protective 
(Pritchard Jones et al. [79]). 
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5.2 METHOD 
5.2.1 PATIENT COHORT 
As previously, in accordance with ethical approval from Liverpool (Adult) 
Research Ethics Committee (08/H1005/115), all patients included in this study 
were coded at Whiston Hospital at the point of sample preparation and the detail 
of the coding kept by Dr. Kate Nelson, see Chapter 2 section 2.2. As a result 
samples remained anonymous throughout the study and were further kept 
blinded until final analysis was completed. In compliance with the Human Tissue 
Act (section 7, subsections 1 and 3), samples were excised prior to 1st Sept 2006 
and informed consent was not a requirement. 
The group of interest for this chapter of work, the ‘false negative’ patients (i.e. a 
group of patients who were initially thought to be lymph node disease free as 
identified by a negative SLNB, but subsequently developed lymph node disease), 
were identified as an important group of interest for the reasons stated above as 
they are effectively under-staged. Therefore, through the Cancer Registry 
Services (St Helens’ and Knowsley Trust) list of patients that underwent SLNB 
at Whiston Hospital between 1999-2005, Dr Kate Nelson identified a total of 28 
‘false negative’ patients from the 241 patients that underwent SLNB between 
1999-2005 at Whiston Hospital. SLNB samples were available for 14 of theses 
patients along with 11 corresponding primary melanomas. The rest of the 
primary tumours and nodes were excised elsewhere, usually in the referring 
hospital. 
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To confirm that these nodes were not missed during their initial histopathological 
examination using standard laboratory protocols with haematoxylin and eosin 
staining, further immunohistochemical analysis of these SLNs was undertaken 
by Miss Natalie Rimmer at the Histopathology Department, Whiston Hospital, 
staining with the melanoma specific markers Melan-A and S100 (Dako, 
Cambridgeshire, UK). Melan-A is a protein antigen found on melanocytes. 
Antibodies against the antigen are used in the medical specialty of anatomic 
pathology in order to recognise cells of melanocytic differentiation, useful for the 
diagnosis of a melanoma [155, 156]. Furthermore, several members of the S-100 
protein family are useful as markers for certain tumours and epidermal 
differentiation. It is regularly used as a reliable marker in melanoma[157].  
 
 
 
Melanoma 
diagnosis and 
excision 
SLN biopsy 
performed 
Positive SLN 
biopsy 
Negative SLN 
biopsy 
Completion 
lymphadenectomy 
Clear of 
metastases 
No later 
metastases 
Later 
metastases 
No further 
metastases 
Later metastases 
(False Negative?) 
Figure 2-1 Patient Selection 
Flow chart to illustrate the categorising of patients and 
subsequent selection. 
Figure 34 Flow Chart to Illustrate Method 
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The above chart illustrates how the false negative cohort of interest was 
indentified.  
5.2.2 IMMUNOHISTOCHEMISTRY 
Archival sentinel lymph node biopsy tissue was sectioned and subsequently 
stained immunohistochemically for Pan VEGF, VEGFxxxb, VEGF-C, LYVE-1 
and CD31. 
Immunohistochemistry methods used were as per those described in Chapter 
Two section 2.3.. Furthermore, following accessing patients’ case notes and 
acquiring mortality data, false negative patients were sorted into alive and dead 
at 5 years cohorts. Available primary tumours were stained with pan VEGF and 
VEGFxxxb to examine the theory that in line with prior work, VEGFxxxb 
expression may be protective. 
5.2.3 ANALYSIS 
Analysis was performed as per methods previously described in chapter 2 
sections 2.4 and 2.5 and statistical analysis was as per section 2.7 
5.3 RESULTS 
5.3.1 PATIENT DEMOGRAPHICS 
Out of 241 patients whose histology reports were accessed, 28 patients 
fell into the ‘false negative’ group who following a negative SLN subsequently 
went on to develop further disease. (13.0%). Patient records were accessed for 
27/28 these patients, allowing collection of demographic data, with one patient’s 
care being taken over by another hospital and further records other than nodal 
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relapse information was untraceable, therefore this patient was excluded.  The 
mean age of this group was 52.8 years old. The mean time to recurrence was 2.8 
years (range 0.9-6.5 years). Mean Breslow thickness was 3.78mm (range 2-
11mm). The most common site of the primary was the lower limb (n=10) and 
trunk (n=10)., followed by the upper limb (n=4). Other sites affected were the 
head and neck (n=2). Nodal relapse site was unknown in two patients. Archived 
samples were available for 14 SLN and 11 primary tumours. 
Five year follow up was possible as although the research project began 
in 2009, follow up data was collected after experiments were completed between 
2010 and 2012. The information collected revealed that 50.7% of these patients 
were dead at 5 years. For this deceased cohort, median Breslow thickness was 
3.1mm. Survival for this thickness, with no ulceration and no apparent metastasis 
(nodal or distant) is approximately 78.7% at 5 years1). It is clear therefore that 
according to our statistics, the false negative group has a higher mortality rate 
than ‘true negative’ patients. 
!! "#$!
 
 
 
 Breslow 
Thickness (mm) 
Age 
(years) 
Melanoma specific 
Mortality at 5 
years (%) 
SLN Negative 4.00 ± 0.6 59.73 ± 3.2 0 
SLN Positive 5.17 ±1.0 46.27 ± 4.4 22.5 
False Negative 3.78 ± 0.6 52.81 ± 2.7 50.7 
Table 5 Demographics of patient groups 
 
5.3.2 FURTHER PATHOLOGICAL STAINING 
 
Further immunohistochemistry for melanoma specific markers Melan-A 
and S100 of the original SLN of patients who later relapsed with disease, 
revealed no cases of ‘pathological failure’. Below are examples of this staining. 
This work was carried out by Miss. Natalie Rimmer of the Histopathology 
Department of Whiston Hospital and her protocol and accompanying description 
of work is included in the appendix. 
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Figure 35 IHC staining of ‘false negative’ SLN for S-100 
 
Figure 36 IHC Staining of 'false negative' SLN for Melan-A 
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5.3.3 IMMUNOHISTOCHEMISTRY RESULTS 
 
Figure 37 Pan VEGF Staining in False Negative SLNBs, showing staining 
intensity (A), Percentage Score (B) and Combined Staining Score (C) 
 
Staining patterns were not significantly different across the patient groups 
with regard to intensity. (Figures are expressed as staining score ± SEM). SLN 
positive patients scored 1.15±0.17, SLN negative patients scored 1.51±0.17 and 
the false negative subset scored 1.36±0.21. Similarly, percentage staining scored 
revealed no significant patterns. SLN positive patients scored 1.72±0.30, SLN 
negative patients scored 1.84±0.24 and the false negative cohort percentage 
staining score was 1.89±0.27. When combined, staining scores for SLN positive 
patients were 2.87±0.36, SLN negative patients had a combined score of 
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2.37±0.28 and finally, the false negative groups combined staining score was  
3.27±0.42.  
 
Figure 38 Antiangiogenic VEGF staining of False negative SLNs, showing 
staining intensity (A), staining percentage (B) and combined staining score 
(C) 
 
Staining for VEGFxxxb revealed some different patterns to those just seen 
above. (All scores are again expressed as mean score ± SEM). Intensity scoring 
was as follows. SLN positive patients scored 1.00±0.25, SLN negative patients 
scored 1.20±0.20 and false negative patients scored 1.53±0.20. Average 
percentage staining scores were next examined with SLN positive patients 
scoring 0.97±0.24 , SLN negative patients scored 1.16±0.21 and False negative 
patients scored 1.89±0.24. Finally, combined staining scores were examined with 
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SLN positive patients scoring 2.19±0.42, SLN negative patients scoring 
2.37±0.42 and lastly, False negative patients scoring 3.3±0.41. A trend has 
clearly emerged here, with VEGFxxxb results illustrating significantly higher 
staining within the false negative cohort of patients than node positive or true 
node negative patients (p<0.05 ANOVA).  Perhaps further patterns could be 
identified why with mortality data which is presented later in this chapter.    
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Figure 39 VEGF-C staining in False negative SLNs, staining intensity (A), 
percentage score (B) and combined score (C) 
 
VEGF-C staining was as follows with scores representing mean staining 
scores ±SEM. Intensity average staining scores revealed SLN positive patients to 
have scores of 1.15±0.17, SLN negative patients scored 1.51±0.17 and false 
negative patients scored 0.87±0.25. Percentage staining scores were as follows, 
SLN positive patients scored 1.72±0.32, SLN negative patients scored 1.84±0.23 
and false negative patients scored 1.02±0.31. Finally combined staining scored 
showed SLN positive patients to score 2.87±0.36, SLN negative patients scored 
3.27±0.28 and false negative patients scored 1.91±0.54.  A trend has been 
identified for VEGF-C staining, showing that VEGF-C staining within the false 
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negative SLN is lower when measuring intensity, percentage and combined 
score. This is a statistically significant difference with respect to percentage and 
combined scores(p<0.05 ANOVA).  
 
Figure 40 Vessel Marker Immunohistochemistry in False Negative SLNs 
showing staining results of LYVE-1 and CD31 immunohistochemistry 
 
Following the identification of three vessel ‘hotspots’ as detailed in 
Chapter 2, average vessel counts and areas were calculated. LYVE-1 lymphatic 
vessel counts for SLN positive patients were 6.93±0.81, SLN negative patients 
were 12.1±2.22 and False Negative patients scored 9.31±1.58. LYVE-1 vessel 
areas for SLN positive patients were 36083±5618, SLN negative patients scored 
46666±19924 and false negative patients scored 58831±25104. 
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CD31 vessel count scores for SLN positive patients were 5.87±0.76, for SLN 
negative patients was 8.63±1.02 and for False Negative patients was 6.82±0.92. 
Area scores for CD31 for SLN positive patients were 44066±4814, SLN negative 
patients were 84682±44206 and false negative patients were 75331±47303. 
The only significant finding within this group of experiments was LYVE-
1 vessel counts in SLN negative patients was significantly higher than the other 
cohorts. Area data showed no significant findings for LYVE-1 and CD31 data 
showed no significant patterns and no significant patterns were identified within 
the microenvironment around the false negative SLN. 
 
Next, as my patient demographics for this group have illustrated, these 
patients have a high mortality when compared with their true negative 
counterparts. I examined the mortality statistics which I had available to me for 
the 27/28 patients who were deemed falsely negative. I examined staining 
patterns in the primary tumours for pan VEGF and VEGFxxxb, bearing in mind 
that previous studies have found VEGFxxxb within the tumour to be 
protective[79]. As previously mentioned, only 11 primary tumours were 
available to me, with the rest of the tumours being excised by referring hospitals. 
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Figure 41 Staining of false negative patient's tumours comparing alive 
versus dead patients 
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This set of experiments did not reveal any significant patterns, with 
combined VEGFxxxb staining in the main cohort being 2.12±0.34 in alive patients 
versus 3.13±1.01 in dead patients. In the false negative cohort staining was 
3.42±0.49 in alive patients versus 3.31±0.70 in dead patients. Similarly, no 
significant patterns were drawn when examining pan VEGF staining with 
combined pan VEGF staining in the main cohort being 2.86±0.27 in alive 
patients versus 3.16±0.32 in dead patients. In the false negative cohort staining 
was 3.42±0.49 in alive patients versus 3.31±0.70 in dead patients. 
 
5.4 DISCUSSION 
5.4.1 INTERPRETATION OF RESULTS 
In summary, with regard to my first aim, when examining the 
microenvironment surrounding false negative sentinel nodes and comparing this 
with the microenvironment of true negative and true positive nodes, staining for 
LYVE-1 and CD31 (lymphatic and blood vessels) revealed no significant 
different patterns within the false negative nodal environment. Therefore with 
regard to detecting ‘physiological’ failures, it does not appear possible that with 
the use of these growth factors any patterns are predicted. 
With regard to VEGF-C and VEGFxxxb, there was a significant trend 
identified whereby false negative sentinel nodes showed a decrease in VEGF-C 
and and increase in VEGFxxxb. Perhaps a protective or immune mechanism 
which will be discussed below. 
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The second aim of work was to try to identify whether, in keeping with 
work carried out by Pritchard-Jones et al., could we again show VEGFxxxb 
tumour expression to be protective with regards to mortality. As shown above, in 
the cohort of patients who had a primary tumour available (n=11). This was not 
possible from my set of experiments and will be discussed below. 
 
5.4.2 CAN WE USE ANGIOGENIC AND LYMPHANGIOGENIC GROWTH 
FACTORS TO IDENTIFY PATIENTS WHOSE NODES ARE BEST 
EQUIPPED TO SUPPORT SUCCESSFUL METASTASIS? I.E THE 
PHYSIOLOGICAL SUBSET?  
 
VEGF-C was found to be significantly lower across board in false 
negative SLNs. This may imply a link with the findings of Chapter 3 in that 
tumoural influences help to decide whether a metastasis arrives at SLN or not or 
perhaps that VEGF-C expression from the SLN promotes its potentiation, all 
theories discussed in Chapter 3 discussion. Chapter 4 however found no 
correlation or relationship between tumoural and nodal expression of VEGF-C, 
suggesting that it is isolated expression from the SLN which may potentiate 
lymphatic metastasis. In each chapter of my work, there are some significant 
findings regarding VEGF-C which would support further larger studies in this 
area for clarification. Hirakawa et al. published work in 2007 where a model of 
transgenic mice that overexpressed VEGF-C and green fluorescent protein 
specifically in the skin underwent chemically-induced skin carcinogenesis[126]. 
They found that in contrast to VEGF-A, VEGF-C does not increase the growth 
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of primary tumours, but instead induced expansion of lymphatic networks within 
SLNs, even before the onset of metastasis. Once the metastatic cells arrived at 
the SLNs, the extent of lymphangiogenesis at these sites increased. Of 
importance, in mice with metastasis-containing SLNs, tumours that expressed 
VEGF-C were more likely to metastasise to additional organs, such as distal 
lymph nodes and lungs. No metastases were observed in distant organs in the 
absence of lymph node metastases. These findings indicated an important role of 
VEGF-C-induced lymph node lymphangiogenesis in the promotion of cancer 
metastasis beyond the SLNs. The authors concluded that VEGF-C is therefore a 
good target to slow or even prevent the onset of metastasis. Our findings within 
this chapter (and within chapter 3) seem to support these theories.  
A study by Cianfarani et al. [69] which was published in 2012 involved a 
cohort of 36 node SLN positive patients and 26 SLN negative patients. Similar 
techniques as detailed above in my method were employed to investigate VEGF-
C expression within the tumour and correlations were performed depending on 
nodal outcome. VEGF-C expression in primary melanoma specimens was 
significantly associated with SLN-positive (p < 0.001), particularly in thin 
melanomas[200]. A similar trend was demonstrated by Massi et. al their 2006 
case control study of 45 patients[201]. Boone et. al demonstrated in their 2008 
study that VEGF-C immunohistochemical staining on melanoma tissues of 113 
patients with known sentinel lymph node status showed high VEGF-C 
expression in melanoma cells was positively associated with the presence of a 
positive sentinel lymph node[202]. We were unable to show this trend as 
mentioned above, however as detailed previously, our work was slightly 
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different as a difference in nodal staining patterns was deciphered and therefore 
incorporated into the staining scores.  
I found no change in the architecture of the SLN with regard to vessel 
densities or diameters when comparing SLN negative, positive and false negative 
patients. LYVE-1 vessel counts were statistically higher in SLN negative 
patients. As LYVE-1 is a marker for lymphatic vessel wall endothelium, this 
contradicts my theory of VEGF-C presence promoting lymphatic metastasis 
(either through tumoural or nodal expression). There was no similar reduction in 
SLN negative expression of VEGF-C, and no trend identified between VEGF-C 
and LYVE-1 expression. We would expect that when VEGF-C was raised, we 
would see a concurrent rise in LYVE-1 and vice-versa. This was not seen in my 
results. I would recommend in any larger scale investigations of VEGF-C 
expression, that LYVE-1 staining is also incorporated into staining experiments 
and this relationship investigated further. One explanation in the increased 
number of LYVE-1 vessel counts in SLN negative patients can be found by 
looking at a review article published by Choi et al[227]. The paper indicated that 
lymphatic vessels are not mere passive conduits for immune cells but actively 
participate in modulating the immune responses. Perhaps therefore any rise in 
number of lymphatics, in the absence of detection of onward lymphatic spread of 
disease is a representation of the body’s immune potential.  
A number of in vitro animal and human studies have shown a causal 
relationship between lymphatic vessel density and tumour metastasis [82]. 
Shields et al. in 2004 published work examining lymphatic densities and linked 
this with lymphatic metastasis of melanoma. Lymphatic density inside and 
around 21 archival human melanoma samples were quantified using LYVE-1 
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staining, and this was compared with normal dermis, basal cell carcinoma and 
Merkel cell carcinoma, a skin tumour thought to metastasise through a vascular 
route. Lymphatic capillary density as determined by immunohistochemical 
staining with LYVE-1, was significantly increased around melanomas compared 
with normal dermis, basal cell carcinomas and merkel cell carcinomas. 
Lymphatic density discriminated between melanomas that subsequently 
metastasised and those that did not, (p<0.01, Mann-Whitney). The results 
showed that lymphatic density was increased around melanomas, and that 
lymphatic density and tumour cell invasion of lymphatics may help to predict 
metastasis. To this end, a prognostic index was calculated using lymphatic 
density, lymphatic invasion and thickness that clearly discriminated metastatic 
from nonmetastatic tumours. More recently and expanding on this work, Emmett 
et al. undertook a retrospective analysis of 102 malignant melanomas from 
patients with more than 5 years follow up to evaluate the Shields’ on a larger 
scale and to compare with existing indicators[83]. It was found that the Shields’ 
index accurately predicted outcome in 90% of patients with metastases and 84% 
of patients without metastases. For these, Shields’ index was more predictive 
than Breslow thickness or LVD. This non invasive analysis was concluded to be 
a simple and useful prognostic tool in determining onward spread and therefore 
prognosis [84]. Our findings with regard to VEGF-C in chapter 3 would support 
this work, but not our findings with regard to LYVE-1 in this chapter.  
 
5.4.3 CAN WE SHOW A PATTERN BETWEEN THE BALANCE OF PRO AND 
ANTI-ANGIOGENIC GROWTH FACTORS RELEASED AND SURVIVAL? 
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THIS HAS PREVIOUSLY FOUND TO BE PROTECTIVE (PRITCHARD 
JONES ET AL. [79]). 
  
I found that where present, anti-angiogenic factors did not appear to be 
associated with survival and found no protective relationship as previously 
described by Pritchard Jones et al.[79]. 
Overall the false negative subset of patients had a higher mortality than 
their primary diagnosis would predict from prognostic information available. 
With regards to survival, 5-year follow up of these patients revealed that 50.7% 
of these patients were dead at 5 years i.e survival at 5 years was 49.3%. For this 
deceased cohort, median Breslow thickness was 3.1mm. Survival for this 
thickness, with no ulceration and no apparent metastasis is approximately 78.7% 
at 5 years1). It is clear therefore that according to our statistics, the false negative 
group has a higher mortality rate than ‘true negative’ patients. For similar 
Breslow thickness disease with palpable nodal metastases, expected 5 year 
survival is 53%[53]. This would imply that as a general group, my results have 
shown that false negative patients have similar survival statistics as those with 
clinically palpable nodal disease at diagnosis. 
Based on these findings of this small study, it may be worth considering 
targeting therapeutics and clinical care in this higher mortality group. 
There is an argument for the use of biomarker tests to aid SLN bx 
assessment, for example by introducing a test to tell us what the angiogenic or 
lymphangiogenic status of a tumour or node may be, however my findings do not 
support this notion.   
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Based on the demographics of the small group of false negative patients 
which I identified, their outcomes are generally poor and so further investigation 
would be welcomed within this group. The literature detailed above regarding 
lymphatics and literature available on angiogenesis would imply that this group 
would benefit from further such large scale investigation 
A limitation of my findings is of course my limited sample size, but given 
the relative paucity of data available on the outcome of ‘false negative’ patients, 
supportive evidence, it would be useful to explore this area further in studies 
with adequate follow up periods and larger numbers than my own small study. A 
further limitation is that I have based my categories of patients on 5 year follow 
up data. It is possible that by following up for a longer period of years, further 
false negative patients may have been identified. 
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6 CHAPTER 6 
CONCLUSIONS 
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6.1 CONCLUSIONS 
Malignant Melanoma is the fastest increasing cancer in the UK, and the 
deadliest of all skin cancers [69]. The current staging technique relies on tumour 
thickness as the best predictor of outcome with Sentinel Lymph Node Biopsy 
being used to guide knowledge of lymphatic spread in clinically node negative 
patients [53]. Despite thin melanoma (<1mm Breslow thickness) conferring the 
most favourable outcome (88% 10 year survival)[228], some 15% of patients 
with thin melanomas will go on to develop metastasis with a ten-year survival of 
43%[8]. One of the challenges facing clinicians is to develop a method for 
identifying this subgroup at an early stage as well as delivering accurate 
prognostic information based on evidence which we can gain from the literature.  
Sentinel Lymph Node Biopsy has recently been found to improve 
melanoma specific survival rates in those patients with an intermediate 
melanoma thickness and it has been shown to improve disease free survival in all 
melanoma patients in the long awaited MSLT-1 10 year follow up data [128] but 
in the absence of any other robust clinical trials, we await further evidence which 
may dispel the controversies which surround what clinical and survival benefits 
can be gained from this procedure.  
Furthermore, on review of the literature, it is apparent that SLNB as a 
technique not only poses a clinical risk, but the biopsy itself may be falsely 
negative. There are several reasons for this; surgical, pathological or 
physiological. The cases of surgical and pathological failures may well be 
minimised with greater levels of experience, equipment or more intensive 
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sampling, however it is the physiological subset, where metastatic cells may be 
en-route to the SLN but not have quite arrived at time of SLNB which may 
perhaps be amenable to identification using the techniques described in my 
method chapter. Given that at time of writing it became apparent that the “Seed 
and Soil” theory has been demonstrated in several animal models, whereby the 
primary tumour was found to be responsible through its release of angiogenic 
and lymphangiogenic growth factors to control and modify the 
microenvironment around the SLN prior to the arrival of a metastases, it seemed 
appropriate to investigate this in human melanoma as part of my work. 
 
The first aim of this thesis was to measure the expression of VEGF 
(angiogenic and antiangiogenic) within the primary melanoma and having 
correlated this to the nodal status, determine whether any patterns could be 
established which may allow prediction of nodal status. There was no significant 
relationship established from my set of experiments. I next performed 
immunohistochemistry on positive and negative SLN samples to see whether a 
different angiogenic or lymphangiogenic profile may be delineated. I found a 
significant increase in intranodal expression of VEGF-C within positive SLNBs. 
This increase may be due to tumoural influences or due to VEGF-C expression 
by the node being a necessity for lymphatic metastasis. This may be of clinical 
significance as either an identifier of lymphatic spread or perhaps as a target to 
prevent onward spread of disease and warrants further large scale work. 
To examine the findings of Chapter 3 further and to also move on to 
investigating the “Seed and Soil” theory, I next investigated with 
immunohistochemistry, utilising both blood vessel and lymphatic vessel markers 
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whether the primary melanoma may be controlling the microenvironment around 
the SLN. Tumoural and nodal expressions of each factor were correlated. This 
linked with the findings of Chapter 3 and I did not find any evidence that release 
of VEGF-C from the tumour was controlling the nodal microenvironment, 
implying that the high levels of intranodal VEGF-C appear to be expressed 
independently of the tumour’s influences. The remaining experiments found no 
convincing evidence for the “Seed and Soil” theory. 
A final chapter of work emerged when sorting through outcomes of the 
patients involved in the study. 28 patients (13%) who initially had excision of 
their melanoma and a negative SLNB later relapsed with nodal disease. These 
patients were at risk of higher mortality than their true negative and true positive 
counterparts as per AJCC classification prognostic information [51]. These 
patients were incorporated into my experiments as an additional area of interest. 
Blood and Lymphatic vessel immunohistochemistry was performed on nodal 
samples. In contradiction to prior findings of Chapter 3, significantly increased 
LYVE-1 was found in SLN negative patients. One explanation for this is that the 
lymphatic system may be part of an immune response to prevent a metastasis 
from occurring [211].  
 
!
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Appendix 1 
“Further Immunohistochemistry on False Negative SLNB- Protocol” 
(performed by Natalie Rimmer, Histopathology Dept, Whiston Hospital) 
Method 
This study took place at Whiston Hospital which was chosen as the designated 
hub for SLN procedure for the Merseyside and Cheshire NHS network in 2009. 
The study used formalin fixed paraffin wax embedded SLNB tissue. All SLNB 
specimens underwent current protocol which is to section the SLN at four 
different successively deeper levels. Each section was cut at 4 !m thick and 
placed onto a glass slide. Three spare sections were taken from each level. Tissue 
sections were then incubated in an oven at 75°C for 30 minutes to ensure section 
adherance to the slide. A section from each level was then stained with H&E 
using the Gemini autostainer.  
Sample selection 
The samples were examined microscopically by the pathologist. Any SLNB 
reported as negative on H&E was then returned for IHC staining using S100B 
and MelanA antibodies. Each request was given to a member of staff 
independent of this study who was then responsible for assigning the sample a 
case and sample number and removing any patient identifiable information. This 
ensured that each case remained anonymised to the researcher. This member of 
staff also kept an independent record of histology number, sample number, and 
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case number to ensure the reporting pathologist recieved the correct slides for 
final reporting. 
Sample preparation 
Once the request was received the three spare sections of tissue taken were 
retrieved from the archives and labelled with the assigned case and sample 
number. One section was stained with S100B, one with MelanA and the other 
used as a negative control. For each batch of requests received, established in 
house controls for S100B and MelanA were used. All of the negative control 
tissue was dewaxed using the Gemini autostainer which takes the tissue through 
a series of xylene and alcohol washes to remove wax from the tissue so that the 
stain can penetrate through the tissue. Dewaxing of the test tissue and positive 
controls occurs during the antigen retrieval process. Antigen retrieval was 
required as, when tissues are fixed with formalin the formalin produces a matrix 
around the cells which blocks some antigens on the outside of the cells. Antigen 
retrieval is required to break the matrix so that the antibody can attach to the site. 
Antigen retrieval was performed at a pH of 8 using Thermo 
Ethylenediaminetetraacetic acid (EDTA) buffer solution pH8 on a Thermo PT 
module, previously validated protocols were used as well as recommendations 
from the antibody supplier (Dako) see appendix 5.  
Staining the samples with immunohistochemistry 
Antibody dilutions were made from antibody diluent and antibodies using 
previously validated protocols and following recommendations made by the 
supplier (Dako; see appendix 6). Dilution for S100B was 0.2: 1000!l, and 
MelanA was 10:1000!l. Following antigen retrieval the tissue was stained using 
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an ID labs detection kit. The kit contained a protein block, link antibody and 
enzyme label. The tissue was stained using a Dako auto-immunostainer. The 
method used by the machine is the Avidin Biotin Complex (ABC) method. 
Firstly, peroxidase blocking solution was applied to the tissue for 10 minutes, 
followed by the protein block for 10 minutes. The primary antibody was then 
applied to the tissue (S100B/ MelanA) for 30 minutes. This was followed by the 
application of the biotin labelled link antibody for 10 minutes. Peroxidase 
labelled streptavidin biotin complex was then applied for 10 minutes followed by 
the chromagen containing DAB substrate for 10 minutes. 
The slides were then rinsed with buffer and washed in water. The slides were 
then counterstained, dehydrated and cleared manually using Gills Haematoxylin, 
and a series of water, alcohol and xylene changes. The slides were then mounted 
using an automatic coverslipper and KP coverslipping tape. 
 
Reporting of the samples 
Slides were then passed to the member of staff independent from the study who 
ensured the reporting pathologist recieved the correct slides for the correct 
patient. The slides were given to the reporting pathologist for microscopic 
examination first, who issued a final report. This ensured that during the 
prospective phase of the study there was no delay in results for any of the 
patients. The reporting pathologist kept an independent record of the case and 
sample number along with their result. The slides were then passed back to that 
member of staff. The slides were then examined by the two members of staff 
involved in this study and results were recorded. The samples were simply 
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reported as positive regardless of amount of positivity identified (i.e individual 
cells, small or large clusters of cells), or negative. Slides were examined using an 
Olympus BX40 microscope. The results from all individuals involved in the 
study were compared to identify interobserver reliability. 
!! "#$!
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